Non-peptide somatostatin type 5 receptor agonist and use thereof

By developing a compound that selectively activates SSTR5, the complex structure and high cost of existing peptide drugs have been solved, and the efficient regulation of SSTR5 receptors has been achieved, which significantly inhibits insulin and growth hormone secretion, providing a more effective Hyperinsulinemia treatment plan.

CN114585614BActive Publication Date: 2024-12-03CRINETICS PHARMACEUTICALS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202080072298.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-08-14
Filing Date
2020-08-10
Publication Date
2024-12-03
Estimated Expiration
2040-08-10

AI Technical Summary

Technical Problem

Existing somatostatin regulators, such as peptide drugs such as octreotide, are complex and expensive in structure and require frequent injections, resulting in injection site responses and insufficient selective regulation of SSTR5 receptors, which cannot effectively inhibit insulin and growth hormone. secretion.

Method used

A structurally novel compound was developed to selectively activate the somatostatin receptor subtype 5 (SSTR5) to inhibit insulin secretion, promote glucose release, and inhibit growth hormone secretion for the treatment of hyperinsulinemia and related disease. This compound has high selectivity to SSTR5 receptors, far exceeding its activity on other receptor subtypes, and provides more effective endocrine regulation.

Benefits of technology

By selectively activating the SSTR5 receptor, this compound significantly inhibits the secretion of insulin and growth hormone, providing a more effective treatment for hyperinsulinemia and growth hormone-related diseases, reducing injection site responses and reducing treatment costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003596123600000021
    Figure BDA0003596123600000021
  • Figure BDA0003596123600000101
    Figure BDA0003596123600000101
  • Figure BDA0003596123600000141
    Figure BDA0003596123600000141
Patent Text Reader

Abstract

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 886,764, filed on August 14, 2019, which is incorporated herein by reference in its entirety.

[0003] Statement Regarding Federally Funded Research

[0004] This invention was made with U.S. government support under Grant No. DK115290 awarded by the National Institutes of Health. The government has certain rights in this invention. Technical Field

[0005] Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat conditions, diseases, or disorders that would benefit from modulation of somatostatin activity. Background Art

[0006] Somatostatin is a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation by interacting with G protein-coupled somatostatin receptors and inhibiting the release of many secondary hormones. Six subtypes of somatostatin receptor proteins (SSTR1, SSTR2a, SSTR2b, SSTR3, SSTR4, SSTR5) have been identified, which are encoded by five different somatostatin receptor genes. Modulating specific subtypes of somatostatin receptors or combinations thereof is attractive for treating conditions, diseases or disorders that would benefit from modulation of somatostatin activity. Summary of the invention

[0007] The compounds described herein are somatostatin modulator compounds. In some embodiments, the compounds described herein regulate one or more of the subtype somatostatin receptor proteins. In some embodiments, the compounds described herein regulate a subtype somatostatin receptor. In some embodiments, the compounds described herein regulate the SST5 receptor. Somatostatin peptide analogs formulated as reservoir injections, such as octreotide, lanreotide, and pasireotide, are routinely used to normalize hormone levels for the treatment of adenomas, pancreatic neuroendocrine tumors, and carcinoid tumors that secrete growth hormone (GH). It is reported that octreotide is also used to treat congenital hyperinsulinism (CHI, sometimes referred to as congenital hyperinsulinemia of infants, or persistent hyperinsulinemia hypoglycemia of infants), a condition that causes abnormally high insulin levels in individuals, which in turn leads to frequent episodes of hypoglycemia (hypoglycemia). Depot formulations of these peptide drugs are very expensive and require frequent trips to the doctor's office for painful injections, which can lead to injection site reactions. The compounds described herein are molecules that are structurally distinct from the peptide analogs. The compounds described herein are somatostatin modulators that selectively activate the somatostatin receptor subtype 5 (SSTR5), which in turn inhibits insulin secretion, promotes glucose release, and also inhibits GH secretion.

[0008] In one aspect, described herein are compounds of formula (I), or a pharmaceutically acceptable salt, or a pharmaceutically acceptable solvate thereof:

[0009]

[0010] in:

[0011] Ring A is a carbocyclic ring or a heterocyclic ring;

[0012] X is N or C–R a ; Y is N or C–R b ; Z is N or C–R c ;

[0013] R a , R b and R c are independently hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted monocyclic carbocycle, or substituted or unsubstituted monocyclic heterocycle;

[0014] R f For -L 1 -R g ;

[0015] L 1 does not exist, C 1 -C 6 Alkylene, C 1 -C 6 Fluoroalkylene, or C 1 -C 6 heteroalkylene;

[0016] R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 、-C(=O)N(R 9 ) 2 , or a substituted or unsubstituted monocyclic heterocycle;

[0017] R 1 and R 2 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 6 Cycloalkyl, or substituted or unsubstituted C 3 -C 5 Heterocycloalkyl;

[0018] R 3 Hydrogen, -CN, –CO 2 R 9 、–C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 heteroalkyl;

[0019] R 4 and R 5 are independently hydrogen, halogen, –OR 9 , –N(R 9 ) 2 、–CN、–CO 2 R 9 、–C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 heteroalkyl;

[0020] R 6 is substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 Fluoroalkyl, substituted or unsubstituted C 1 -C 8 Heteroalkyl, or -L 2 -R 6a ;

[0021] L 2 is absent, substituted or unsubstituted C 1 -C 8 Alkylene, or -CHR 6b -;

[0022] R 6a is substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0023] R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl;

[0024] R 7 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0025] or R 6 and R 7 together with the nitrogen to which they are attached, form a substituted or unsubstituted N-containing heterocyclic ring;

[0026] Each R 8 , R 11 and R 12 are independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted monocyclic carbocycle, substituted or unsubstituted monocyclic heterocycle, –CN, –OR 9 , –C(=O)R 10 , –CO 2 R 9 、–C(=O)N(R 9 ) 2 , –N(R 9 ) 2 ,–NR9 C(=O)R 10 ,–NR 9 C(=O)OR 10 ,–NR 9 C(=O)N(R 9 ) 2 , –C(R 9 )=N-OR 9 ,–SR 9 , –S(=O)R 9 ,–SO 2 R 9 , or –SO 2 N(R 9 ) 2 ;

[0027] or R 11 With adjacent R 8 And R 11 and the adjacent R 8 The atoms joined together form a fused substituted or unsubstituted carbocyclic ring, or a fused substituted or unsubstituted heterocyclic ring;

[0028] Each R 9 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 7 Cycloalkyl, substituted or unsubstituted monocyclic 3- to 8-membered heterocycloalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted monocyclic heteroaryl;

[0029] or two R on the same N atom 9 together with the N atom to which they are attached, form a substituted or unsubstituted N-containing heterocyclic ring;

[0030] Each R 10 are independently substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 7 cycloalkyl, substituted or unsubstituted monocyclic 3- to 8-membered heterocycloalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted monocyclic heteroaryl; and

[0031] n is 0-3.

[0032] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are selected by one skilled in the art to provide stable moieties and compounds.

[0033] Also described herein is a pharmaceutical composition comprising a compound as described herein, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, dermal administration, or ocular administration. In some embodiments, the pharmaceutical composition is formulated for administration to a mammal by oral administration. In some embodiments, the pharmaceutical composition is in the form of a tablet, a pill, a capsule, a liquid, a suspension, a gel, a dispersion, a solution, an emulsion, an ointment, or a lotion. In some embodiments, the pharmaceutical composition is in the form of a tablet, a pill, or a capsule.

[0034] Also described herein is a method for treating a disease or condition in a mammal that will benefit from the regulation of somatostatin receptor activity, the method comprising administering a compound as described herein or a pharmaceutically acceptable salt or solvate thereof to a mammal in need thereof. In some embodiments, the compound as described herein or a pharmaceutically acceptable salt or solvate thereof is administered orally. In some embodiments, the disease or condition is persistent or recurrent hyperinsulinemia, hypoglycemia, acromegaly, neuroendocrine tumors, insulinomas, Cushing's disease, ophthalmic diseases or conditions, cancer, pain, neurodegenerative diseases or conditions, inflammatory diseases or conditions, mental illnesses or conditions, or a combination thereof. In some embodiments, the disease or condition is hyperinsulinemia hypoglycemia. In some embodiments, the disease or condition is hypoglycemia due to endogenous insulin, drug-induced hyperinsulinemia, or hypoglycemia caused by exogenous insulin.

[0035] Any of the above aspects is a further embodiment, wherein an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is: (a) systemically administered to a mammal; and / or (b) orally administered to a mammal; and / or (c) intravenously administered to a mammal; and / or (d) administered by inhalation; and / or (e) administered by nasal administration; and / or (f) administered to a mammal by injection; and / or (g) topically administered to a mammal; and / or (h) administered by ocular administration; and / or (i) rectally administered to a mammal; and / or (j) non-systemically or topically administered to a mammal.

[0036] Any of the above aspects is a further embodiment comprising a single administration of an effective amount of the compound, including further embodiments wherein the compound is administered to a mammal once daily or the compound is administered to a mammal multiple times over a one-day period. In some embodiments, the compound is administered in accordance with a continuous dosing regimen. In some embodiments, the compound is administered in accordance with a continuous daily dosing regimen.

[0037] In any of the embodiments disclosed herein, the mammal is a human.

[0038] In some embodiments, the compounds provided herein are administered orally to a human.

[0039] An article of manufacture is provided, comprising packaging material, a compound of formula (I) or a pharmaceutically acceptable salt thereof within the packaging material, and a label indicating that the compound or composition, or a pharmaceutically acceptable salt, tautomer, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug or pharmaceutically acceptable solvate thereof, is used to modulate one or more subtypes of somatostatin receptor proteins, or to treat, prevent or ameliorate one or more symptoms of a disease or condition that would benefit from modulation of one or more subtypes of somatostatin receptor proteins.

[0040] Other objects, features and advantages of the compounds, methods and compositions described herein will become apparent through the following detailed description. However, it should be understood that the detailed description and specific examples, while describing specific embodiments, are given by way of illustration only, as various changes and modifications within the spirit and scope of the present disclosure will become apparent to those skilled in the art through this detailed description. DETAILED DESCRIPTION

[0041] Somatostatin (SST), also known as somatostatin release inhibitory factor (SRIF), was originally isolated from the sheep hypothalamus as a 14 amino acid peptide (Brazeau et al., Science 179, 77-79, 1973). Subsequently, a 28 amino acid peptide with an N-terminal extension was isolated, which has similar biological activity to the 14 amino acid somatostatin (Pradayrol et al., FEBS Letters, 109, 55-58, 1980; Esch et al., Proc. Natl. Acad. Sci. USA, 77, 6827–6831, 1980). SST is a regulatory peptide produced by several cell types in response to other neuropeptides, neurotransmitters, hormones, cytokines and growth factors. SST acts through endocrine and paracrine pathways to affect its target cells. Many of these effects are related to the inhibition of the secretion of other hormones, most notably growth hormone (GH). They are produced by a variety of cell types in the central nervous system (CNS) and intestine and have multiple functions, including regulating the secretion of growth hormone (GH), insulin, glucagon, and many other antiproliferative hormones.

[0042] These pleiotropic effects of somatostatin are mediated by six somatostatin receptor proteins (SSTR1, SSTR2a, SSTR2b, SSTR3, SSTR4, SSTR5). These six somatostatin receptor proteins are encoded by five different somatostatin receptor genes (Reisine and Bell, Endocr Rev. 16, 427-442, 1995; Patel and Srikant, Trends Endocrinol Metab 8, 398-405, 1997). All of these receptors are members of the class A subgroup of the GPCR superfamily.

[0043] Any one or a combination of somatostatin receptor subtypes may be selectively modulated. In some embodiments, selective modulation of any one somatostatin receptor subtype relative to other somatostatin receptor subtypes reduces undesirable side effects in various clinical applications.

[0044] In one aspect, the compounds described herein are modulators of SSTR5. In some embodiments, the compounds described herein selectively modulate the activity of SSTR5 relative to other somatostatin receptors. In some embodiments, the compounds described herein selectively modulate the activity of SSTR5 relative to SSTR2.

[0045] In some embodiments, the compounds described herein are suitable for oral administration to a mammal in need of treatment with a somatostatin modulator.

[0046] In some embodiments, the somatostatin receptor modulators described herein are used for a wide range of therapeutic applications. In some embodiments, the somatostatin receptor modulators described herein are used to treat a variety of diseases or conditions, such as, but not limited to, acromegaly, neuroendocrine tumors, and hyperinsulinemia. In some embodiments, the somatostatin receptor modulators described herein are used to treat hyperinsulinemia in mammals.

[0047] In some embodiments, the somatostatin receptor modulators described herein inhibit the secretion of various hormones and nutritional factors in mammals. In some embodiments, the compounds are used to inhibit certain endocrine secretions, such as, but not limited to, GH, IGF-1, and insulin. The inhibition of certain endocrine secretions can be used to treat conditions such as acromegaly, hyperinsulinemia, endocrine tumors such as carcinoids, VIPomas, insulinomas, and glucagonomas. In some embodiments, the somatostatin receptor modulators described herein are used to inhibit exocrine secretions in the pancreas, stomach, and intestines for the treatment of conditions associated with diseases such as AIDS or cholera, such as pancreatitis, fistulas, bleeding ulcers, and diarrhea. Disorders involving autocrine or paracrine secretion of trophic factors such as IGF-1 (as well as some endocrine factors) that may be treated by administration of the compounds described herein include breast, prostate, and lung cancers (small cell and non-small cell epidermoid carcinomas), as well as hepatoma, neuroblastoma, insulinoma, colon and pancreatic adenocarcinoma (ductal type), chondrosarcoma, and melanoma, as well as atherosclerosis associated with restenosis after vascular transplantation and angioplasty.

[0048] In some embodiments, the somatostatin receptor modulators described herein are used to inhibit mediators of neurogenic inflammation (e.g., substance P or tachykinins) and can be used to treat rheumatoid arthritis; psoriasis; local inflammation, such as that associated with sunburn, eczema or other sources of itching; inflammatory bowel disease; irritable bowel syndrome; allergies, including asthma and other respiratory diseases. In some other embodiments, the somatostatin receptor modulators described herein act as neuromodulators in the central nervous system and can be used to treat Alzheimer's disease and other forms of dementia, pain, and headaches. In some embodiments, the somatostatin receptor modulators described herein provide cytoprotection in conditions involving visceral blood flow, including cirrhosis of the liver and esophageal varices.

[0049] In some embodiments, the somatostatin receptor modulators described herein are used to treat hyperinsulinemia in a mammal. Hyperinsulinemia can lead to several conditions, such as, but not limited to, hypoglycemia or low blood sugar, diabetes or uncontrolled blood sugar that fluctuates between high and low levels, increased risk of polycystic ovary syndrome (PCOS), increased production of very low density lipoprotein (VLDL) (known as hypertriglyceridemia), cardiovascular disease or heart disease, coronary artery disease (high insulin levels damage the endothelial cells lining the coronary arteries), hypertension or high blood pressure, hypothyroidism, increased risk of weight gain and lethargy.

[0050] Hyperinsulinemia refers to higher than normal levels of insulin in a person or animal's blood. Normal insulin secretion and blood levels are closely related to the level of glucose in the blood, so a given insulin level may be normal for one blood glucose level but low or high for another. Hyperinsulinemia may be associated with several types of medical problems, which can be roughly divided into two major, largely non-overlapping categories: those that tend to have decreased sensitivity to insulin and high blood glucose levels (hyperglycemia) and those that tend to have excessive insulin secretion and low glucose levels (hypoglycemia).

[0051] Hyperinsulinemic hypoglycemia (HH) is one of the most common causes of persistent hypoglycemia in infants. It is a heterogeneous condition caused by increased insulin secretion from the beta cells of the pancreas. HH can lead to apnea, seizures, developmental delays, learning disabilities, epilepsy, and even death. The most severe form of HH is inherited and is called congenital hyperinsulinemia (CHI). As with many rare diseases, while there are currently no medications specifically for patients with CHI, some medications have been adapted for use, including but not limited to diazoxide and octreotide.

[0052] The pancreas is the primary site of somatostatin action, where it inhibits the synthesis and secretion of the two main hormones that control glucose homeostasis: glucagon and insulin. Different somatostatin receptor subtypes control these important processes: the SST2 receptor inhibits glucagon, while both SST2 and SST5 are responsible for inhibiting insulin.

[0053] Hypoglycemia due to excess endogenous insulin may be congenital or acquired, becoming apparent in the neonatal period or many years later. Hypoglycemia may be severe and life-threatening or mild and occasionally troublesome. By far the most common type of severe but transient hyperinsulinemic hypoglycemia occurs incidentally in patients with type 1 diabetes taking insulin.

[0054] Hypoglycemia caused by endogenous insulin includes, but is not limited to, congenital hyperinsulinemia, transient neonatal hyperinsulinemia, focal hyperinsulinemia (KATP channel disorders), diffuse hyperinsulinemia, acquired forms of hyperinsulinemia, insulinoma (insulin-secreting tumor), adult islet cell hyperplasia, autoimmune insulin syndrome, non-insulinoma pancreatic hypoglycemia, reactive hypoglycemia, side effects of gastric bypass surgery, or gastric dumping syndrome.

[0055] Drug-induced hyperinsulinemia results from exposure to certain drugs such as, but not limited to, sulfonylureas, aspirin, pentamidine, quinine, disopyramide, Bordetella pertussis vaccine or infection, D-chiro-inositol, and inositol.

[0056] Hypoglycemia results from exogenous (injected) insulin, including, but not limited to, insulin self-injected for treatment of diabetes (i.e., diabetic hypoglycemia), surreptitious self-injection of insulin (e.g., Munchausen syndrome), self-injection of insulin during attempted or successful suicide, insulin augmentation therapy, and insulin-induced coma for treatment of depression.

[0057] Compound

[0058] The compounds of formula (I), including their pharmaceutically acceptable salts, prodrugs, active metabolites and pharmaceutically acceptable solvates, are somatostatin receptor modulators. In some embodiments, the compounds of formula (I), including their pharmaceutically acceptable salts, prodrugs, active metabolites and pharmaceutically acceptable solvates, are SST5 receptor modulators.

[0059] In some embodiments, the compounds described herein are SST5 selective modulators. In some embodiments, the compounds described herein are at least 10 times, at least 15 times, at least 20 times, at least 30 times, at least 40 times, at least 50 times, at least 100 times, at least 200 times, at least 300 times, at least 400 times, or more than 500 times more selective than SST1, SST2, SST3, and / or SST4 receptor activity when modulating SST5 receptor activity. In some embodiments, the compounds described herein are at least 10 times, at least 15 times, at least 20 times, at least 30 times, at least 40 times, at least 50 times, at least 100 times, at least 200 times, at least 300 times, at least 400 times, or more than 500 times more selective than SST2 receptor activity when modulating SST5 receptor activity.

[0060] In one aspect, provided herein is a compound of formula (I), or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof:

[0061]

[0062] in:

[0063] Ring A is a carbocyclic ring or a heterocyclic ring;

[0064] X is N or C–R a ; Y is N or C–R b ; Z is N or C–R c ;

[0065] R a , R b and R c are independently hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , –CO 2 R 9 、–C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted monocyclic carbocycle, or substituted or unsubstituted monocyclic heterocycle;

[0066] R f For -L 1 -R g ;

[0067] L 1 does not exist, C 1 -C 6 Alkylene, C 1 -C 6 Fluoroalkylene, or C 1 -C 6 heteroalkylene;

[0068] R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 、-C(=O)N(R 9 ) 2 , or a substituted or unsubstituted monocyclic heterocycle;

[0069] R 1 and R 2are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 6 Cycloalkyl, or substituted or unsubstituted C 3 -C 5 Heterocycloalkyl;

[0070] R 3 Hydrogen, -CN, –CO 2 R 9 、–C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 heteroalkyl;

[0071] R 4 and R 5 are independently hydrogen, halogen, –OR 9 , –N(R 9 ) 2 、–CN、–CO 2 R 9 、–C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 heteroalkyl;

[0072] R 6 is substituted or unsubstituted C 1 -C8 Alkyl, substituted or unsubstituted C 1 -C 8 Fluoroalkyl, substituted or unsubstituted C 1 -C 8 Heteroalkyl, or -L 2 -R 6a ;

[0073] L 2 is absent, substituted or unsubstituted C 1 -C 8 Alkylene, or -CHR 6b -;

[0074] R 6a is substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0075] R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl;

[0076] R 7 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0077] or R 6 and R 7together with the nitrogen to which they are attached, form a substituted or unsubstituted N-containing heterocyclic ring;

[0078] Each R 8 , R 11 and R 12 are independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted monocyclic carbocycle, substituted or unsubstituted monocyclic heterocycle, –CN, –OR 9 , –C(=O)R 10 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 ,–NR 9 C(=O)R 10 ,–NR 9 C(=O)OR 10 ,–NR 9 C(=O)N(R 9 ) 2 , –C(R 9 )=N-OR 9 ,–SR 9 , –S(=O)R 9 ,–SO 2 R 9 , or –SO 2 N(R 9 ) 2 ;

[0079] or R 11 With adjacent R 8 And R 11 and the adjacent R 8 The atoms joined together form a fused substituted or unsubstituted carbocyclic ring, or a fused substituted or unsubstituted heterocyclic ring;

[0080] Each R 9 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3-C 7 Cycloalkyl, substituted or unsubstituted monocyclic 3- to 8-membered heterocycloalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted monocyclic heteroaryl;

[0081] or two R on the same N atom 9 together with the N atom to which they are attached, form a substituted or unsubstituted N-containing heterocyclic ring;

[0082] Each R 10 are independently substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 7 cycloalkyl, substituted or unsubstituted monocyclic 3- to 8-membered heterocycloalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted monocyclic heteroaryl; and

[0083] n is 0-3.

[0084] For any and all embodiments, the substituents are selected from a subset of the listed alternatives. For example, in some embodiments, R 1 and R 2 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 In some embodiments, R 1 and R 2 are independently hydrogen or substituted or unsubstituted C 1 -C 6 In some embodiments, R 1 and R 2 are independently hydrogen or C 1 -C 6 In some embodiments, R 1 is hydrogen and R 2 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 In some embodiments, R 1is hydrogen and R 2 is hydrogen or substituted or unsubstituted C 1 -C 6 Alkyl. 1 is hydrogen and R 2 is hydrogen or C 1 -C 6 In some embodiments, R 1 and R 2 Each is hydrogen.

[0085] In some embodiments, R 3 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 In some embodiments, R 3 Hydrogen, -CN, –CO 2 R 9 、–C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C 4 Alkyl, substituted or unsubstituted C 1 -C 4 Fluoroalkyl or substituted or unsubstituted C 1 -C 4 In some embodiments, R 3 is hydrogen, substituted or unsubstituted C 1 -C 4 Alkyl, substituted or unsubstituted C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted C 1 -C 4 In some embodiments, R 3 Hydrogen, -CN, –CO 2 R 9 、–C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 In some embodiments, R 3is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 In some embodiments, R 3 Hydrogen, -CN, –CO 2 R 9 、–C(=O)N(R 9 ) 2 , or substituted or unsubstituted C 1 -C 6 In some embodiments, R 3 is hydrogen, or substituted or unsubstituted C 1 -C 6 In some embodiments, R 3 For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Fluoroalkoxy, or C 1 -C 6 In some embodiments, R 3 Hydrogen, -CN, –CO 2 R 9 、–C(=O)N(R 9 ) 2 , C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl or C 1 -C 4 In some embodiments, R 3 For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl or C 1 -C 4 In some embodiments, R 3 Hydrogen, -CN, –CO 2 R 9 、–C(=O)N(R 9 ) 2 , C 1 -C 6 Alkyl, or C 1 -C 6 In some embodiments, R 3 For hydrogen, C1 -C 6 Alkyl, or C 1 -C 6 In some embodiments, R 3 is hydrogen or C 1 -C 6 In some embodiments, R 3 Hydrogen, -CN, –CO 2 R 9 , –C(=O)N(R 9 ) 2 , or C 1 -C 6 In some embodiments, R 3 Hydrogen, -CN, –CO 2 CH 3 , –CO 2 CH 2 CH 3 、–C(=O)NH 2 、–C(=O)NHCH 3 、–C(=O)N(CH 3 ) 2 、-CH 3 、-CH 2 OH, -CH 2 OCH 3 、-CH 2 CH 2 F, -CH 2 CHF 2 , or -CH 2 CF 3 In some embodiments, R 3 Hydrogen, -CN, –CO 2 CH 3 , –CO 2 CH 2 CH 3 、–C(=O)NH 2 、–C(=O)NHCH 3 、–C(=O)N(CH 3 ) 2 、-CH 3 、-CH 2 OH, -CH 2 OCH 3 , or -CH 2 CHF 2 In some embodiments, R 3 Hydrogen, -CH 3 、-CH 2 OH, -CH 2 OCH 3、-CH 2 CH 2 F, -CH 2 CHF 2 , or -CH 2 CF 3 In some embodiments, R 3 Hydrogen, -CH 3 、-CH 2 OH, -CH 2 OCH 3 , or -CH 2 CHF 2 In some embodiments, R 3 is hydrogen or -CH 3 In some embodiments, R 3 In some embodiments, R 3 -CH 3 .

[0086] In some embodiments, R 4 and R 5 are independently hydrogen, halogen, –OR 9 , –N(R 9 ) 2 、–CN、–CO 2 R 9 , –C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 In some embodiments, R 4 and R 5 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 In some embodiments, R 4 and R 5 are independently hydrogen, halogen, C 1 -C 6 Alkyl, or C 1 -C 6 In some embodiments, R 4 and R 5 Each is independently hydrogen or halogen. In some embodiments, R 4 and R 5 are each independently hydrogen or -F.

[0087] In some embodiments, R1 is hydrogen; R 2 is hydrogen or C 1 -C 6 Alkyl; R 3 For hydrogen, C 1 -C 6 Alkyl, or C 1 -C 6 fluoroalkyl; and R 4 and R 5 are independently hydrogen, halogen, C 1 -C 6 Alkyl, or C 1 -C 6 In some embodiments, R 1 and R 2 Each is hydrogen; R 3 is hydrogen or -CH 3 ; and R 4 and R 5 In some embodiments, R 1 is hydrogen; R 2 is hydrogen or C 1 -C 6 Alkyl; R 3 For hydrogen, C 1 -C 6 Alkyl, or C 1 -C 6 Fluoroalkyl; R 4 For hydrogen, halogen, C 1 -C 6 Alkyl, or C 1 -C 6 fluoroalkyl; and R 5 For hydrogen, halogen, C 1 -C 6 Alkyl, or C 1 -C 6 In some embodiments, R 1 is hydrogen; R 2 is hydrogen; R 3 Hydrogen, -CH 3 、-CH 2 OH, -CH 2 OCH 3 、-CH 2 CH 2 F, -CH 2 CHF 2 , or -CH 2 CF 3 ; R 4 is hydrogen or F; and R 5 is hydrogen or F. In some embodiments, R 1 is hydrogen; R 2is hydrogen or C 1 -C 6 Alkyl; R 3 For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl or C 1 -C 4 Heteroalkyl; R 4 For hydrogen, halogen, C 1 -C 4 Alkyl, or C 1 -C 4 fluoroalkyl; and R 5 For hydrogen, halogen, C 1 -C 4 Alkyl, or C 1 -C 4 Fluoroalkyl.

[0088] In some embodiments, the compound has the structure of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof:

[0089]

[0090] In some embodiments, the compound has the structure of Formula (Ia) or a pharmaceutically acceptable salt or solvate thereof:

[0091]

[0092] In some embodiments, the compound has the structure of Formula (Ib) or a pharmaceutically acceptable salt or solvate thereof:

[0093]

[0094] In some embodiments, X is C-R a ; Y is N; and Z is C–R c ; or X is CH; Y is N; and Z is C–R c ; or X is C–R a ; Y is N; and Z is CH; or X is N; Y is C–R b ; and Z is C–R c ; or X is C–R a ; Y is C–R b ; and Z is N; or X is N; Y is N; and Z is C–R c ; or X is C–R a ; Y is N; and Z is N. In some embodiments, X is C—R a ; Y is N; and Z is C–R c In some embodiments, X is CH; Y is N; and Z is C—Rc In some embodiments, X is C-R a ; Y is N; and Z is CH. In some embodiments, X is N; Y is C—R b ; and Z is C–R c In some embodiments, X is C-R a ; Y is C–R b ; and Z is N. In some embodiments, X is N; Y is N; and Z is C-R c In some embodiments, X is C-R a ; Y is N; and Z is N.

[0095] In some embodiments, X is N or CH; Y is N or CH; and Z is N or C-R c .

[0096] In some embodiments, R a , R b and R c are independently hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 In some embodiments, R a , R b and R c are independently hydrogen, halogen, –CN, –OR f , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 In some embodiments, R a , R b and R c are independently hydrogen, halogen, –CN, –OR f , C 1 -C 6 Alkyl, C 1 -C 6Fluoroalkyl, C 1 -C 6 In some embodiments, R a , R b and R c are independently hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 In some embodiments, R a , R b and R c are independently hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , –CO 2 R 9 、–C(=O)N(R 9 ) 2、 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, substituted or unsubstituted monocyclic C 3 -C 6 Cycloalkyl, or substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl.

[0097] In some embodiments, R a , R b and R c are independently hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , –CO 2 R 9 、–C(=O)N(R 9 ) 2 , C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C1 -C 6 Heteroalkyl, substituted or unsubstituted monocyclic C 3 -C 6 Cycloalkyl, substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl; R f For -L 1 -R g ; L 1 does not exist, or C 1 -C 6 Alkylene; and R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 、-C(=O)N(R 9 ) 2 , substituted or unsubstituted monocyclic C 2 -C 5 In some embodiments, R a , R b and R c are independently hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 Heteroalkyl; R f For -L 1 -R g ; L 1 Does not exist or C 1 -C 6 Alkylene; and R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, or -CO 2 R 9 .

[0098] In some embodiments, R a , R b and R c are independently hydrogen, -F, -Cl, -CN, -CH 3 、-CH 2 CH 3, -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 ) 2 , -CH(CH 3 )(CH 2 CH 3 ), -C(CH 3 ) 3 , -CH 2 F, -CHF 2 , -CF 3 , -CH 2 CF 3 , -OCH 3 , -OCH 2 CH 3 , -OCF 3 , -OCH 2 CHF 2 , -OCH 2 CF 3 , -OCH 2 CH 2 OCH 3 , -O-(cyclopropyl), -O-CH 2 -(cyclopropyl), -O-CH 2 -(phenyl), -OCH 2 CO 2 H, -OCH 2 CH 2 CO 2 H, -OCH 2 CH 2 CH 2 CO 2 H, -OCH 2 CO 2 CH 3 , -OCH 2 CH 2 CO 2 CH 3 , -OCH 2 CH 2 CH 2 CO 2 CH 3 , -OCH 2 CO 2 CH 2 CH3 、-OCH 2 CH 2 CO 2 CH 2 CH 3 、-OCH 2 CH 2 CH 2 CO 2 CH 2 CH 3 , -CO 2 CH 3 , -CO 2 CH 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 、-C(=O)N(CH 3 ) 2 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl. In some embodiments, R a , R b and R c are independently hydrogen, -F, -Cl, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCH 2 CH 3 、-OCH 2 CHF 2 、-OCH 2 CF 3 、-OCH 2 CH 2 OCH 3 , -O-(cyclopropyl), -O-CH 2 -(cyclopropyl), -O-CH 2 -(phenyl), -OCH 2 CO 2 H, -OCH 2 CH 2 CO 2 H, -OCH 2 CH 2 CH 2 CO 2 H, -OCH 2 CO 2 CH 3 、-OCH 2 CH 2 CO 2 CH 3 、-OCH 2 CH 2CH 2 CO 2 CH 3 、-OCH 2 CO 2 CH 2 CH 3 、-OCH 2 CH 2 CO 2 CH 2 CH 3 , or -OCH 2 CH 2 CH 2 CO 2 CH 2 CH 3 In some embodiments, R a , R b and R c are independently hydrogen, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , -CO 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 , or -C(=O)N(CH 3 ) 2 In some embodiments, R a , R b and R c are independently hydrogen, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , -CO 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 , or -C(=O)N(CH 3 ) 2 , or cyclopropyl. In some embodiments, R a , R b and R c are each independently hydrogen or -CN.

[0099] In some embodiments, the compound has the structure of Formula (II), or a pharmaceutically acceptable salt or solvate thereof:

[0100]

[0101] In some embodiments, the compound has the structure of Formula (IIa) or (IIb), or a pharmaceutically acceptable salt or solvate thereof:

[0102]

[0103] In some embodiments, the compound has the structure of Formula (IIa), or a pharmaceutically acceptable salt or solvate thereof:

[0104]

[0105] In some embodiments, the compound has the structure of Formula (IIb), or a pharmaceutically acceptable salt or solvate thereof:

[0106]

[0107] In some embodiments, the compound has the structure of Formula (IX), or a pharmaceutically acceptable salt or solvate thereof:

[0108]

[0109] In some embodiments, the compound has the structure of Formula (IIa) or (IIb), or a pharmaceutically acceptable salt or solvate thereof:

[0110]

[0111] In some embodiments, the compound has the structure of Formula (X), or a pharmaceutically acceptable salt or solvate thereof:

[0112]

[0113] In some embodiments, the compound has the structure of Formula (Xa) or (Xb), or a pharmaceutically acceptable salt or solvate thereof:

[0114]

[0115] In some embodiments, Ring A is phenyl, monocyclic heteroaryl, or bicyclic heteroaryl.

[0116] In some embodiments, Ring A is phenyl.

[0117] In some embodiments, ring A is a monocyclic heteroaryl; and n is 0, 1, or 2. In some embodiments, ring A is pyrrolyl, furanyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or triazinyl. In some embodiments, ring A is pyrazolyl, thiazolyl, isoxazolyl, pyridinyl, or pyrimidinyl. In some embodiments, ring A is pyridinyl.

[0118] In some embodiments, ring A is phenyl or a monocyclic heteroaryl. In some embodiments, ring A is phenyl; or ring A is pyridyl; or ring A is pyrazolyl, thiazolyl, isoxazolyl or pyrimidinyl. In some embodiments, ring A is phenyl or pyridyl.

[0119] In some embodiments, the compound has the structure of Formula (III), or a pharmaceutically acceptable salt or solvate thereof:

[0120]

[0121] In some embodiments, the compound has the structure of Formula (IIIa) or (IIIb), or a pharmaceutically acceptable salt or solvate thereof:

[0122]

[0123] In some embodiments, the compound has the structure of Formula (IV), or a pharmaceutically acceptable salt or solvate thereof:

[0124]

[0125] in:

[0126] A 1 and A 2 Each independently is C–R 8 or N; and

[0127] A 3 C–R 12 or N.

[0128] In some embodiments, the compound has the structure of Formula (IVa) or (IVb), or a pharmaceutically acceptable salt or solvate thereof:

[0129]

[0130] In some embodiments, A 1 C–R 8 ; A 2 C–R 8 , and A 3C–R 12 ; or A 1 N; A 2 C–R 8 , and A 3 C–R 12 ; or A 1 C–R 8 ; A 2 is N, and A 3 C–R 12 ; or A 1 C–R 8 ; A 2 C–R 8 , and A 3 is N. In some embodiments, A 1 C–R 8 ; A 2 C–R 8 , and A 3 C–R 12 In some embodiments, A 1 N; A 2 C–R 8 , and A 3 C–R 12 In some embodiments, A 1 C–R 8 ; A 2 is N, and A 3 C–R 12 In some embodiments, A 1 C–R 8 ; A 2 C–R 8 , and A 3 is N.

[0131] In some embodiments, the compound has the structure of Formula (IVa-1) or (IVb-1), or a pharmaceutically acceptable salt or solvate thereof:

[0132]

[0133]

[0134] in:

[0135] A 1 C–R 8 ; and A 2 C–R 8 ;or

[0136] A 1 is N; and A 2 C–R 8 ;or

[0137] A 1 C–R 8 ; and A 2 is N.

[0138] In some embodiments, the compound has the structure of Formula (IVa-2), (IVb-2), (IVa-3), (IVb-3), (IVa-4), (IVb-4), (IVa-5), or (IVb-5), or a pharmaceutically acceptable salt or solvate thereof:

[0139]

[0140] In some embodiments, the compound has the structure of Formula (V), or a pharmaceutically acceptable salt or solvate thereof:

[0141]

[0142] in:

[0143] A 2 C–R 8 or N.

[0144] In some embodiments, the compound has the structure of Formula (Va) or (Vb), or a pharmaceutically acceptable salt or solvate thereof:

[0145]

[0146] In some embodiments, the compound has the structure of Formula (Va-1), (Vb-1), (Va-2), or (Vb-2), or a pharmaceutically acceptable salt or solvate thereof:

[0147]

[0148] In some embodiments, each R 8 are independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted monocyclic carbocycle, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 ,–NR 9 C(=O)R 10 ,–SO 2 R9 , or –SO 2 N(R 9 ) 2 In some embodiments, each R 8 are independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 , or –NR 9 C(=O)R 10 In some embodiments, each R 8 are independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 In some embodiments, each R 8 are independently hydrogen, halogen, C 1 -C 6 Alkyl, or C 1 -C 6 In some embodiments, each R 8 is independently hydrogen or halogen. In some embodiments, each R 8 are independently hydrogen, -F or -Cl.

[0149] In some embodiments, the compound has the structure of Formula (Va-3) or (Vb-3), or a pharmaceutically acceptable salt or solvate thereof:

[0150]

[0151] In some embodiments, R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted monocyclic carbocycle, substituted or unsubstituted monocyclic heterocycle, –CN, –OR 9 , –CO 2 R9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 ,–NR 9 C(=O)R 10 ,–NR 9 C(=O)OR 10 ,–NR 9 C(=O)N(R 9 ) 2 , –C(R 9 )=N-OR 9 ,–SR 9 , –S(=O)R 9 ,–SO 2 R 9 or –SO 2 N(R 9 ) 2 In some embodiments, R 11 and R 12 are independently hydrogen, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 , or –NR 9 C(=O)R 10 , substituted or unsubstituted monocyclic C 3 -C 8 Cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, or substituted or unsubstituted monocyclic C 1 -C 5 In some embodiments, R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R9 ) 2 , or –NR 9 C(=O)R 10 , or a substituted or unsubstituted monocyclic carbocyclic ring. In some embodiments, R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 , or –NR 9 C(=O)R 10 , or a substituted or unsubstituted monocyclic C 3 -C 8 In some embodiments, R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , or substituted or unsubstituted monocyclic cycloalkyl. In some embodiments, R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , or a substituted or unsubstituted monocyclic C 3 -C 8 In some embodiments, R 11 and R 12 are independently hydrogen, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , or a substituted or unsubstituted monocyclic C 3 -C 8 In some embodiments, R 11 and R 12are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 In some embodiments, R 11 and R 12 are independently hydrogen, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, –CN, or –OR 9 In some embodiments, R 11 and R 12 are independently hydrogen, -F, -Cl, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , or -OCHF 2 In some embodiments, R 11 and R 12 Each is independently halogen. In some embodiments, R 11 and R 12 Each is independently -F or -Cl. In some embodiments, R 11 and R 12 Each is -F.

[0152] In some embodiments, R 11 With adjacent R 8 And R 11 and the adjacent R 8 The atoms connected together form a fused substituted or unsubstituted carbocyclic ring, or a fused substituted or unsubstituted heterocyclic ring. 11 With adjacent R 8 And R 11 and the adjacent R 8 The atoms are joined together to form a fused substituted or unsubstituted C 3 -C 8 Cycloalkyl, or fused substituted or unsubstituted C 2 -C 5 In some embodiments, R 11 With adjacent R 8 And R 11 and the adjacent R 8 The atoms are joined together to form a fused substituted or unsubstituted C 2 -C 5 In some embodiments, R11 With adjacent R 8 And R 11 and the adjacent R 8 The linked atoms together form a fused substituted or unsubstituted dioxolane or a fused substituted or unsubstituted dioxane.

[0153] In some embodiments, each R 8 are independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 , or –NR 9 C(=O)R 10 ; and R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted monocyclic carbocycle, substituted or unsubstituted monocyclic heterocycle, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 ,–NR 9 C(=O)R 10 ,–NR 9 C(=O)OR 10 ,–NR 9 C(=O)N(R 9 ) 2 , –C(R 9 )=N-OR 9 ,–SR 9 , –S(=O)R 9 ,–SO 2 R 9 , or –SO 2 N(R 9 ) 2In some embodiments, each R 8 are independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 fluoroalkyl; and R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 , or –NR 9 C(=O)R 10 , or a substituted or unsubstituted monocyclic carbocyclic ring. In some embodiments, each R 8 are independently hydrogen or halogen; and R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , or substituted or unsubstituted monocyclic cycloalkyl. In some embodiments, each R 8 are independently hydrogen or halogen; and R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , or substituted or unsubstituted monocyclic cycloalkyl. In some embodiments, each R 8 are independently hydrogen, -F or -Cl; and R 11 and R 12 are independently hydrogen, -F, -Cl, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 or -OCHF 2 .

[0154] In some embodiments, the compound has the structure of Formula (VI), or a pharmaceutically acceptable salt or solvate thereof:

[0155]

[0156] In some embodiments, R 3 is hydrogen or -CH 3 ; R 8 is hydrogen or halogen; R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 ; R c For hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted monocyclic C 3 -C 6 Cycloalkyl, or substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl; R f For -L 1 -R g ; L 1 Does not exist or C 1 -C 6 Alkylene; and R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 、-C(=O)N(R 9 ) 2 , substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl.

[0157] In some embodiments, the compound has the structure of Formula (VIa) or (VIb), or a pharmaceutically acceptable salt or solvate thereof:

[0158]

[0159] In some embodiments, R 3 is hydrogen or -CH 3 ; R 8 is hydrogen or halogen; R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 ; R c For hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted monocyclic C 3 -C 6 Cycloalkyl, or substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl; R f For -L 1 -R g ; L 1 Does not exist or C 1 -C 6 Alkylene; and R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 、-C(=O)N(R 9 ) 2 , substituted or unsubstituted monocyclic C 2 -C 5 In some embodiments, R cFor hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 Heteroalkyl; R f For -L 1 -R g ; L 1 Does not exist or C 1 -C 6 Alkylene; and R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, or -CO 2 R 9 .

[0160] In some embodiments, R 8 is hydrogen, -F or -Cl; R 11 and R 12 are independently hydrogen, -F, -Cl, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 or -OCHF 2 ; and R c Hydrogen, -F, -Cl, -CN, -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 、-CH 2 CH 2 CH 2 CH 3 、-CH 2 CH(CH 3 ) 2 、-CH(CH 3 )(CH 2 CH 3 )、-C(CH 3 ) 3 、-CH 2 F, -CHF 2 , -CF3 ,-CH 2 CF 3 ,-OCH 3 ,-OCH 2 CH 3 ,-OCF 3 ,-OCH 2 CHF 2 ,-OCH 2 CF 3 ,-OCH 2 CH 2 OCH 3 ,-O-(cyclopropyl),-O-CH 2 -(cyclopropyl),-O-CH 2 -(phenyl),-OCH 2 CO 2 H,-OCH 2 CH 2 CO 2 H,-OCH 2 CH 2 CH 2 CO 2 H,-OCH 2 CO 2 CH 3 ,-OCH 2 CH 2 CO 2 CH 3 ,-OCH 2 CH 2 CH 2 CO 2 CH 3 ,-OCH 2 CO 2 CH 2 CH 3 ,-OCH 2 CH 2 CO 2 CH 2 CH 3 ,-OCH 2 CH 2 CH 2 CO 2 CH 2 CH 3 ,-CO 2 CH 3 ,-CO 2 CH 2 CH 3 ,-C(=O)NH 2 ,-CONHCH 3 ,-C(=O)N(CH 3) 2 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl. In some embodiments, R c Hydrogen, -F, -Cl, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCH 2 CH 3 、-OCH 2 CHF 2 、-OCH 2 CF 3 、-OCH 2 CH 2 OCH 3 , -O-(cyclopropyl), -O-CH 2 -(cyclopropyl), -O-CH 2 -(phenyl), -OCH 2 CO 2 H, -OCH 2 CH 2 CO 2 H, -OCH 2 CH 2 CH 2 CO 2 H, -OCH 2 CO 2 CH 3 、-OCH 2 CH 2 CO 2 CH 3 、-OCH 2 CH 2 CH 2 CO 2 CH 3 、-OCH 2 CO 2 CH 2 CH 3 、-OCH 2 CH 2 CO 2 CH 2 CH 3 , or -OCH 2 CH 2 CH 2 CO 2 CH 2 CH 3 In some embodiments, R c Hydrogen, -CN, -CH 3 , -CF 3 、-OCH 3、-OCF 3 , -CO 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 , or -C(=O)N(CH 3 ) 2 , or cyclopropyl. In some embodiments, R c Hydrogen, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , -CO 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 , or -C(=O)N(CH 3 ) 2 .

[0161] In some embodiments, the compound has the structure of Formula (VIa-1) or (VIb-1), or a pharmaceutically acceptable salt or solvate thereof:

[0162]

[0163] In some embodiments, R 3 is hydrogen or -CH 3 ; and R c Hydrogen, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , -CO 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 , or -C(=O)N(CH 3 ) 2 In some embodiments, R 11 and R 12 are independently hydrogen, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, –CN, or –OR 9 In some embodiments, R 11 and R 12 are independently hydrogen, -F, -Cl, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF3 , or -OCHF 2 In some embodiments, R 11 and R 12 Each is independently halogen. In some embodiments, R 11 and R 12 Each is independently -F or -Cl. In some embodiments, R 11 and R 12 Each is -F.

[0164] In some embodiments, ring A is a bicyclic heteroaryl. In some embodiments, ring A is a 9-membered or 10-membered bicyclic heteroaryl. In some embodiments, ring A is indolyl, isoindolyl, indazolyl, benzimidazolyl, azaindolyl, benzisoxazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoxadiazolyl, benzothiadiazolyl, quinolyl, isoquinolyl, quinoxalinyl, or quinazolinyl. In some embodiments, ring A is benzimidazolyl, indazolyl, or benzoxadiazolyl. In some embodiments, ring A is benzimidazolyl.

[0165] In some embodiments, the compound has the structure of Formula (VII), or a pharmaceutically acceptable salt or solvate thereof:

[0166]

[0167] in:

[0168] R 8 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 3 -C 6 Cycloalkyl.

[0169] In some embodiments, the compound has the structure of Formula (VIIa) or (VIIb), or a pharmaceutically acceptable salt or solvate thereof:

[0170]

[0171] In some embodiments, R c For hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , C 1 -C 6 Alkyl, C 1 -C 6Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 Heteroalkyl; R f For -L 1 -R g ; L 1 Does not exist or C 1 -C 6 Alkylene; and R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, or -CO 2 R 9 In some embodiments, R 8 Hydrogen, -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 、-CH 2 CH 2 CH 2 CH 3 、-CH 2 CH(CH 3 ) 2 、-CH(CH 3 )(CH 2 CH 3 ), or -C(CH 3 ) 3 ; and R c Hydrogen, -F, -Cl, -CN, -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 、-CH 2 CH 2 CH 2 CH 3 、-CH 2 CH(CH 3 ) 2 、-CH(CH 3 )(CH 2 CH 3 )、-C(CH 3 ) 3 、-CH2 F, -CHF 2 , -CF 3 , -CH 2 CF 3 , -OCH 3 , -OCH 2 CH 3 , -OCF 3 , -OCH 2 CHF 2 , -OCH 2 CF 3 , -OCH 2 CH 2 OCH 3 , -O-(cyclopropyl), -O-CH 2 -(cyclopropyl), -O-CH 2 -(phenyl), -OCH 2 CO 2 H, -OCH 2 CH 2 CO 2 H, -OCH 2 CH 2 CH 2 CO 2 H, -OCH 2 CO 2 CH 3 , -OCH 2 CH 2 CO 2 CH 3 , -OCH 2 CH 2 CH 2 CO 2 CH 3 , -OCH 2 CO 2 CH 2 CH 3 , -OCH 2 CH 2 CO 2 CH 2 CH 3 , -OCH 2 CH 2 CH 2 CO 2 CH 2 CH 3 , -CO 2 CH 3 , -CO 2 CH 2 CH 3 , -C(=O)NH 2 , -CONHCH3 、-C(=O)N(CH 3 ) 2 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl. In some embodiments, R 8 Hydrogen, -CH 3 、-CH 2 CH 3 ; and R c Hydrogen, -F, -Cl, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCH 2 CH 3 、-OCH 2 CHF 2 、-OCH 2 CF 3 、-OCH 2 CH 2 OCH 3 , -O-(cyclopropyl), -O-CH 2 -(cyclopropyl), -O-CH 2 -(phenyl), -OCH 2 CO 2 H, -OCH 2 CH 2 CO 2 H, -OCH 2 CH 2 CH 2 CO 2 H, -OCH 2 CO 2 CH 3 、-OCH 2 CH 2 CO 2 CH 3 、-OCH 2 CH 2 CH 2 CO 2 CH 3 、-OCH 2 CO 2 CH 2 CH 3 、-OCH 2 CH 2 CO 2 CH 2 CH 3 , or -OCH 2 CH 2 CH 2 CO 2 CH2 CH 3 In some embodiments, R c Hydrogen, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , -CO 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 , or -C(=O)N(CH 3 ) 2 , or cyclopropyl. In some embodiments, R c Hydrogen, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , -CO 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 , or -C(=O)N(CH 3 ) 2 .

[0172] In some embodiments, n is 0, 1, 2, or 3. In some embodiments, n is 0, 1, or 2. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 2 or 3. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3.

[0173] In some embodiments, for Among them A 1 and A 2 Each independently is C–R 8 or N; and A 3 C–R 12 Or N. In some embodiments, for Among them A 2 C–R 8 Or N. In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for Where R 8 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 3 -C 6 Cycloalkyl.

[0174] In some embodiments, R 7 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 3 -C 4 Cycloalkyl, or substituted or unsubstituted C 2 -C 3 In some embodiments, R 7 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 3 -C 4 In some embodiments, R 7 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 In some embodiments, R 7 is hydrogen or C 1 -C 6 In some embodiments, R 7 is hydrogen or -CH 3 In some embodiments, R 7 In some embodiments, R 7 -CH 3 .

[0175] In some embodiments, R 6 is substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8Fluoroalkyl, substituted or unsubstituted C 1 -C 8 Heteroalkyl, or -L 2 -R 6a ; L 2 is absent, substituted or unsubstituted C 1 -C 8 Alkylene, or -CHR 6b -; R 6a is substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 Heteroaryl; R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl.

[0176] In some embodiments, R 6 is substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 Fluoroalkyl, or substituted or unsubstituted C 1 -C 8 In some embodiments, R 6 C 1 -C 8 Alkyl, C 1 -C 8 Fluoroalkyl, or substituted or unsubstituted C 1 -C 8 In some embodiments, R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 1 -C 6 In some embodiments, R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or C 1-C 6 In some embodiments, R 6 is substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 In some embodiments, R 6 is substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 In some embodiments, R 6 C 1 -C 6 Alkyl or C 1 -C 6 In some embodiments, R 6 C 1 -C 6 In some embodiments, R 6 C 1 -C 6 In some embodiments, R 6 -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 、-CH 2 CH 2 CH 2 CH 3 、-CH 2 CH(CH 3 ) 2 、-CH(CH 3 )(CH 2 CH 3 )、-CH(CH 2 CH 3 )(CH 2 CH 3 )、-CH(CH 2 CH 2 CH 3 )(CH 2 CH 3 )、-C(CH 3 )(CHCH 3 ) 2 、-C(CH 3 ) 3 、-CH 2F, -CHF 2 , -CF 3 、-CH 2 CF 3 、-CH(CF 3 )(CH 3 )、-CH(CF 3 )(CH 2 CH 3 ),-CH 2 CF 2 CH 3 , or -CH(CH 3 )(CH 2 CF 3 In some embodiments, R 6 -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(CH 3 )(CH 2 CH 3 )、-CH(CH 2 CH 3 )(CH 2 CH 3 ),-CH 2 CF 3 、-CH(CF 3 )(CH 3 ), or -CH(CF 3 )(CH 2 CH 3 ).

[0177] In some embodiments, R 6 For -L 2 -R 6a .

[0178] In some embodiments, L 2 is absent, substituted or unsubstituted C 1 -C 8 Alkylene, or -CHR 6b -. In some embodiments, L 2 is absent, substituted or unsubstituted C 1 -C 6 Alkylene, or -CHR 6b-. In some embodiments, L 2 does not exist, C 1 -C 6 Alkylene, or -CHR 6b -. In some embodiments, L 2 does not exist, C 1 -C 4 Alkylene, or -CHR 6b -. In some embodiments, L 2 Does not exist, -CH 2 -、-CH 2 CH 2 -、-CH 2 CH 2 CH 2 -, or -CHR 6b -. In some embodiments, L 2 -CH 2 -、-CH 2 CH 2 -、-CH 2 CH 2 CH 2 -, or -CHR 6b -. In some embodiments, L 2 -CH 2 -or-CHR 6b -. In some embodiments, L 2 -CH 2 -、-CH(CH 3 )- or -CH(CF 3 )-.

[0179] In some embodiments, R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 In some embodiments, R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 4 In some embodiments, R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or C 3 -C4 In some embodiments, R 6b For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or C 3 -C 4 In some embodiments, R 6b Hydrogen, -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 , -CHF 2 、-CH 2 F, -CF 3 In some embodiments, R 6b Hydrogen, -CH 3 , -CHF 2 , -CF 3 In some embodiments, R 6b Hydrogen, -CH 3 , -CF 3 , or cyclopropyl. In some embodiments, R 6b Hydrogen, -CH 3 , or -CF 3 .

[0180] In some embodiments, R 6a is a substituted or unsubstituted monocyclic C 3 -C 8 Cycloalkyl, substituted or unsubstituted polycyclic C 5 -C 10 cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted indanyl, substituted or unsubstituted tetrahydronaphthyl, substituted or unsubstituted naphthyl, substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, substituted or unsubstituted polycyclic C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted monocyclic C 1 -C 5 Heteroaryl, or substituted or unsubstituted bicyclic C 6 -C 9 In some embodiments, R 6a is a substituted or unsubstituted monocyclic C 3 -C 6Cycloalkyl, substituted or unsubstituted bridged C 5 -C 10 Cycloalkyl, substituted or unsubstituted spirocyclic C 5 -C 10 In some embodiments, R 6a is a substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, substituted or unsubstituted bridged C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted spirocyclic C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted monocyclic C 1 -C 5 Heteroaryl, or substituted or unsubstituted bicyclic C 6 -C 9 Heteroaryl.

[0181] In some embodiments, R 6a is a substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 5 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted monocyclic C 2 -C 3 Heterocycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 4 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 In some embodiments, R 6a is a substituted or unsubstituted monocyclic 3-membered or 4-membered monocyclic cycloalkyl, a 3-membered or 4-membered monocyclic heterocycloalkyl, a substituted or unsubstituted monocyclic or bicyclic C 5 -C 10 cycloalkyl, or substituted or unsubstituted 5- to 10-membered heteroaryl.

[0182] In some embodiments, R 6a is substituted or unsubstituted C 3 -C 4 Cycloalkyl, or substituted or unsubstituted 3-membered or 4-membered C 2 -C 3 In some embodiments, R 6ais substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted azetidinyl, or substituted or unsubstituted oxetanyl. In some embodiments, R 6a is substituted or unsubstituted C 3 -C 4 In some embodiments, R 6a is substituted or unsubstituted cyclopropyl, or substituted or unsubstituted cyclobutyl. In some embodiments, R 6a is a substituted or unsubstituted cyclopropyl. 6a is a substituted or unsubstituted cyclobutyl group.

[0183] In some embodiments, L 2 is absent, substituted or unsubstituted C 1 -C 8 Alkylene, or -CHR 6b -; R 6a is substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl; and R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 In some embodiments, L 2 does not exist, C 1 -C 6 Alkylene, or -CHR 6b -; R 6a is a substituted or unsubstituted monocyclic C 3 -C 8 Cycloalkyl, substituted or unsubstituted polycyclic C 5 -C 10 cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted indanyl, substituted or unsubstituted tetrahydronaphthyl, substituted or unsubstituted naphthyl, substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, substituted or unsubstituted polycyclic C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted monocyclic C 1-C 5 Heteroaryl, or substituted or unsubstituted bicyclic C 6 -C 9 heteroaryl; and R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl.

[0184] In some embodiments, L 2 does not exist, C 1 -C 4 Alkylene, or -CHR 6b -; and R 6b For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 In some embodiments, R 6a is a substituted or unsubstituted monocyclic C 3 -C 6 Cycloalkyl, substituted or unsubstituted bridged C 5 -C 10 Cycloalkyl, substituted or unsubstituted spirocyclic C 5 -C 10 In some embodiments, R 6a is a substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, substituted or unsubstituted bridged C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted spirocyclic C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted monocyclic C 1 -C 5 Heteroaryl, or substituted or unsubstituted bicyclic C 6 -C 9 Heteroaryl.

[0185] In some embodiments, R 6a is substituted or unsubstituted C 3 -C 4 Cycloalkyl, or substituted or unsubstituted 3-membered or 4-membered C 2 -C3 heterocycloalkyl; and R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 4 In some embodiments, L 2 Does not exist, -CH 2 -、-CH 2 CH 2 -、-CH 2 CH 2 CH 2 -, or -CHR 6b -; R 6a is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted azetidinyl, or substituted or unsubstituted oxetanyl; and R 6b Hydrogen, -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 , -CHF 2 、-CH 2 F, -CF 3 , cyclopropyl or cyclobutyl.

[0186] In some embodiments, R 6 and R 7 Together with the nitrogen to which they are attached, they form a substituted or unsubstituted N-containing heterocyclic ring. 6 and R 7 Together with the nitrogen to which they are attached, they form a substituted or unsubstituted N-containing heterocyclic ring that is monocyclic, bicyclic, or polycyclic. 6 and R 7 Together with the nitrogen to which they are attached, they form a substituted or unsubstituted N-containing heterocycloalkyl. 6 and R 7 Together with the nitrogen to which they are attached, they form a substituted or unsubstituted monocyclic N-containing heterocycloalkyl, or a substituted or unsubstituted polycyclic N-containing heterocycloalkyl. 6 and R 7 Together with the nitrogen to which they are attached, they form a substituted or unsubstituted monocyclic N-containing heterocycloalkyl containing 1-2 N atoms, 0-2 O atoms, and 0-1 S. In some embodiments, R 6and R 7 Together with the nitrogen to which they are attached, they form a substituted or unsubstituted bicyclic N-containing C 5 -C 10 Heterocycloalkyl, wherein the bicyclic N-containing C 5 -C 10 Heterocycloalkyl is a fused bicyclic C 5 -C 10 Heterocycloalkyl, bridged bicyclic C 5 -C 10 Heterocycloalkyl, or spirobicyclic C 5 -C 10 Heterocycloalkyl.

[0187] In certain embodiments,

[0188] R 7 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 fluoroalkyl; and

[0189] R 6 is substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 Fluoroalkyl, substituted or unsubstituted C 1 -C 8 Heteroalkyl, or -L 2 -R 6a ;

[0190] L 2 is absent, substituted or unsubstituted C 1 -C 8 Alkylene, or -CHR 6b -;

[0191] R 6a is substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0192] R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl;

[0193] or R 6 and R 7 Together with the nitrogen to which they are attached they form a substituted or unsubstituted N-containing heterocycloalkyl.

[0194] In some embodiments,

[0195] X is N or CH;

[0196] Y is N or CH;

[0197] Z is N or C–R c ;

[0198] R c For hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 heteroalkyl;

[0199] R f For -L 1 -R g ;

[0200] L 1 does not exist, C 1 -C 6 Alkylene, or C 1 -C 6 Fluoroalkylene;

[0201] R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 , or -C(=O)N(R 9 ) 2 ;

[0202] R 1 is hydrogen;

[0203] R 2 H or C 1 -C 6 alkyl;

[0204] R 3 For hydrogen, C 1 -C 6 Alkyl or C 1 -C 6 Fluoroalkyl;

[0205] R 4 For hydrogen, halogen, C 1 -C 6 Alkyl or C 1 -C 6 Fluoroalkyl;

[0206] R 5 For hydrogen, halogen, C 1 -C 6 Alkyl or C 1 -C 6 Fluoroalkyl;

[0207] R 6 C 1 -C 8 Alkyl, C 1 -C 8 Fluoroalkyl, or -L 2 -R 6a ;

[0208] L 2 does not exist, C 1 -C 6 Alkylene, or -CHR 6b -;

[0209] R 6a is substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0210] R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl;

[0211] R 7 H or C 1 -C 6 alkyl;

[0212] or R 6 and R 7 Together with the nitrogen to which they are attached they form a substituted or unsubstituted heterocyclic ring.

[0213] In some embodiments, X is N or CH;

[0214] Y is N or CH;

[0215] Z is N or C–R c ;

[0216] R c Hydrogen, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , -CO 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 , or -C(=O)N(CH 3 ) 2 ;

[0217] R 1 is hydrogen;

[0218] R 2 is hydrogen;

[0219] R 3 Hydrogen, -CH 3 、-CH 2 OH, -CH 2 OCH 3 、-CH 2 CH 2 F, -CH 2 CHF 2 , or -CH 2 CF 3 ;

[0220] R 4 is hydrogen or F;

[0221] R 5 is hydrogen or F;

[0222] R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or -L 2 -R 6a ;

[0223] L 2 does not exist, C 1-C 6 Alkylene or -CHR 6b -;

[0224] R 6a is a substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 5 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted monocyclic C 2 -C 3 Heterocycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 4 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0225] R 6b For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl;

[0226] R 7 H or C 1 -C 6 alkyl;

[0227] or R 6 and R 7 Together with the nitrogen to which they are attached they form a substituted or unsubstituted heterocyclic ring.

[0228] In some embodiments, the compound has the structure of Formula (VIII) or a pharmaceutically acceptable salt or solvate thereof:

[0229]

[0230] in:

[0231] Ring A is phenyl or pyridyl;

[0232] R a and R c are independently hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , –CO 2 R 9 , –C(=O)N(R 9 ) 2, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, substituted or unsubstituted monocyclic C 3 -C 6 Cycloalkyl, or substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl;

[0233] R f For -L 1 -R g ;

[0234] L 1 does not exist, or C 1 -C 6 Alkylene;

[0235] R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 , or -C(=O)N(R 9 ) 2 , or a substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl;

[0236] R 1 is hydrogen;

[0237] R 2 H or C 1 -C 6 alkyl;

[0238] R 3 For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl or C 1 -C 4 heteroalkyl;

[0239] R 4 For hydrogen, halogen, C 1 -C 4 Alkyl or C 1 -C 4 Fluoroalkyl;

[0240] R 5 For hydrogen, halogen, C 1 -C 4 Alkyl or C1 -C 4 Fluoroalkyl;

[0241] R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or -L 2 -R 6a ;

[0242] L 2 does not exist, C 1 -C 6 Alkylene or -CHR 6b -;

[0243] R 6a is a substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 5 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted monocyclic C 2 -C 3 Heterocycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 4 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0244] R 6b For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl;

[0245] R 7 H or C 1 -C 6 alkyl;

[0246] Each R 8 are independently hydrogen, halogen, C 1 -C 6 Alkyl, or C 1 -C 6 Fluoroalkyl;

[0247] R 11 and R 12 are independently hydrogen, halogen, C 1 -C6 Alkyl, C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 , or –NR 9 C(=O)R 10 , or a substituted or unsubstituted monocyclic C 3 -C 8 Cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, or substituted or unsubstituted monocyclic C 1 -C 5 heteroaryl;

[0248] Each R 9 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl;

[0249] or two R on the same N atom 9 together with the N atom to which they are attached, form a substituted or unsubstituted N-containing heterocyclic ring;

[0250] Each R 10 are independently substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 fluoroalkyl; and

[0251] n is 0-3.

[0252] In some embodiments, the compound has the structure of Formula (VIIIa) or (VIIIb) or a pharmaceutically acceptable salt or solvate thereof:

[0253]

[0254] In some embodiments, the compound has the structure of Formula (VIIIa-1) or (VIIIb-1) or a pharmaceutically acceptable salt or solvate thereof:

[0255]

[0256] In some embodiments, R 3is hydrogen or -CH 3 ; R 4 and R 5 Each is hydrogen; each R 8 are independently hydrogen or halogen; and R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 .

[0257] In some embodiments, R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or -L 2 -R 6a ; L 2 does not exist, C 1 -C 6 Alkylene or -CHR 6b -; R 6a is a substituted or unsubstituted monocyclic 3-4 membered C 3 -C 4 Cycloalkyl, substituted or unsubstituted monocyclic or bicyclic 5-10 membered C 5 -C 10 Cycloalkyl, substituted or unsubstituted 6-10 membered C 6 -C 10 Aryl, substituted or unsubstituted monocyclic 3-4 membered C 2 -C 3 Heterocycloalkyl, substituted or unsubstituted monocyclic or bicyclic 5-10 membered C 4 -C 10 Heterocycloalkyl, or substituted or unsubstituted 5-10 membered C 1 -C 9 Heteroaryl; R 6b For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl; R 7 is hydrogen or C 1 -C 6 alkyl.

[0258] In some embodiments, R 6 C 1 -C 6Alkyl, C 1 -C 6 Fluoroalkyl, or -L 2 -R 6a ; L 2 does not exist, C 1 -C 4 Alkylene or -CHR 6b -; R 6a is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted aziridine, substituted or unsubstituted oxetanyl, or substituted or unsubstituted theitanyl; R 6b For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl; R 7 is hydrogen or C 1 -C 6 alkyl.

[0259] In some embodiments, the compound has the structure of Formula (IX) or a pharmaceutically acceptable salt or solvate thereof:

[0260]

[0261] in:

[0262] A 1 C–R 8 ; and A 2 C–R 8 ;or

[0263] A 1 is N; and A 2 C–R 8 ;or

[0264] A 1 C–R 8 ; and A 2 is N;

[0265] R a and R c are independently hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , C 1 -C6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, substituted or unsubstituted monocyclic C 3 -C 6 Cycloalkyl, or substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl;

[0266] R f For -L 1 -R g ;

[0267] L 1 does not exist, or C 1 -C 6 Alkylene;

[0268] R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 , or -C(=O)N(R 9 ) 2 , or a substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl;

[0269] R 3 For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl or C 1 -C 4 heteroalkyl;

[0270] R 4 For hydrogen, halogen, C 1 -C 4 Alkyl or C 1 -C 4 Fluoroalkyl;

[0271] R 5 For hydrogen, halogen, C 1 -C 4 Alkyl or C 1 -C4 fluoroalkyl;

[0272] R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or -L 2-R 6a ;

[0273] L 2 does not exist, C 1 -C 6 Alkylene or -CHR 6b -;

[0274] R 6a is a substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 5 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted monocyclic C 2 -C 3 Heterocycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 4 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0275] R 6b For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl;

[0276] R 7 H or C 1 -C 6 alkyl;

[0277] Each R 8 are independently hydrogen, halogen, C 1 -C 6 Alkyl, or C 1 -C 6 Fluoroalkyl;

[0278] R 11 and R 12 are independently hydrogen, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 )2 , or –NR 9 C(=O)R 10 , or a substituted or unsubstituted monocyclic C 3 -C 8 Cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, or substituted or unsubstituted monocyclic C 1 -C 5 heteroaryl;

[0279] Each R 9 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl;

[0280] or two R on the same N atom 9 together with the N atom to which they are attached, form a substituted or unsubstituted N-containing heterocyclic ring; and

[0281] Each R 10 are independently substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl.

[0282] In some embodiments, the compound has the structure of Formula (IXa) or (IXb) or a pharmaceutically acceptable salt or solvate thereof:

[0283]

[0284] In some embodiments, the compound has the structure of Formula (VIIIa-1) or (VIIIb-1) or a pharmaceutically acceptable salt or solvate thereof:

[0285]

[0286] In some embodiments, R 3 is hydrogen or -CH 3 ; R 4 and R 5 Each is hydrogen; each R 8 are independently hydrogen or halogen; and R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C6 alkyl, substituted or unsubstituted C 1 -C 6Fluoroalkyl, –CN, –OR 9 .

[0287] In some embodiments, R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or -L 2 -R 6a ; L 2 does not exist, C 1 -C 6 Alkylene or -CHR 6b -; R 6a is a substituted or unsubstituted monocyclic 3-4 membered C 3 -C 4 Cycloalkyl, substituted or unsubstituted monocyclic or bicyclic 5-10 membered C 5 -C 10 Cycloalkyl, substituted or unsubstituted 6-10 membered C 6 -C 10 Aryl, substituted or unsubstituted monocyclic 3-4 membered C 2 -C 3 Heterocycloalkyl, substituted or unsubstituted monocyclic or bicyclic 5-10 membered C 4 -C 10 Heterocycloalkyl, or substituted or unsubstituted 5-10 membered C 1 -C 9 Heteroaryl; R 6b For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl; R 7 is hydrogen or C 1 -C 6 alkyl.

[0288] In some embodiments, R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or -L 2 -R 6a ; L 2 does not exist, C 1 -C 4 Alkylene or -CHR 6b -; R 6ais substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted aziridine, substituted or unsubstituted oxetanyl, or substituted or unsubstituted theitanyl; R 6b For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl; R 7 is hydrogen or C 1 -C 6 alkyl.

[0289] In some embodiments, each R 9 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 3 -C 7 Cycloalkyl, or substituted or unsubstituted monocyclic 3- to 8-membered heterocycloalkyl; or two R on the same N atom 9 Together with the N atom to which they are attached, they form a substituted or unsubstituted N-containing heterocyclic ring; and each R 10 are independently substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 3 -C 7 In some embodiments, each R 9 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl; or two R on the same N atom 9 Together with the N atom to which they are attached, they form a substituted or unsubstituted N-containing heterocyclic ring; and each R 10 are independently substituted or unsubstituted C 1 -C 6 Alkyl or substituted or unsubstituted C 1 -C 6 In some embodiments, each R 9 are independently hydrogen, C 1 -C6 Alkyl, or C 1 -C 6 Fluoroalkyl; or two R on the same N atom 9 Together with the N atom to which they are attached, they form a substituted or unsubstituted N-containing heterocyclic ring; and each R 10 Independently for C 1 -C 6 Alkyl or C 1 -C 6 Fluoroalkyl.

[0290] In one aspect, provided herein is a compound of formula (A1) or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof:

[0291]

[0292] in:

[0293] Ring A is a carbocyclic ring or a heterocyclic ring;

[0294] X is N or C–R a ; Y is N or C–R b ; Z is N or C–R c ;

[0295] R L is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl;

[0296] R a , R b and R c are independently hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted monocyclic carbocycle, or substituted or unsubstituted monocyclic heterocycle;

[0297] Rf For -L 1 -R g ;

[0298] L 1 does not exist, C 1 -C 6 Alkylene, C 1 -C 6 Fluoroalkylene, or C 1 -C 6 heteroalkylene;

[0299] R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 、-C(=O)N(R 9 ) 2 , or a substituted or unsubstituted monocyclic heterocycle;

[0300] R 1 and R 2 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 6 Cycloalkyl, or substituted or unsubstituted C 3 -C 5 Heterocycloalkyl;

[0301] R 3 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 heteroalkyl;

[0302] R 4 and R 5 are independently hydrogen, halogen, –OR 9 , –N(R 9 ) 2、–CN、–CO 2 R 9 , –C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 heteroalkyl;

[0303] R 6 is substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 Fluoroalkyl, substituted or unsubstituted C 1 -C 8 Heteroalkyl, or -L 2 -R 6a ;

[0304] L 2 is absent, substituted or unsubstituted C 1 -C 8 Alkylene, or -CHR 6b -;

[0305] R 6a is substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0306] R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl;

[0307] R 7 is hydrogen, substituted or unsubstituted C 1-C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0308] or R 6 and R 7 together with the nitrogen to which they are attached, form a substituted or unsubstituted N-containing heterocyclic ring;

[0309] Each R 8 , R 11 and R 12 are independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted monocyclic carbocycle, substituted or unsubstituted monocyclic heterocycle, –CN, –OR 9 , –C(=O)R 10 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 ,–NR 9 C(=O)R 10 ,–NR 9 C(=O)OR 10 ,–NR 9 C(=O)N(R 9 ) 2 , –C(R 9 )=N-OR 9 ,–SR 9 , –S(=O)R 9 ,–SO 2 R 9 , or –SO 2 N(R 9 ) 2 ;

[0310] or R 11 With adjacent R 8 And R 11 and the adjacent R 8 The atoms joined together form a fused substituted or unsubstituted carbocyclic ring, or a fused substituted or unsubstituted heterocyclic ring;

[0311] Each R 9 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 7 Cycloalkyl, substituted or unsubstituted monocyclic 3- to 8-membered heterocycloalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted monocyclic heteroaryl;

[0312] or two R on the same N atom 9 together with the N atom to which they are attached, form a substituted or unsubstituted N-containing heterocyclic ring;

[0313] Each R 10 are independently substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 7 cycloalkyl, substituted or unsubstituted monocyclic 3- to 8-membered heterocycloalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted monocyclic heteroaryl; and

[0314] n is 0-3.

[0315] In some embodiments, R L is substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 In some embodiments, R L C 1 -C 6 Alkyl or C 1 -C 6 In some embodiments, R L C1 -C 6 In some embodiments, R L -CH 3 .

[0316] In some embodiments, R 1 and R 2 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 In some embodiments, R 1 and R 2 are independently hydrogen or substituted or unsubstituted C 1 -C 6 In some embodiments, R 1 and R 2 are independently hydrogen or C 1 -C 6 In some embodiments, R 1 is hydrogen and R 2 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 In some embodiments, R 1 is hydrogen and R 2 is hydrogen or substituted or unsubstituted C 1 -C 6 Alkyl. 1 is hydrogen and R 2 is hydrogen or C 1 -C 6 In some embodiments, R 1 and R 2 Each is hydrogen.

[0317] In some embodiments, R 1 is hydrogen; R 2 is hydrogen or substituted or unsubstituted C 1 -C 6 alkyl; and R L is substituted or unsubstituted C 1 -C 6 In some embodiments, R 1 is hydrogen; R 2 is hydrogen; and RL -CH 3 .

[0318] In some embodiments, X, Y, Z, R a , R b , R c As described for formula (I).

[0319] In some embodiments, X is C-R a ; Y is N; and Z is C–R c ; or X is CH; Y is N; and Z is C–R c ; or X is C–R a ; Y is N; and Z is CH; or X is N; Y is C–R b ; and Z is C–R c ; or X is C–R a ; Y is C–R b ; and Z is N; or X is N; Y is N; and Z is C–R c ; or X is C–R a ; Y is N; and Z is N. In some embodiments, X is N or CH; Y is N or CH; and Z is N or C-R c .

[0320] In some embodiments, R a , R b and R c are independently hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 Heteroalkyl; R f For -L 1 -R g ; L 1 Does not exist or C 1 -C 6 Alkylene; and R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, or -CO 2 R 9 In some embodiments, R a , R b and R care independently hydrogen, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , -CO 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 , or -C(=O)N(CH 3 ) 2 , or cyclopropyl.

[0321] In some embodiments, Ring A, each R 8 , R 11 , R 12 and n are as described for formula (I).

[0322] In some embodiments, ring A is phenyl, monocyclic heteroaryl or bicyclic heteroaryl. In some embodiments, ring A is phenyl or monocyclic heteroaryl. In some embodiments, ring A is phenyl; or ring A is pyridyl; or ring A is ring A is pyrazolyl, thiazolyl, isoxazolyl or pyrimidinyl. In some embodiments, ring A is phenyl or pyridyl. In some embodiments, ring A is bicyclic heteroaryl. In some embodiments, ring A is benzimidazolyl, indazolyl, or benzoxadiazolyl.

[0323] In some embodiments, each R 8 are independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted monocyclic carbocycle, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 ,–NR 9 C(=O)R 10 ,–SO 2 R 9 , or –SO 2 N(R 9 ) 2 In some embodiments, each R 8 are independently hydrogen, halogen, C 1 -C 6 Alkyl, or C 1 -C 6 In some embodiments, each R 8are independently hydrogen or halogen.

[0324] In some embodiments, R 11 For halogen, substituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted monocyclic carbocycle, substituted or unsubstituted monocyclic heterocycle, –CN, –OR 9 , –C(=O)R 10 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 ,–NR 9 C(=O)R 10 ,–NR 9 C(=O)OR 10 ,–NR 9 C(=O)N(R 9 ) 2 , –C(R 9 )=N-OR 9 ,–SR 9 , –S(=O)R 9 ,–SO 2 R 9 , or –SO 2 N(R 9 ) 2 In some embodiments, R 11 For halogen, substituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted monocyclic carbocycle, substituted or unsubstituted monocyclic heterocycle, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 ,–NR 9 C(=O)R 10 ,–NR 9 C(=O)OR 10 ,–NR9 C(=O)N(R 9 ) 2 , –C(R 9 )=N-OR 9 ,–SR 9 , –S(=O)R 9 ,–SO 2 R 9 , or –SO 2 N(R 9 ) 2 In some embodiments, R 11 For halogen, substituted C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 , or –NR 9 C(=O)R 10 , substituted or unsubstituted monocyclic C 3 -C 8 Cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, or substituted or unsubstituted monocyclic C 1 -C 5 In some embodiments, R 11 For halogen, substituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 , or –NR 9 C(=O)R 10 , or a substituted or unsubstituted monocyclic carbocyclic ring. In some embodiments, R 11 For halogen, substituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 , or –NR 9 C(=O)R 10 , or a substituted or unsubstituted monocyclic C 3 -C 8 In some embodiments, R 11 For halogen, substituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , or substituted or unsubstituted monocyclic cycloalkyl. In some embodiments, R 11 For halogen, substituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , or a substituted or unsubstituted monocyclic C 3 -C 8 In some embodiments, R 11 For halogen, substituted C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , or a substituted or unsubstituted monocyclic C 3 -C 8 In some embodiments, R 11 For halogen, substituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 In some embodiments, R 11 For halogen, C 1 -C 6 Fluoroalkyl, –CN, or –OR 9 In some embodiments, R 11 -F, -Cl, -CN, -CF 3 、-OCH 3 、-OCF 3 , or -OCHF 2 In some embodiments, R 11 In some embodiments, R11 In some embodiments, R 11 In some embodiments, R 11 It is -Cl.

[0325] In some embodiments, R 11 With adjacent R 8 And R 11 and the adjacent R 8 The atoms connected together form a fused substituted or unsubstituted carbocyclic ring, or a fused substituted or unsubstituted heterocyclic ring. 11 With adjacent R 8 And R 11 and the adjacent R 8 The atoms are joined together to form a fused substituted or unsubstituted C 3 -C 8 Cycloalkyl, or fused substituted or unsubstituted C 2 -C 5 Heterocycloalkyl.

[0326] In some embodiments, R 12 is hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted monocyclic carbocycle, substituted or unsubstituted monocyclic heterocycle, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 ,–NR 9 C(=O)R 10 ,–NR 9 C(=O)OR 10 ,–NR 9 C(=O)N(R 9 ) 2 , –C(R 9 )=N-OR 9 ,–SR 9 , –S(=O)R 9 ,–SO 2 R 9 , or –SO 2 N(R 9 ) 2In some embodiments, R 12 For hydrogen, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 , or –NR 9 C(=O)R 10 , substituted or unsubstituted monocyclic C 3 -C 8 Cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, or substituted or unsubstituted monocyclic C 1 -C 5 In some embodiments, R 12 is hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , or a substituted or unsubstituted monocyclic C 3 -C 8 In some embodiments, R 12 For hydrogen, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, –CN, or –OR 9 In some embodiments, R 12 Hydrogen, -F, -Cl, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , or -OCHF 2 In some embodiments, R 12 is hydrogen or halogen. In some embodiments, R 12 It is hydrogen, -F or -Cl.

[0327] In some embodiments, n is 0, 1, 2, or 3. In some embodiments, n is 0, 1, or 2. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 2 or 3. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3.

[0328] In some embodiments, for Among them A 1 and A 2 Each independently is C–R 8 or N; and A 3 C–R 12 Or N. In some embodiments, for Among them A 2 C–R 8 Or N. In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for In some embodiments, for Where R 8 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 3 -C 6 Cycloalkyl.

[0329] In some embodiments, R 6 and R 7 As described for formula (I).

[0330] In some embodiments, R 7 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 3 -C 4In some embodiments, R 7 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 In some embodiments, R 7 is hydrogen or C 1 -C 6 alkyl.

[0331] In some embodiments, R 6 is substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 Fluoroalkyl, substituted or unsubstituted C 1 -C 8 Heteroalkyl, or -L 2 -R 6a ; L 2 is absent, substituted or unsubstituted C 1 -C 8 Alkylene, or -CHR 6b -; R 6a is substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 Heteroaryl; R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl.

[0332] In some embodiments, R 6 is substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 Fluoroalkyl, or substituted or unsubstituted C 1 -C 8 In some embodiments, R 6 C 1 -C 6Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 1 -C 6 In some embodiments, R 6 is substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 In some embodiments, R 6 is substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 In some embodiments, R 6 C 1 -C 6 Alkyl or C 1 -C 6 Fluoroalkyl.

[0333] In some embodiments, R 6 For -L 2 -R 6a .

[0334] In some embodiments, L 2 is absent, substituted or unsubstituted C 1 -C 8 Alkylene, or -CHR 6b -. In some embodiments, L 2 is absent, substituted or unsubstituted C 1 -C 6 Alkylene, or -CHR 6b -. In some embodiments, L 2 does not exist, C 1 -C 6 Alkylene, or -CHR 6b -. In some embodiments, L 2 does not exist, C 1 -C 4 Alkylene, or -CHR 6b -. In some embodiments, L 2 Does not exist, -CH 2 -、-CH 2 CH 2 -、-CH 2 CH 2 CH 2 -, or -CHR 6b -. In some embodiments, L 2 -CH2 -、-CH 2 CH 2 -、-CH 2 CH 2 CH 2 -, or -CHR 6b -. In some embodiments, L 2 -CH 2 -or-CHR 6b -. In some embodiments, L 2 -CH 2 -、-CH(CH 3 )- or -CH(CF 3 )-.

[0335] In some embodiments, R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 In some embodiments, R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 4 In some embodiments, R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or C 3 -C 4 In some embodiments, R 6b For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or C 3 -C 4 In some embodiments, R 6b Hydrogen, -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 , -CHF 2 、-CH 2 F, -CF3 In some embodiments, R 6b Hydrogen, -CH 3 , -CHF 2 , -CF 3 In some embodiments, R 6b Hydrogen, -CH 3 , -CF 3 , or cyclopropyl. In some embodiments, R 6b Hydrogen, -CH 3 , or -CF 3 .

[0336] In some embodiments, R 6a is a substituted or unsubstituted monocyclic C 3 -C 8 Cycloalkyl, substituted or unsubstituted polycyclic C 5 -C 10 cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted indanyl, substituted or unsubstituted tetrahydronaphthyl, substituted or unsubstituted naphthyl, substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, substituted or unsubstituted polycyclic C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted monocyclic C 1 -C 5 Heteroaryl, or substituted or unsubstituted bicyclic C 6 -C 9 In some embodiments, R 6a is a substituted or unsubstituted monocyclic C 3 -C 6 Cycloalkyl, substituted or unsubstituted bridged C 5 -C 10 Cycloalkyl, substituted or unsubstituted spirocyclic C 5 -C 10 In some embodiments, R 6a is a substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, substituted or unsubstituted bridged C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted spirocyclic C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted monocyclic C 1 -C 5Heteroaryl, or substituted or unsubstituted bicyclic C 6 -C 9 Heteroaryl.

[0337] In some embodiments, R 6a is a substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 5 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted monocyclic C 2 -C 3 Heterocycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 4 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 In some embodiments, R 6a is a substituted or unsubstituted monocyclic 3-membered or 4-membered monocyclic cycloalkyl, a 3-membered or 4-membered monocyclic heterocycloalkyl, a substituted or unsubstituted monocyclic or bicyclic C 5 -C 10 cycloalkyl, or substituted or unsubstituted 5- to 10-membered heteroaryl.

[0338] In some embodiments, R 6a is substituted or unsubstituted C 3 -C 4 Cycloalkyl, or substituted or unsubstituted 3-membered or 4-membered C 2 -C 3 In some embodiments, R 6a is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted azetidinyl, or substituted or unsubstituted oxetanyl. In some embodiments, R 6a is substituted or unsubstituted C 3 -C 4 In some embodiments, R 6a is substituted or unsubstituted cyclopropyl, or substituted or unsubstituted cyclobutyl. In some embodiments, R 6a is a substituted or unsubstituted cyclopropyl. 6a is a substituted or unsubstituted cyclobutyl group.

[0339] In some embodiments, R 6 is substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C8 Fluoroalkyl, substituted or unsubstituted C 1 -C 8 Heteroalkyl, or -L 2 -R 6a ; L 2 is absent, substituted or unsubstituted C 1 -C 8 Alkylene, or -CHR 6b -; R 6a is substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl; and R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 In some embodiments, R 6 C 1 -C 8 Alkyl, C 1 -C 8 Fluoroalkyl, substituted or unsubstituted C 1 -C 8 Heteroalkyl, or -L 2 -R 6a ; L 2 does not exist, C 1 -C 6 Alkylene, or -CHR 6b -; R 6a is a substituted or unsubstituted monocyclic C 3 -C 8 Cycloalkyl, substituted or unsubstituted polycyclic C 5 -C 10 cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted indanyl, substituted or unsubstituted tetrahydronaphthyl, substituted or unsubstituted naphthyl, substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, substituted or unsubstituted polycyclic C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted monocyclic C 1 -C 5 Heteroaryl, or substituted or unsubstituted bicyclic C6 -C 9 heteroaryl; and R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl.

[0340] In some embodiments, R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, or -L 2 -R 6a ; L 2 does not exist, C 1 -C 4 Alkylene, or -CHR 6b -; and R 6b For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 In some embodiments, R 6a is a substituted or unsubstituted monocyclic C 3 -C 6 Cycloalkyl, substituted or unsubstituted bridged C 5 -C 10 Cycloalkyl, substituted or unsubstituted spirocyclic C 5 -C 10 In some embodiments, R 6a is a substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, substituted or unsubstituted bridged C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted spirocyclic C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted monocyclic C 1 -C 5 Heteroaryl, or substituted or unsubstituted bicyclic C 6 -C 9 Heteroaryl.

[0341] In some embodiments, R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Heteroalkyl, or -L 2 -R 6a ; L 2 does not exist, C 1 -C 4 Alkylene, or -CHR 6b -; R 6a is substituted or unsubstituted C 3 -C 4 Cycloalkyl, or substituted or unsubstituted 3-membered or 4-membered C 2 -C 3 heterocycloalkyl; and R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 4 In some embodiments, R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Heteroalkyl, or -L 2 -R 6a ; L 2 Does not exist, -CH 2 -、-CH 2 CH 2 -、-CH 2 CH 2 CH 2 -, or -CHR 6b -; R 6a is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted azetidinyl, or substituted or unsubstituted oxetanyl; and R 6b Hydrogen, -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 , -CHF2 、-CH 2 F, -CF 3 , cyclopropyl or cyclobutyl.

[0342] In some embodiments, R 6 and R 7 Together with the nitrogen to which they are attached, they form a substituted or unsubstituted N-containing heterocyclic ring. 6 and R 7 Together with the nitrogen to which they are attached, they form a substituted or unsubstituted N-containing heterocycloalkyl. 6 and R 7 Together with the nitrogen to which they are attached they form a substituted or unsubstituted monocyclic N-containing heterocycloalkyl group containing 1-2 N atoms, 0-2 O atoms and 0-1 S.

[0343] In some embodiments, X is N or CH;

[0344] Y is N or CH;

[0345] Z is N or C–R c ;

[0346] R c For hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 heteroalkyl;

[0347] R f For -L 1 -R g ;

[0348] L 1 does not exist, C 1 -C 6 Alkylene, or C 1 -C 6 Fluoroalkylene;

[0349] R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 , or -C(=O)N(R 9 )2 ;

[0350] R 1 is hydrogen;

[0351] R 2 H or C 1 -C 6 alkyl;

[0352] R L C 1 -C 6 Alkyl or C 1 -C 6 Fluoroalkyl;

[0353] R 6 C 1 -C 8 Alkyl, C 1 -C 8 Fluoroalkyl, or -L 2 -R 6a ;

[0354] L 2 does not exist, C 1 -C 6 Alkylene, or -CHR 6b -;

[0355] R 6a is substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0356] R 6b For hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl;

[0357] R 7 H or C 1 -C 6 alkyl;

[0358] or R 6 and R 7 Together with the nitrogen to which they are attached they form a substituted or unsubstituted heterocyclic ring.

[0359] In some embodiments, X is N or CH;

[0360] Y is N or CH;

[0361] Z is N or C–R c ;

[0362] R c is hydrogen, -F, -Cl, -CN, -CH 3 , -CF 3 , -OCH 3 , -OCH 2 CH 3 , -OCH 2 CHF 2 , -OCH 2 CF 3 , -OCH 2 CH 2 OCH 3 , -O-(cyclopropyl), -O-CH 2 -(cyclopropyl), -O-CH 2 -(phenyl), -OCH 2 CO 2 H, -OCH 2 CH 2 CO 2 H, -OCH 2 CH 2 CH 2 CO 2 H, -OCH 2 CO 2 CH 3 , -OCH 2 CH 2 CO 2 CH 3 , -OCH 2 CH 2 CH 2 CO 2 CH 3 , -OCH 2 CO 2 CH 2 CH 3 , -OCH 2 CH 2 CO 2 CH 2 CH 3 , or -OCH 2 CH 2 CH 2 CO 2 CH 2 CH 3 ;

[0363] R 1 is hydrogen;

[0364] R 2 is hydrogen;

[0365] R L C 1 -C 6 alkyl;

[0366] R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or -L 2 -R 6a ;

[0367] L 2 does not exist, C 1 -C 6 Alkylene or -CHR 6b -;

[0368] R 6a is a substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 5 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted monocyclic C 2 -C 3 Heterocycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 4 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0369] R 6b For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl;

[0370] R 7 H or C 1 -C 6 alkyl;

[0371] or R 6 and R 7 Together with the nitrogen to which they are attached they form a substituted or unsubstituted heterocyclic ring.

[0372] In some embodiments, the compound has the structure of Formula (A2) or a pharmaceutically acceptable salt or solvate thereof:

[0373]

[0374] in:

[0375] Ring A is phenyl or pyridyl;

[0376] R a and R c are independently hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, substituted or unsubstituted monocyclic C 3 -C 6 Cycloalkyl, or substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl;

[0377] R f For -L 1 -R g ;

[0378] L 1 does not exist, or C 1 -C 6 Alkylene;

[0379] R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 , or -C(=O)N(R 9 ) 2 , or a substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl;

[0380] R 1 is hydrogen;

[0381] R 2 H or C 1-C 6 alkyl;

[0382] R L C 1 -C 6 Alkyl or C 1 -C 6 Fluoroalkyl;

[0383] R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or -L 2 -R 6a ;

[0384] L 2 does not exist, C 1 -C 6 Alkylene or -CHR 6b -;

[0385] R 6a is a substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 5 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted monocyclic C 2 -C 3 Heterocycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 4 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl;

[0386] R 6b For hydrogen, C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl;

[0387] R 7 H or C 1 -C 6 alkyl;

[0388] Each R 8 are independently hydrogen, halogen, C 1 -C 6 Alkyl, or C 1 -C 6Fluoroalkyl;

[0389] R 11 and R 12 are independently hydrogen, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 , or –NR 9 C(=O)R 10 , or a substituted or unsubstituted monocyclic C 3 -C 8 Cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, or substituted or unsubstituted monocyclic C 1 -C 5 heteroaryl;

[0390] Each R 9 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl;

[0391] or two R on the same N atom 9 together with the N atom to which they are attached, form a substituted or unsubstituted N-containing heterocyclic ring; and

[0392] Each R 10 are independently substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl.

[0393] n is 0-3.

[0394] In some embodiments, each R 9 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 3 -C 7Cycloalkyl, or substituted or unsubstituted monocyclic 3- to 8-membered heterocycloalkyl; or two R on the same N atom 9 Together with the N atom to which they are attached, they form a substituted or unsubstituted N-containing heterocyclic ring; and each R 10 are independently substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 3 -C 7 In some embodiments, each R 9 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl; or two R on the same N atom 9 Together with the N atom to which they are attached, they form a substituted or unsubstituted N-containing heterocyclic ring; and each R 10 are independently substituted or unsubstituted C 1 -C 6 Alkyl or substituted or unsubstituted C 1 -C 6 In some embodiments, each R 9 are independently hydrogen, C 1 -C 6 Alkyl, or C 1 -C 6 Fluoroalkyl; or two R on the same N atom 9 Together with the N atom to which they are attached, they form a substituted or unsubstituted N-containing heterocyclic ring; and each R 10 Independently for C 1 -C 6 Alkyl or C 1 -C 6 Fluoroalkyl.

[0395] In some embodiments, the compounds described herein have the following structure:

[0396]

[0397] in,

[0398] As described in Table 1;

[0399] R 3 As described in Table 1;

[0400] R 4As described in Table 1;

[0401] R c As described in Table 1; and

[0402] NR 6 R 7 As described in Table 1.

[0403] In some embodiments, the compounds described herein have the following structure:

[0404]

[0405] in,

[0406] As described in Table 2;

[0407] R c as described in Table 2; and

[0408] NR 6 R 7 As described in Table 2.

[0409] In some embodiments, the compounds described herein have the following structure:

[0410]

[0411] in,

[0412] R 11 As described in Table 3;

[0413] R 12 as described in Table 3; and

[0414] NR 6 R 7 As described in Table 3.

[0415] In some embodiments, the compounds described herein have the following structure:

[0416]

[0417] in,

[0418] As described in Table 4;

[0419] R c as described in Table 4; and

[0420] NR 6 R 7 As described in Table 4.

[0421] In some embodiments, the compounds described herein have the following structure:

[0422]

[0423] in,

[0424] R c As described in Table 5;

[0425] R d As described in Table 5;

[0426] R e as described in Table 5; and

[0427] NR 6 R 7 As described in Table 5.

[0428] In some embodiments, the compounds described herein have the following structure:

[0429]

[0430] in,

[0431] NR 6 R 7 As described in Table 6.

[0432] In some embodiments, the compounds described herein have the following structure:

[0433]

[0434] in,

[0435] R c as described in Table 7; and

[0436] NR 6 R 7 As described in Table 7.

[0437] In some embodiments, the compounds described herein have the following structure:

[0438]

[0439] in,

[0440] X is N or C-R as described herein a ,

[0441] Y is N or CH,

[0442] Z is N or C-R as described herein c ,

[0443] R d As described in this article

[0444] R e As described in this article and

[0445] R 6 and R 7 As described in this article.

[0446] In some embodiments, R d As described in this article

[0447] In some embodiments, X is N. In some embodiments, X is C-R a In some embodiments, X is CH.

[0448] In some embodiments, Y is N. In some embodiments, Y is CH.

[0449] In some embodiments, Z is N. In some embodiments, Z is C-R as described in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, or Table 7. c In some embodiments, Z is CH.

[0450] In some embodiments, X is CH, Y is N, and Z is C-R as described in Table 1, Table 2, Table 3, Table 4, or Table 5. c .

[0451] In some embodiments, X is CH, Y is CH, and Z is N.

[0452] In some embodiments, X is N, Y is CH, and Z is C-R as described in Table 7. c .

[0453] In some embodiments, R d As described in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6 or Table 7

[0454] In some embodiments, R d As described in Table 1, Table 5, Table 6 or Table 7 In some embodiments, R d As described in Table 1 In some embodiments, R d for

[0455] In some embodiments, R d As described in Table 2 In some embodiments, R d for

[0456] In some embodiments, R d As described in Table 3 In some embodiments, R d for

[0457] In some embodiments, R d As described in Table 4 In some embodiments, R d for

[0458] In some embodiments, R e As described in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6 or Table 7

[0459] In some embodiments, R e As described in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6 or Table 7 In some embodiments, Re is

[0460] In some embodiments, R e As described in Table 1, Table 2, Table 3, Table 4, Table 6 or Table 7 In some embodiments, R e for In some embodiments, R e for In some embodiments, R e for In some embodiments, R e for

[0461] In some embodiments, R e As described in Table 5 In some embodiments, R e for

[0462] In some embodiments, R 6 and R 7 As described in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6 or Table 7. In some embodiments, As described in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6 or Table 7. In some embodiments, for

[0463] In some embodiments, for

[0464]

[0465] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are selected by one skilled in the art to provide stable moieties and compounds.

[0466] Exemplary compounds described herein include those described in the following table:

[0467] Table 1:

[0468]

[0469]

[0470]

[0471]

[0472]

[0473]

[0474]

[0475]

[0476]

[0477]

[0478]

[0479]

[0480]

[0481]

[0482]

[0483]

[0484]

[0485]

[0486]

[0487]

[0488]

[0489]

[0490]

[0491]

[0492]

[0493]

[0494] The compounds in Table 1 are named:

[0495] 1-1: 4-[(3S)-3-aminopyrrolidin-1-yl]-N,5-bis(3,5-dimethylphenyl)pyridine-3-carboxamide;

[0496] 1-3: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-(3-chloro-5-fluorophenyl)-5-(3,5-dimethylphenyl)pyridine-3-carboxamide;

[0497] 1-4: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-4-fluorophenyl)-N-(2-fluorophenyl)pyridine-3-carboxamide;

[0498] 1-7: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-cyanophenyl)-N-cyclohexylpyridine-3-carboxamide;

[0499] 1-8: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-cyanophenyl)-N-(1-methylcyclobutyl)pyridine-3-carboxamide;

[0500] 1-9: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-benzyl-5-(3-cyanophenyl)pyridine-3-carboxamide;

[0501] 1-10: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyanophenyl)-N-(4,4-difluorocyclohexyl)pyridine-3-carboxamide;

[0502] 1-11: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-dimethylcyclohexyl)-5-(3,5-dimethylphenyl)pyridine-3-carboxamide;

[0503] 1-12: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-dimethylphenyl)pyridine-3-carboxamide;

[0504] 1-13: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide;

[0505] 1-14: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-difluorocyclohexyl)-5-(3,5-dimethylphenyl)pyridine-3-carboxamide;

[0506] 1-15: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-fluoro-5-methylphenyl)-N-[1-(trifluoromethyl)cyclopentyl]pyridine-3-carboxamide;

[0507] 1-16: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0508] 1-17: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(2,3-dihydro-1H-inden-1-yl)-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide;

[0509] 1-18: N-(adamantan-2-yl)-4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide;

[0510] 1-19: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(1-ethylcyclobutyl)-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide;

[0511] 1-20: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,4,5-trifluorophenyl)pyridine-3-carboxamide;

[0512] 1-21: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0513] 1-22: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(3,3-dimethylcyclobutyl)pyridine-3-carboxamide;

[0514] 1-23: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclopropyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0515] 1-24: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(1-cyclopropylethyl)-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide;

[0516] 1-25: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(dicyclopropylmethyl)-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide;

[0517] 1-26: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(cyclopropylmethyl)-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide;

[0518] 1-27: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-fluoro-5-methylphenyl)-N-(1-methyl-1H-pyrazol-3-yl)pyridine-3-carboxamide;

[0519] 1-28: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide;

[0520] 1-29: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-tert-butyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0521] 1-30: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-difluorocyclobutyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0522] 1-31: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(pentan-3-yl)pyridine-3-carboxamide;

[0523] 1-32: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(1-methylcyclopropyl)methyl]pyridine-3-carboxamide;

[0524] 1-33: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(cyclobutylmethyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0525] 1-34: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(1-methylcyclobutyl)pyridine-3-carboxamide;

[0526] 1-35: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-(3,3-difluorocyclobutyl)pyridine-3-carboxamide;

[0527] 1-37: 4-[(3R,4R)-3-amino-4-fluoropyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0528] 1-38: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(3-methylbutan-2-yl)pyridine-3-carboxamide;

[0529] 1-39: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(2,4-dimethylpentan-3-yl)pyridine-3-carboxamide;

[0530] 1-40: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(2-cyclopropylpropan-2-yl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0531] 1-41: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0532] 1-42: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(2,2-difluorocyclopropyl)methyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0533] 1-43: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(2,2-dimethylcyclopropyl)methyl]pyridine-3-carboxamide;

[0534] 1-44: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1R)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0535] 1-45: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(1,1,1-trifluoro-3-methylbutan-2-yl)pyridine-3-carboxamide;

[0536] 1-46: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(2-methylpropyl)pyridine-3-carboxamide;

[0537] 1-47: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(1-fluorocyclobutyl)methyl]pyridine-3-carboxamide;

[0538] 1-48: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0539] 1-49: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0540] 1-50: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(3,3-difluorocyclobutyl)methyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0541] 1-51: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(dicyclopropylmethyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0542] 1-52: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[trans-2-fluorocyclohexyl]pyridine-3-carboxamide;

[0543] 1-53: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(2R)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0544] 1-54: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0545] 1-55: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(trans-3-fluorocyclobutyl]pyridine-3-carboxamide;

[0546] 1-56: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(1-cyclobutyl-2,2,2-trifluoroethyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0547] 1-57: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(2-methylbutyl)pyridine-3-carboxamide;

[0548] 1-58: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(2-ethylbutyl)pyridine-3-carboxamide;

[0549] 1-59: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[cis-3-fluorocyclobutyl]pyridine-3-carboxamide;

[0550] 1-60: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(4,4,4-trifluorobutan-2-yl)pyridine-3-carboxamide;

[0551] 1-61: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-(dicyclopropylmethyl)pyridine-3-carboxamide;

[0552] 1-62: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(2,2-difluoropropyl)pyridine-3-carboxamide;

[0553] 1-64: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0554] 1-65: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3-fluorophenyl)pyridine-3-carboxamide;

[0555] 1-66: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,4-difluorophenyl)pyridine-3-carboxamide;

[0556] 1-67: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0557] 1-68: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-(3,3-difluorocyclobutyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0558] 1-69: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0559] 1-70: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-(dicyclopropylmethyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0560] 1-71: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0561] 1-72: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(pentan-3-yl)pyridine-3-carboxamide;

[0562] 1-73: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-cycloheptyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0563] 1-74: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide;

[0564] 1-76: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(pentan-3-yl)pyridine-3-carboxamide;

[0565] 1-77: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0566] 1-78: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-cyclopentyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0567] 1-79: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-(3,3-difluorocyclobutyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0568] 1-80: 4-[(3S)-3-aminopyrrolidin-1-yl]-3-(3,5-difluorophenyl)-5-(piperidine-1-carbonyl)pyridine-2-carbonitrile;

[0569] 1-81: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-cyclohexyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0570] 1-82: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-cyclopentyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0571] 1-83: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[cis-2-fluorocyclohexyl]pyridine-3-carboxamide;

[0572] 1-84: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3-chlorophenyl)-6-cyanopyridine-3-carboxamide;

[0573] 1-85: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(2-methylpropyl)pyridine-3-carboxamide;

[0574] 1-86: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-(cyclopropylmethyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0575] 1-87: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-cyclobutyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0576] 1-88: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(oxan-4-yl)pyridine-3-carboxamide;

[0577] 1-89: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(oxan-3-yl)pyridine-3-carboxamide;

[0578] 1-90: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3-chloro-5-fluorophenyl)-6-cyanopyridine-3-carboxamide;

[0579] 1-91: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(propan-2-yl)pyridine-3-carboxamide;

[0580] 1-92: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide;

[0581] 1-93: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-cyclohexyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0582] 1-94: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3-cyano-5-methoxyphenyl)pyridine-3-carboxamide;

[0583] 1-95: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1S)-1-(pyridin-2-yl)ethyl]pyridine-3-carboxamide;

[0584] 1-96: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-methoxyphenyl)-N-[(1S)-1-cyclopropylethyl]pyridine-3-carboxamide;

[0585] 1-97: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1S)-1-phenylethyl]pyridine-3-carboxamide;

[0586] 1-98: 4-[(3S)-3-amino-3-(hydroxymethyl)pyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0587] 1-101: 4-[(3R,4R)-3-amino-4-fluoropyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0588] 1-103: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1S)-1-(pyridin-2-yl)ethyl]pyridine-3-carboxamide;

[0589] 1-104: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1-methyl-1H-pyrazol-5-yl)methyl]pyridine-3-carboxamide;

[0590] 1-105: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1-methyl-1H-pyrazol-3-yl)methyl]pyridine-3-carboxamide;

[0591] 1-106: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1-methyl-1H-imidazol-2-yl)methyl]pyridine-3-carboxamide;

[0592] 1-107: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1-methyl-1H-pyrazol-4-yl)methyl]pyridine-3-carboxamide;

[0593] 1-108: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(pyrimidin-2-yl)methyl]pyridine-3-carboxamide;

[0594] 1-109: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(4-benzylpiperazine-1-carbonyl)-3-(3,5-difluorophenyl)pyridine-2-carbonitrile;

[0595] 1-110: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(3-phenylpropyl)pyridine-3-carboxamide;

[0596] 1-111: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(1-phenylpiperidin-4-yl)pyridine-3-carboxamide;

[0597] 1-112: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclohexyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0598] 1-113: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(2,2-dimethyloxan-4-yl)pyridine-3-carboxamide;

[0599] 1-114: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1,2-oxazol-3-yl)methyl]pyridine-3-carboxamide;

[0600] 1-115: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2-hydroxyphenyl)methyl]pyridine-3-carboxamide;

[0601] 1-116: 4-[(3R)-3-amino-3-(methoxymethyl)pyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0602] 1-118: 4-[(3S)-3-amino-3-(2,2-difluoroethyl)pyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0603] 1-120: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-[3-(difluoromethoxy)phenyl]pyridine-3-carboxamide;

[0604] 1-122: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide;

[0605] 1-123: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methylpyridine-3-carboxamide;

[0606] 1-124: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3-fluorophenyl)-6-methylpyridine-3-carboxamide;

[0607] 1-125: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methylpyridine-3-carboxamide;

[0608] 1-126: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[1-(pyrimidin-2-yl)ethyl]pyridine-3-carboxamide;

[0609] 1-127: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-[3-(trifluoromethoxy)phenyl]pyridine-3-carboxamide;

[0610] 1-130: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide;

[0611] 1-132: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[1-(1,2-oxazol-3-yl)ethyl]pyridine-3-carboxamide;

[0612] 1-133: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[1-(1-methyl-1H-1,2,3-triazol-4-yl)ethyl]pyridine-3-carboxamide;

[0613] 1-135: 4-[(3R,4R)-3-amino-4-fluoropyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0614] 1-137: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-difluorocyclobutyl)-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide;

[0615] 1-138: 4-[(3R,4R)-3-amino-4-fluoropyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-cyano-N-[(1S)-1-cyclopropylethyl]pyridine-3-carboxamide;

[0616] 1-140: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0617] 1-141: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide;

[0618] 1-143: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-[3-(difluoromethoxy)-5-fluorophenyl]pyridine-3-carboxamide;

[0619] 1-144: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide;

[0620] 1-145: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-3,3-difluorocyclopentyl]-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide;

[0621] 1-146: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-difluorocyclobutyl)-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide;

[0622] 1-147: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-6-methyl-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0623] 1-149: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-[3-(difluoromethoxy)phenyl]pyridine-3-carboxamide;

[0624] 1-150: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide;

[0625] 1-151: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3,5-difluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0626] 1-152: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide;

[0627] 1-153: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methoxypyridine-3-carboxamide;

[0628] 1-154: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-6-methoxy-5-[3-(trifluoromethoxy)phenyl]pyridine-3-carboxamide;

[0629] 1-163: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(2,2-difluoro-2H-1,3-benzodioxol-4-yl)pyridine-3-carboxamide;

[0630] 1-164: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-[3-fluoro-5-(trifluoromethyl)phenyl]-6-methoxypyridine-3-carboxamide;

[0631] 1-165: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-[3-(difluoromethoxy)phenyl]-6-methoxypyridine-3-carboxamide;

[0632] 1-168: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-[3-(difluoromethoxy)phenyl]-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0633] 1-171: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methyl-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0634] 1-172: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-difluorocyclobutyl)-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methylpyridine-3-carboxamide;

[0635] 1-173: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methylpyridine-3-carboxamide;

[0636] 1-174: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methylpyridine-3-carboxamide;

[0637] 1-175: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)pyridine-3-carboxamide;

[0638] 1-176: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-ethoxypyridine-3-carboxamide;

[0639] 1-177: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-6-(2,2-difluoroethoxy)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0640] 1-178: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-6-(cyclopropylmethoxy)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0641] 1-179: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-(2-methoxyethoxy)pyridine-3-carboxamide;

[0642] 1-180: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-[3-(difluoromethoxy)-5-fluorophenyl]-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0643] 1-181: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide;

[0644] 1-184: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(2,2-difluoro-2H-1,3-benzodioxol-4-yl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0645] 1-188: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0646] 1-189: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide;

[0647] 1-190: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide;

[0648] 1-191: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyclopropyloxy-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0649] 1-192: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide;

[0650] 1-193: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3,5-difluorophenyl)-6-methoxy-N-[4-(trifluoromethyl)cyclohexyl]pyridine-3-carboxamide;

[0651] 1-194: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-(1-cyclopropyl-2,2,2-trifluoroethyl)-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide;

[0652] 1-195: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-(trifluoromethyl)pyridine-3-carboxamide;

[0653] 1-196: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-{3-fluorobicyclo[1.1.1]pentan-1-yl}-6-methoxypyridine-3-carboxamide;

[0654] 1-197: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-methoxyphenyl)-N-[(1S)-1-cyclopropylethyl]-6-(trifluoromethyl)pyridine-3-carboxamide;

[0655] 1-198: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-(trifluoromethyl)pyridine-3-carboxamide;

[0656] 1-199: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide;

[0657] 1-200: ethyl 2-({4-[(3S)-3-aminopyrrolidin-1-yl]-5-[(4,4-difluorocyclohexyl)carbamoyl]-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)acetate;

[0658] 1-201: ethyl 3-({4-[(3S)-3-aminopyrrolidin-1-yl]-5-[(4,4-difluorocyclohexyl)carbamoyl]-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)propanoate;

[0659] 1-202: ethyl 4-({4-[(3S)-3-aminopyrrolidin-1-yl]-5-[(4,4-difluorocyclohexyl)carbamoyl]-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)butanoate;

[0660] 1-203: 2-({4-[(3S)-3-aminopyrrolidin-1-yl]-5-[(4,4-difluorocyclohexyl)carbamoyl]-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)acetic acid

[0661] 1-204: 3-({4-[(3S)-3-aminopyrrolidin-1-yl]-5-[(4,4-difluorocyclohexyl)carbamoyl]-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)propanoic acid;

[0662] 1-205: 4-({4-[(3S)-3-aminopyrrolidin-1-yl]-5-[(4,4-difluorocyclohexyl)carbamoyl]-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)butanoic acid;

[0663] 1-209: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,4-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide;

[0664] 1-210: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclohexyl-5-(3,5-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide;

[0665] 1-211: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide;

[0666] 1-212: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3,5-difluorophenyl)-6-(trifluoromethyl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0667] 1-213: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-cyclohexyl-5-(3,5-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide;

[0668] 1-214: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide;

[0669] 1-215: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-dichlorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide;

[0670] 1-216: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-{3-fluorobicyclo[1.1.1]pentan-1-yl}-6-(trifluoromethyl)pyridine-3-carboxamide;

[0671] 1-217: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-{3-fluorobicyclo[1.1.1]pentan-1-yl}-6-(trifluoromethyl)pyridine-3-carboxamide;

[0672] 1-218: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-(cyclopropylmethyl)-5-(3,5-difluorophenyl)-N-methylpyridine-3-carboxamide;

[0673] 1-219: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-N-methylpyridine-3-carboxamide;

[0674] 1-222: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide;

[0675] 1-223: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(1-hydroxycyclopentyl)methyl]-6-methylpyridine-3-carboxamide;

[0676] 1-224: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(1-cyclopropyl-2-hydroxyethyl)-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide;

[0677] 1-225: 4-(3-aminopyrrolidin-1-yl)-6-cyano-5-(3,5-difluorophenyl)-N-(1,1,1-trifluoropropane-2-yl)pyridine-3-carboxamide;

[0678] 1-226: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(1,1,1-trifluoropropan-2-yl)pyridine-3-carboxamide;

[0679] 1-227: 4-[(3R)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2R)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0680] 1-228: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0681] 1-229: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methoxypyridine-3-carboxamide;

[0682] 1-230: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3,5-difluorophenyl)-6-methyl-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0683] 1-231: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methyl-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0684] 1-232: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-[3-(difluoromethoxy)phenyl]-6-methyl-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide;

[0685] 1-233: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide;

[0686] 1-234: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-{3-fluorobicyclo[1.1.1]pentan-1-yl}pyridine-3-carboxamide;

[0687] 1-235: (3S)-1-[3-(3,5-difluorophenyl)-2-methoxy-5-(piperidine-1-carbonyl)pyridin-4-yl]pyrrolidin-3-amine;

[0688] 1-236: (3S)-1-[3-(3,5-difluorophenyl)-5-(4,4-difluoropiperidine-1-carbonyl)-2-methoxypyridin-4-yl]pyrrolidin-3-amine;

[0689] 1-237: (3S)-1-[3-(3,5-difluorophenyl)-5-(3,3-difluoropiperidine-1-carbonyl)-2-methoxypyridin-4-yl]pyrrolidin-3-amine;

[0690] 1-238: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methoxy-N-[(1,2-oxazol-3-yl)methyl]pyridine-3-carboxamide;

[0691] 1-239: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methoxy-N-[(1,2-oxazol-3-yl)methyl]pyridine-3-carboxamide;

[0692] 1-240: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methoxy-N-[(1S)-1-(pyridin-2-yl)ethyl]pyridine-3-carboxamide;

[0693] 1-241: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methoxy-N-[(1S)-1-(pyridin-2-yl)ethyl]pyridine-3-carboxamide;

[0694] 1-242: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methyl-N-[(1,2-oxazol-3-yl)methyl]pyridine-3-carboxamide;

[0695] 1-243: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methyl-N-[(1S)-1-(pyridin-2-yl)ethyl]pyridine-3-carboxamide;

[0696] 1-244: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-cyano-N-[(1,2-oxazol-3-yl)methyl]pyridine-3-carboxamide;

[0697] 1-245: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-cyano-N-[(1S)-1-(pyridin-2-yl)ethyl]pyridine-3-carboxamide;

[0698] 1-246: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-(2-hydroxyethoxy)pyridine-3-carboxamide;

[0699] 1-247: 2-({4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-{[(1S)-1-cyclopropylethyl]carbamoyl}-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)acetic acid;

[0700] 1-259: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,4-difluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0701] 1-260: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(4-chloro-3-fluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0702] 1-261: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-4-fluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide;

[0703] 1-262: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,4-difluorophenyl)-6-methoxypyridine-3-carboxamide;

[0704] 1-263: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(4-chloro-3-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methoxypyridine-3-carboxamide;

[0705] 1-264: 3-({4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-{[(1S)-1-cyclopropylethyl]carbamoyl}-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)propanoic acid;

[0706] 1-265: 4-({4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-{[(1S)-1-cyclopropylethyl]carbamoyl}-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)butanoic acid;

[0707] 1-266: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-[(oxetan-3-yl)methoxy]pyridine-3-carboxamide;

[0708] 1-267: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-(benzyloxy)-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0709] 1-268: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-methoxyphenyl)-N-(4,4-difluorocyclohexyl)-6-methylpyridine-3-carboxamide;

[0710] 1-269: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-methoxyphenyl)-N-(3,3-difluorocyclobutyl)-6-methylpyridine-3-carboxamide;

[0711] 1-272: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methylpyridine-3-carboxamide;

[0712] 1-273: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-{3-fluorobicyclo[1.1.1]pentan-1-yl}-6-methoxypyridine-3-carboxamide;

[0713] 1-275: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-methoxyphenyl)-6-methyl-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide;

[0714] 1-276: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methyl-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0715] 1-277: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-(4,4-difluorocyclohexyl)-6-methylpyridine-3-carboxamide;

[0716] 1-278: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-{3-fluorobicyclo[1.1.1]pentan-1-yl}-6-methylpyridine-3-carboxamide;

[0717] 1-279: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,4-difluorophenyl)-6-methyl-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0718] 1-280: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-methoxyphenyl)-N-[(1S)-1-cyclopropylethyl]-6-methylpyridine-3-carboxamide;

[0719] 1-281: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyclopropyl-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0720] 1-282: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methoxypyridine-3-carboxamide;

[0721] 1-283: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide;

[0722] 1-284: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-(4,4-difluorocyclohexyl)-6-methoxypyridine-3-carboxamide;

[0723] 1-285: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-(3,3-difluorocyclobutyl)-6-methoxypyridine-3-carboxamide;

[0724] 1-286: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-{3-fluorobicyclo[1.1.1]pentan-1-yl}-6-methoxypyridine-3-carboxamide;

[0725] 1-287: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-4-fluorophenyl)-6-methyl-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide;

[0726] 1-288: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,4-difluorophenyl)-6-methylpyridine-3-carboxamide;

[0727] 1-289: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-4-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methylpyridine-3-carboxamide;

[0728] 1-290: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyclopropyl-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide.

[0729] In some embodiments, provided herein are pharmaceutically acceptable salts of the compounds described in Table 1.

[0730] Table 2:

[0731]

[0732]

[0733]

[0734]

[0735]

[0736] The compounds in Table 2 are named:

[0737] 1-5: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-2'-cyano-N-(3-methylphenyl)-[3,4'-bipyridine]-5-carboxamide;

[0738] 1-6: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,5-dimethylphenyl)-2'-methyl-[3,4'-bipyridine]-5-carboxamide;

[0739] 1-121: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(1-methyl-1H-pyrazol-3-yl)pyridine-3-carboxamide;

[0740] 1-128: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(2-methyl-1,3-thiazol-5-yl)pyridine-3-carboxamide;

[0741] 1-129: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-2-cyano-N-[(1S)-1-cyclopropylethyl]-2'-(trifluoromethyl)-[3,4'-bipyridine]-5-carboxamide;

[0742] 1-131: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-2',6'-dimethyl-[3,4'-bipyridine]-5-carboxamide;

[0743] 1-134: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(1,2-oxazol-4-yl)pyridine-3-carboxamide;

[0744] 1-142: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5'-fluoro-[3,3'-bipyridine]-5-carboxamide;

[0745] 1-148: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-6-methyl-5-(1-methyl-1H-pyrazol-4-yl)pyridine-3-carboxamide;

[0746] 1-155: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-6-methyl-5-[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]pyridine-3-carboxamide;

[0747] 1-156: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(1-cyclopropyl-1H-pyrazol-4-yl)-N-[(1S)-1-cyclopropylethyl]-6-methylpyridine-3-carboxamide;

[0748] 1-157: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-2'-methoxy-2-methyl-[3,4'-bipyridine]-5-carboxamide;

[0749] 1-158: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5'-chloro-N-[(1S)-1-cyclopropylethyl]-2-methyl-[3,3'-bipyridine]-5-carboxamide;

[0750] 1-159: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-2-methyl-2'-(trifluoromethyl)-[3,4'-bipyridine]-5-carboxamide;

[0751] 1-160: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5'-fluoro-2-methyl-[3,3'-bipyridine]-5-carboxamide;

[0752] 1-166: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-2-methoxy-2'-(trifluoromethyl)-[3,4'-bipyridine]-5-carboxamide;

[0753] 1-167: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5'-chloro-N-[(1S)-1-cyclopropylethyl]-2-methoxy-[3,3'-bipyridine]-5-carboxamide;

[0754] 1-169: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-2-cyano-2'-(trifluoromethyl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]-[3,4'-bipyridine]-5-carboxamide;

[0755] 1-170: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-2-cyano-2'-methoxy-N-[(2S)-1,1,1-trifluoropropan-2-yl]-[3,4'-bipyridine]-5-carboxamide;

[0756] 1-185: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-methoxy-5-(2-methylpyrimidin-5-yl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0757] 1-187: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0758] 1-206: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-2'-ethoxy-2-(trifluoromethyl)-[3,4'-bipyridine]-5-carboxamide;

[0759] 1-208: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-2'-methoxy-2-(trifluoromethyl)-[3,4'-bipyridine]-5-carboxamide;

[0760] 1-248: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-2-cyano-N-cyclopentyl-2'-(trifluoromethyl)-[3,4'-bipyridine]-5-carboxamide;

[0761] 1-249: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-2-cyano-N-(pentan-3-yl)-2'-(trifluoromethyl)-[3,4'-bipyridine]-5-carboxamide;

[0762] 1-250: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-2-cyano-N-(2-methylpropyl)-2'-(trifluoromethyl)-[3,4'-bipyridine]-5-carboxamide;

[0763] 1-251: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-butyl-2-cyano-2'-(trifluoromethyl)-[3,4'-bipyridine]-5-carboxamide;

[0764] 1-252: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-2-cyano-N-cyclohexyl-2'-methoxy-[3,4'-bipyridine]-5-carboxamide;

[0765] 1-253: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-2-cyano-2'-methoxy-N-(pentan-3-yl)-[3,4'-bipyridine]-5-carboxamide;

[0766] 1-254: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-2-cyano-N-cyclopentyl-2'-methoxy-[3,4'-bipyridine]-5-carboxamide;

[0767] 1-255: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclohexyl-2'-methoxy-2-methyl-[3,4'-bipyridine]-5-carboxamide;

[0768] 1-256: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclopentyl-2'-methoxy-2-methyl-[3,4'-bipyridine]-5-carboxamide;

[0769] 1-257: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclohexyl-2-methyl-2'-(trifluoromethyl)-[3,4'-bipyridine]-5-carboxamide;

[0770] 1-258: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclopentyl-2-methyl-2'-(trifluoromethyl)-[3,4'-bipyridine]-5-carboxamide;

[0771] 1-270: 4-[(3S)-3-Amino-3-methylpyrrolidin-1-yl]-2-cyano-2'-methoxy-N-(2-methylpropyl)-[3,4'-bipyridine]-5-carboxamide.

[0772] In some embodiments, provided herein are pharmaceutically acceptable salts of the compounds described in Table 2.

[0773] Table 3:

[0774]

[0775]

[0776]

[0777]

[0778] * Racemic

[0779] The compounds in Table 3 are named:

[0780] 2-1: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-ethyl-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0781] 2-2: (3S)-3-methyl-1-[3-(4-methyl-1H-1,3-benzodiazol-2-yl)-5-(pyrrolidine-1-carbonyl)pyridin-4-yl]pyrrolidin-3-amine;

[0782] 2-3: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-ethyl-N-methyl-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0783] 2-4: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclopentyl-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0784] 2-5: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(4-methyl-1H-1,3-benzodiazol-2-yl)-N-(oxolan-3-yl)pyridine-3-carboxamide;

[0785] 2-6: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(4-methyl-1H-1,3-benzodiazol-2-yl)-N-phenylpyridine-3-carboxamide;

[0786] 2-7: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(4-methyl-1H-1,3-benzodiazol-2-yl)-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide;

[0787] 2-8: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(2-methoxyethyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0788] 2-9: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(2-hydroxyethyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0789] 2-10: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-methyl-5-(4-methyl-1H-1,3-benzodiazol-2-yl)-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide;

[0790] 2-11: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(4-methyl-1H-1,3-benzodiazol-2-yl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0791] 2-12: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclopropyl-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0792] 2-13: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(cyclopropylmethyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0793] 2-14: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(1-cyclopropylethyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0794] 2-15: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0795] 2-16: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclopentyl-N-methyl-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0796] 2-17: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0797] 2-18: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(4-methyl-1H-1,3-benzodiazol-2-yl)-N-[(2R)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0798] 2-19: (3S)-1-[3-(3,3-dimethylpyrrolidine-1-carbonyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-4-yl]-3-methylpyrrolidin-3-amine;

[0799] 2-20: (3S)-1-[3-(2,2-dimethylpyrrolidine-1-carbonyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-4-yl]-3-methylpyrrolidin-3-amine;

[0800] 2-21: (3S)-1-[3-(3,3-dimethylazetidine-1-carbonyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-4-yl]-3-methylpyrrolidin-3-amine;

[0801] 2-22: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclopropyl-N-methyl-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0802] 2-23: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(cyclopropylmethyl)-N-methyl-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0803] 2-24: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(4-fluoro-1H-1,3-benzodiazol-2-yl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0804] 2-25: (3S)-1-[3-(3,3-difluoropyrrolidine-1-carbonyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-4-yl]-3-methylpyrrolidin-3-amine;

[0805] 2-26: (3S)-1-(3-{2-azatricyclo[3.3.1.13, 7 ]decane-2-carbonyl}-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-4-yl)-3-methylpyrrolidin-3-amine;

[0806] 2-27: (3S)-1-[3-(3-tert-butylpyrrolidine-1-carbonyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-4-yl]-3-methylpyrrolidin-3-amine;

[0807] 2-28: (3S)-1-{3-[(2R,6S)-2,6-dimethylmorpholine-4-carbonyl]-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-4-yl}-3-methylpyrrolidin-3-amine;

[0808] 2-29: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-N-methyl-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0809] 2-30: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(7-fluoro-4-methyl-1H-1,3-benzodiazol-2-yl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0810] 2-31: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(cyclobutylmethyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0811] 2-32: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(4-methyl-1H-1,3-benzodiazol-2-yl)-N-(4,4,4-trifluorobutan-2-yl)pyridine-3-carboxamide;

[0812] 2-33: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[2.2.1]heptane-1-yl}-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0813] 2-34: (3S)-1-[3-(2,3-dihydro-1H-indole-1-carbonyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-4-yl]-3-methylpyrrolidin-3-amine;

[0814] 2-35: (3S)-1-(3-{2-azabicyclo[2.2.2]octane-2-carbonyl}-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-4-yl)-3-methylpyrrolidin-3-amine;

[0815] 2-36: (3S)-3-methyl-1-[3-(4-methyl-1H-1,3-benzodiazol-2-yl)-5-[2-(propan-2-yl)pyrrolidine-1-carbonyl]pyridin-4-yl]pyrrolidin-3-amine;

[0816] 2-37: (3S)-1-{3-[(3aR)-octahydrocyclopenta[b]pyrrole-1-carbonyl]-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-4-yl}-3-methylpyrrolidin-3-amine;

[0817] 2-38: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclohexyl-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridine-3-carboxamide;

[0818] 2-39: (3S)-1-(3-{5-azaspiro[2.4]heptane-5-carbonyl}-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-4-yl)-3-methylpyrrolidin-3-amine;

[0819] 2-40: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(4-methyl-1H-1,3-benzodiazol-2-yl)-N-[(2S)-1,1,1-trifluorobutan-2-yl]pyridine-3-carboxamide;

[0820] 2-41: (3S)-3-methyl-1-[3-(4-methyl-1H-1,3-benzodiazol-2-yl)-5-[(2S)-2-(trifluoromethyl)pyrrolidine-1-carbonyl]pyridin-4-yl]pyrrolidin-3-amine;

[0821] 2-42: (3S)-1-[3-(3-cyclopropylpyrrolidine-1-carbonyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-4-yl]-3-methylpyrrolidin-3-amine;

[0822] 2-43: (3S)-1-[3-(2-cyclopropylpyrrolidine-1-carbonyl)-5-(4-methyl-1H-1,3-benzodiazol-2-yl)pyridin-4-yl]-3-methylpyrrolidin-3-amine;

[0823] 2-44: (3S)-3-methyl-1-[3-(4-methyl-1H-1,3-benzodiazol-2-yl)-5-[3-(trifluoromethyl)pyrrolidine-1-carbonyl]pyridin-4-yl]pyrrolidin-3-amine;

[0824] 2-45: (3S)-1-(3-{2-azatricyclo[3.3.1.13, 7 ]decane-2-carbonyl}-5-(7-chloro-1H-1,3-benzodiazol-2-yl)pyridin-4-yl)-3-methylpyrrolidin-3-amine.

[0825] In some embodiments, provided herein are pharmaceutically acceptable salts of the compounds described in Table 3:

[0826] Table 4:

[0827]

[0828]

[0829]

[0830] The compounds in Table 4 are named:

[0831] 1-161: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(1-methyl-1H-indazol-6-yl)pyridine-3-carboxamide;

[0832] 1-162: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(1-methyl-1H-indazol-4-yl)pyridine-3-carboxamide;

[0833] 1-182: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-methoxy-5-(1-methyl-1H-1,3-benzodiazol-6-yl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0834] 1-183: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-methoxy-5-(1-methyl-1H-indazol-4-yl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide;

[0835] 1-186: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(2,1,3-benzoxadiazol-5-yl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide.

[0836] In some embodiments, provided herein are pharmaceutically acceptable salts of the compounds described in Table 4.

[0837] Table 5:

[0838]

[0839]

[0840]

[0841] *Absolute stereochemistry has not yet been determined

[0842] The compounds in Table 5 are named:

[0843] 1-2: 4-[(3R)-3-aminopyrrolidin-1-yl]-N,5-bis(3,5-dimethylphenyl)pyridine-3-carboxamide;

[0844] 1-36: 4-[3-amino-3-(methoxymethyl)pyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0845] 1-63: 4-[3-(1-aminoethyl)azetidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0846] 1-75: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyanopyridine-3-carboxamide;

[0847] 1-99: 4-[(3R)-3-amino-3-(hydroxymethyl)pyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0848] 1-100: 4-[3-(1-aminoethyl)azetidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0849] 1-102: 4-[(3S,4S)-3-amino-4-fluoropyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0850] 1-117: 4-[(3S)-3-amino-3-(methoxymethyl)pyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0851] 1-119: 4-[(3R)-3-amino-3-(2,2-difluoroethyl)pyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0852] 1-136: 4-[(3S,4S)-3-amino-4-fluoropyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0853] 1-139: 4-[(3S,4S)-3-amino-4-fluoropyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-cyano-N-[(1S)-1-cyclopropylethyl]pyridine-3-carboxamide;

[0854] 1-220: 4-[(3S)-3-amino-3-(fluoromethyl)pyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0855] 1-221: 4-[(3R)-3-amino-3-(fluoromethyl)pyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide;

[0856] 1-274: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-bromo-6-methoxy-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide.

[0857] In some embodiments, provided herein are pharmaceutically acceptable salts of the compounds described in Table 5.

[0858] Table 6:

[0859]

[0860]

[0861]

[0862] The compounds in Table 6 are named:

[0863] 3-1: 3-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-2-(3,5-difluorophenyl)pyridine-4-carboxamide;

[0864] 3-2: 3-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclohexyl-2-(3,5-difluorophenyl)pyridine-4-carboxamide;

[0865] 3-3: 3-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-2-(3,5-difluorophenyl)-N-[(1S)-1-phenylethyl]pyridine-4-carboxamide;

[0866] 3-4: 3-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(dicyclopropylmethyl)-2-(3,5-difluorophenyl)pyridine-4-carboxamide;

[0867] 3-5: 3-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[2.2.1]heptane-1-yl}-2-(3,5-difluorophenyl)pyridine-4-carboxamide;

[0868] 3-6: 3-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cycloheptyl-2-(3,5-difluorophenyl)pyridine-4-carboxamide;

[0869] 3-7: N-(adamantan-1-yl)-3-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-2-(3,5-difluorophenyl)pyridine-4-carboxamide;

[0870] 3-8: 3-[(3S)-3-Amino-3-methylpyrrolidin-1-yl]-N-cyclopentyl-2-(3,5-difluorophenyl)pyridine-4-carboxamide.

[0871] In some embodiments, provided herein are pharmaceutically acceptable salts of the compounds described in Table 6.

[0872] Table 7:

[0873]

[0874]

[0875] The compounds in Table 7 are named:

[0876] 4-1: 3-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-chloro-N-[(1S)-1-cyclopropylethyl]-4-(3,5-difluorophenyl)pyridine-2-carboxamide;

[0877] 4-2: 3-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-4-(3,5-difluorophenyl)-5-methylpyridine-2-carboxamide;

[0878] 4-3: 3-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-cyano-N-[(1S)-1-cyclopropylethyl]-4-(3,5-difluorophenyl)pyridine-2-carboxamide;

[0879] 4-4: 5-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-{[(1S)-1-cyclopropylethyl]carbamoyl}-4-(3,5-difluorophenyl)pyridine-3-carboxylic acid methyl ester;

[0880] 4-5: 3-[(3S)-3-Amino-3-methylpyrrolidin-1-yl]-N2-[(1S)-1-cyclopropylethyl]-4-(3,5-difluorophenyl)pyridine-2,5-dicarboxamide.

[0881] In some embodiments, provided herein are pharmaceutically acceptable salts of the compounds described in Table 7.

[0882] In one aspect, the compounds described herein are in the form of pharmaceutically acceptable salts. Likewise, active metabolites of these compounds having the same type of activity are also included within the scope of the present disclosure. In addition, the compounds described herein may exist in unsolvated form as well as solvated form with pharmaceutically acceptable solvents such as water, ethanol, etc. The solvated forms of the compounds presented herein are also considered to be disclosed herein.

[0883] As used herein, "pharmaceutically acceptable" refers to a substance such as a carrier or diluent that does not abrogate the biological activity or properties of the compound and is relatively non-toxic, i.e., the substance does not cause undesirable biological effects when administered to a subject or does not interact in a deleterious manner with any components of the composition in which it is contained.

[0884] The term "pharmaceutically acceptable salt" refers to a form of a therapeutically active agent that consists of a cationic form of the therapeutically active agent in combination with a suitable anion, or, in an alternative embodiment, consists of an anionic form of the therapeutically active agent in combination with a suitable cation. Handbook of Pharmaceutical Salts: Properties, Selection and Use. International Union of Pure and Applied Chemistry, Wiley-VCH 2002. S. M. Berge, L. D. Bighley, D. C. Monkhouse, J. Pharm. Sci. 1977, 66, 1-19. P. H. Stahl and C. G. Wermuth, eds., Handbook of Pharmaceutical Salts: Properties, Selection and Use, Weinheim / Zürich: Wiley-VCH / VHCA, 2002. Pharmaceutically acceptable salts are generally more soluble and dissolve more rapidly in gastric and intestinal fluids than non-ionic substances, and therefore solid dosage forms thereof are useful. Moreover, because its solubility is generally a function of pH, selective dissolution in one or another part of the digestive tract is possible, and this ability can be manipulated as an aspect of delayed and sustained release properties. Likewise, because salt-forming molecules can equilibrate with the neutral form, biological membrane passage can be modulated.

[0885] In some embodiments, the pharmaceutically acceptable salt is obtained by reacting the compound of formula (I) with an acid. In some embodiments, the compound of formula (I) (i.e., free base form) is alkaline and reacts with an organic acid or an inorganic acid. Inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and metaphosphoric acid. Organic acids include, but are not limited to, 1-hydroxy-2-naphthoic acid; 2,2-dichloroacetic acid; 2-hydroxyethanesulfonic acid; 2-oxoglutaric acid; 4-acetamidobenzoic acid; 4-aminosalicylic acid; acetic acid; adipic acid; ascorbic acid (L); aspartic acid (L); benzenesulfonic acid; benzoic acid; camphoric acid (+); camphor-10-sulfonic acid (+); caprylic acid (decanoic acid); caprylic acid (caproic acid); caprylic acid (octanoic acid); carbonic acid; cinnamic acid; citric acid; cyclamic acid; dodecyl sulfuric acid; ethane-1,2-disulfonic acid; ethanesulfonic acid; formic acid; fumaric acid; galactaric acid; dapoxetine ... Cholic acid; glucoheptonic acid (D); gluconic acid (D); glucuronic acid (D); glutamic acid; glutaric acid; glycerophosphoglyceric acid; glycolic acid; hippuric acid; isobutyric acid; lactic acid (DL); lactobionic acid; lauric acid; maleic acid; malic acid (-L); malonic acid; mandelic acid (DL); methanesulfonic acid; naphthalene-1,5-disulfonic acid; naphthalene-2-sulfonic acid; nicotinic acid; oleic acid; oxalic acid; palmitic acid; pamoic acid; phosphoric acid; propionic acid; pyroglutamic acid (-L); salicylic acid; sebacic acid; stearic acid; succinic acid; sulfuric acid; tartaric acid (+L); thiocyanic acid; toluenesulfonic acid (para); and undecylenic acid.

[0886] In some embodiments, the compound of formula (I) is prepared as a chloride salt, a sulfate salt, a bromide salt, a methanesulfonate salt, a maleate salt, a citrate salt, or a phosphate salt.

[0887] In some embodiments, pharmaceutically acceptable salts are obtained by reacting a compound of formula (I) with a base. In some embodiments, the compound of formula (I) is acidic and reacts with a base. In such cases, the acidic protons of the compound of formula (I) are replaced by metal ions such as lithium, sodium, potassium, magnesium, calcium or aluminum ions. In some cases, the compounds described herein are coordinated with an organic base, such as but not limited to ethanolamine, diethanolamine, triethanolamine, tromethamine, meglumine, N-methylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine. In other cases, the compounds described herein form salts with amino acids such as but not limited to arginine and lysine. Acceptable inorganic bases for forming salts with compounds containing acidic protons include but are not limited to aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydroxide, lithium hydroxide, etc. In some embodiments, the compounds provided herein are prepared as sodium salts, calcium salts, potassium salts, magnesium salts, meglumine salts, N-methylglucamine salts or ammonium salts.

[0888] It should be understood that reference to pharmaceutically acceptable salts includes solvent addition forms. In some embodiments, solvates contain stoichiometric or non-stoichiometric amounts of solvents and are formed during crystallization with pharmaceutically acceptable solvents such as water, ethanol, etc. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein are conveniently prepared or formed in the processes described herein. In addition, the compounds provided herein are optionally present in unsolvated as well as solvated forms.

[0889] The methods and formulations described herein include the use of N-oxides (if appropriate) or pharmaceutically acceptable salts of compounds having the structure of Formula (I), as well as active metabolites of these compounds having the same type of activity.

[0890] In some embodiments, sites on the organic group (e.g., alkyl group, aromatic ring) of the compound of formula (I) are susceptible to various metabolic reactions. Incorporation of suitable substituents on the organic group will reduce, minimize or eliminate the metabolic pathway. In specific embodiments, by way of example only, suitable substituents for reducing or eliminating the sensitivity of the aromatic ring to metabolic reactions are halogen, deuterium, alkyl, haloalkyl group or deuterated alkyl.

[0891] In another embodiment, the compounds described herein are labeled isotopically (eg, with a radioisotope) or by yet other means, including but not limited to the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

[0892] The compounds described herein include isotopically labeled compounds that are identical to those depicted in the various formulas and structures presented herein, except that one or more atoms are replaced by an atom with an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine, chlorine, iodine, phosphorus, for example, 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 35 S. 18 F. 36 Cl, 123 I. 124 I. 125 I. 131 I. 32 P and 33 In one aspect, an isotopically labeled compound as described herein, for example one in which a radioactive isotope such as 3H and 14 C are useful in drug and / or substrate tissue distribution assays. In one aspect, substitution with isotopes such as deuterium affords certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements.

[0893] In some embodiments, the compound of formula (I) has one or more stereocenters, and each stereocenter exists independently in R or S configuration. In some embodiments, the compound of formula (I) exists in R configuration. In some embodiments, the compound of formula (I) exists in S configuration. The compounds proposed herein include all diastereoisomers, single enantiomers, atropisomers and epimer forms and suitable mixtures thereof. The compounds and methods provided herein include all cis (cis), trans (trans), syn (syn), anti (anti), entgegen (E) and zusammen (Z) isomers and suitable mixtures thereof.

[0894] If desired, single stereoisomers are obtained by methods such as stereoselective synthesis and / or separation of stereoisomers via chiral chromatographic columns or separation of diastereomers by achiral or chiral chromatographic columns or crystallization and recrystallization in appropriate solvents or solvent mixtures. In certain embodiments, the compound of formula (I) is prepared into its single stereoisomer by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereomeric compounds / salts, separating the diastereomers and recovering optically pure single enantiomers. In some embodiments, the covalent diastereomeric derivatives of the compounds described herein are used to resolve single enantiomers. In another embodiment, diastereomers are separated by separation / resolution techniques based on solubility differences. In other embodiments, separation of stereoisomers is carried out by chromatography or by forming diastereomeric salts and separating by recrystallization or chromatography or any combination thereof. Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981. In some embodiments, stereoisomers are obtained by stereoselective synthesis.

[0895] In some embodiments, the compounds described herein are prepared into prodrugs. "Prodrug" refers to a medicament that is converted into a parent drug in vivo. Prodrugs are generally useful because they are easier to apply than parent drugs in some cases. For example, they can be bioavailable by oral administration, while parent drugs cannot. Further or alternatively, prodrugs also have improved solubility in pharmaceutical compositions relative to parent drugs. In some embodiments, the design of prodrugs increases effective water solubility. Non-limiting examples of prodrugs are compounds described herein, which are applied as esters ("prodrugs") but are then metabolically hydrolyzed to provide active entities. Another example of prodrugs is a short peptide (polyamino acid) bonded to an acid group, wherein the peptide is metabolized to expose an active portion. In certain embodiments, when applied in vivo, prodrugs are chemically converted into biological, pharmaceutical or therapeutically active forms of the compound. In certain embodiments, prodrugs are enzymatically metabolized into biological, pharmaceutical or therapeutically active forms of the compound by one or more steps or processes.

[0896] Prodrugs of the compounds described herein include, but are not limited to, esters, ethers, carbonates, thiocarbonates, N-acyl derivatives, N-acyloxyalkyl derivatives, N-alkyloxyacyl derivatives, quaternary amine derivatives of tertiary amines, N-Mannich bases, Schiff bases, amino acid conjugates, phosphate esters, and sulfonate esters. See, e.g., Design of Prodrugs, Bundgaard, A., ed., Elseview, 1985 and Method in Enzymology, Widder, K. et al., eds.; Academic, 1985, vol. 42, p. 309-396; Bundgaard, H. "Design and Application of Prodrugs", in A Textbook of Drug Design and Development, Krosgaard-Larsen and H. Bundgaard, eds., 1991, Chapter 5, p. 113-191; and Bundgaard, H., Advanced Drug Delivery Review, 1992, 8, 1-38, each of which is incorporated herein by reference. In some embodiments, the hydroxyl groups of the compounds disclosed herein are used to form prodrugs, wherein the hydroxyl groups are incorporated into acyloxyalkyl esters, alkoxycarbonyloxyalkyl esters, alkyl esters, aryl esters, phosphate esters, glycolipids, ethers, and the like. In some embodiments, the hydroxyl group of the compounds disclosed herein is a prodrug, wherein the hydroxyl group is subsequently metabolized in vivo to provide a carboxylic acid group. In some embodiments, the carboxyl group is used to provide an ester or amide (i.e., a prodrug), which is subsequently metabolized in vivo to provide a carboxylic acid group. In some embodiments, the compounds described herein are prepared as alkyl ester prodrugs.

[0897] Prodrug forms of the compounds described herein, wherein the prodrug is metabolized in vivo to produce a compound of formula (I) as described herein, are included within the scope of the claims. In some cases, some of the compounds described herein are prodrugs of another derivative or active compound.

[0898] In some embodiments, any of the hydroxyl, amino, and / or carboxylic acid groups are functionalized in a suitable manner to provide a prodrug moiety. In some embodiments, the prodrug moiety is as described above.

[0899] In additional or further embodiments, the compounds described herein are metabolized upon administration to an organism in need thereof to produce a metabolite, which is subsequently used to produce a desired effect, including a desired therapeutic effect.

[0900] The "metabolites" of the compounds disclosed herein are derivatives of the compounds formed when the compounds are metabolized. The term "active metabolite" refers to biologically active derivatives of the compounds formed when the compounds are metabolized. As used herein, the term "metabolism" refers to the sum of the following processes (including but not limited to hydrolysis reactions and reactions catalyzed by enzymes) through which specific substances are changed by organisms. Therefore, enzymes can produce specific structural changes in compounds. For example, cytochrome P450 catalyzes a variety of oxidation and reduction reactions, while UDP-glucuronyltransferase catalyzes the transfer of activated glucuronic acid molecules to aromatic alcohols, fatty alcohols, carboxylic acids, amines, and free sulfhydryl groups. The metabolites of the compounds disclosed herein are optionally identified by administering the compounds to a host and analyzing tissue samples from the host, or by incubating the compounds with hepatocytes in vitro and analyzing the resulting compounds.

[0901] In some cases, the heterocyclic ring may exist in tautomeric form. In this case, it will be appreciated that the structure of the compound is shown or named in a tautomeric form, but may also be shown or named in an alternative tautomeric form. The alternative tautomeric form is explicitly included in the present disclosure, for example, the structure shown below. For example, benzimidazole or imidazole may exist in the following tautomeric form:

[0902]

[0903] Synthesis of compounds

[0904] The compounds of formula (I) described herein are synthesized using standard synthetic techniques or using methods known in the art in combination with methods described herein.

[0905] Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC were used.

[0906] The compounds are prepared using standard organic chemistry techniques such as those described in, for example, March's Advanced Organic Chemistry, 6th Edition, John Wiley and Sons, Inc. Alternative reaction conditions for the synthetic transformations described herein may be used, such as variations in solvents, reaction temperatures, reaction times, and different chemical reagents and other reaction conditions.

[0907] In some embodiments, the compounds described herein are prepared as described in Scheme A.

[0908] Option A:

[0909]

[0910] a) DIPEA, THF; b) Pd catalyst, base; c) NaClO 2 , NaH 2 PO 4 , 2-methylbut-2-ene, t-BuOH / water; d) HATU, DIPEA, R 6 R 7 NH, DMF; e) deprotection;

[0911] Nucleophilic substitution of I with a protected aminopyrrolidine affords intermediate II, which is subsequently reacted via an organometallic coupling reaction such as with a boronic acid (R d B(OH) 2 ) or its ester or organic trifluoroborate (R d BF 3 K) and is converted to intermediate III by Suzuki-Miyaura reaction. Aldehyde III is oxidized by an oxidizing agent (e.g., NaClO 2 ) to generate the corresponding acid IV, which is coupled with an amine in the presence of a coupling agent such as HATU or 1-chloro-N,N,2-trimethyl-1-propenylamine (Ghosez reagent) to generate the amide intermediate V. Alternatively, the aldehyde II is oxidized by an oxidizing agent (e.g., NaClO 2 ) to generate acid VII, which can react with amine in the presence of a coupling agent (e.g., HATU) to generate amide intermediate VIII. This compound is subjected to an organometallic coupling reaction such as Suzuki-Miyaura reaction to generate compound V. The protecting group is removed by using an appropriate deprotection method to obtain the final compound VI.

[0912] In some other embodiments, the compounds described herein are prepared as described in Scheme B.

[0913] Option B:

[0914]

[0915] a)TEA, MeCN; b)1-bromopyrrolidine-2,5-dione, HOAc; c)boronic acid / ester, Pd; d)Zn(CN) 2 , Pd; e)NaClO 2 , NaH 2 PO 4 , 2-methylbut-2-ene, t-BuOH / water; f) coupling agent, DIPEA, R 6 R 7 NH, DMF; g) deprotection; h) LiOH, MeOH / water; i) Pd, cO, MeOH; j) (1) NH 3 , MeOH;

[0916] (2)TFAA

[0917] Nucleophilic substitution of IX with a protected aminopyrrolidine provides intermediate X, which is halogenated to provide compound XI. Subsequently, the halogenated intermediate IX is halogenated to provide compound XI. d B(OH) 2 ) or its ester or organic trifluoroborate (R d BF 3 K) an organometallic coupling reaction such as the Suzuki–Miyaura reaction converts XI to intermediate XII. Compound XII is converted to nitrile XIII by using an organometallic cyanation reaction, which is oxidized by an oxidizing agent such as NaClO 2 Treatment to generate acid XIV. The compound can react with amines in the presence of a coupling agent (e.g., HATU) to generate amide XV. Alternatively, 4,6-dichloronicotinate XVII is converted into nitrile XVIII by an organometallic cyanidation reaction, which is nucleophilically substituted with protected aminopyrrolidine to generate intermediate XIX. Subsequently, the compound is treated with a halogenating agent such as NBS or 1-bromopyrrolidine-2,5-dione to generate XX. Intermediate XX is converted into XXI by using an organometallic coupling reaction (e.g., Suzuki-Miyaura reaction), which is hydrolyzed to acid XIV in the presence of a base. Intermediate XIX can also be converted into acid XXV, allowing it to react with amines to generate amide XXVI. Halogenation is then followed by an organometallic coupling reaction, such as a Suzuki-Miyaura reaction, to generate intermediate XV. Intermediate XXVI is also synthesized by using different methods. Nucleophilic substitution of XVII with a protected aminopyrrolidine affords intermediate XXII, which is hydrolyzed under alkaline conditions and then coupled with an appropriate amine to give amide XXIII. This compound is subjected to organometallic carbonylation conditions and the resulting ester XIV is converted to the corresponding amide, which can be easily dehydrated to give nitrile XXVI. The protecting group of intermediate XV is removed by using an appropriate deprotection method to afford the final compound XVI.

[0918] In some other embodiments, the compounds described herein are prepared as described in Scheme C.

[0919] Option C:

[0920]

[0921] a)TEA, MeCN; b)1-bromopyrrolidine-2,5-dione, HOAc; c)R d B(OR) 2 or R d BF 3 K, Pd; d) Zn(CN) 2 , Pd; e)NaClO 2 , NaH 2 PO 4 , 2-methylbut-2-ene, t-BuOH / water; f) coupling agent, DIPEA, R 6 R 7 NH, DMF; g) deprotection; h) LiOH, MeOH / water;

[0922] Nucleophilic substitution of IX with a protected aminopyrrolidine provides intermediate X, which is brominated to provide intermediate XI. Compound XI is then converted to intermediate XII via an organometallic coupling reaction (e.g., Suzuki-Miyaura reaction), which undergoes another organometallic coupling reaction to introduce R c The compound is oxidized by an oxidizing agent such as NaClO 2 The 4,6-dichloronicotinate XVII is treated to generate the acid XXIX, which can react with an amine in the presence of a coupling reagent such as HATU or Ghosez reagent to generate the amide XXX. Alternatively, the protected aminopyrrolidine nucleophilically displaces the 4,6-dichloronicotinate XVII to give the intermediate XXXII, which is hydrolyzed under alkaline conditions and then coupled with an amine to generate the amide XXXIII. This compound is converted to the intermediate XXXIV by an organometallic coupling reaction to introduce R cGroup. Halogenation of intermediate XXXIV leads to the formation of intermediate XXXV, which can be converted into compound XXX by an organometallic coupling reaction (e.g., Suzuki-Miyaura reaction). Alternatively, 4,6-dichloronicotinate XVII is converted into XXXII, which is then converted into XXXVI by an organometallic coupling reaction, and then halogenated to obtain compound XXVII. The compound is converted into intermediate XXXVIII by an organometallic coupling reaction (e.g., Suzuki-Miyaura reaction), which is hydrolyzed under alkaline conditions to generate acid XXIX. The protecting group of intermediate XXX is removed by using an appropriate deprotection method to obtain final compound XXXI.

[0923] In some other embodiments, the compounds described herein are prepared as described in Scheme D.

[0924] Plan D:

[0925]

[0926] a)TEA, MeCN; b)NaOR c′ ; c) 1-bromopyrrolidine-2,5-dione, HOAc; d) R d B(OR) 2 or R d BF 3 K, Pd; e) LiOH, MeOH / water; f) coupling agent, DIPEA, R 6 R 7 NH, DMF; g) deprotection;

[0927] Nucleophilic substitution of 4,6-dichloronicotinate XVII by protected aminopyrrolidine provides intermediate XXXII, which is treated with an alkoxide with or without an organometallic catalyst to generate compound XXXIX. Subsequent halogenation, followed by an organometallic coupling reaction, such as the Suzuki-Miyaura reaction, provides intermediate XLI. This compound is converted to acid XLII under alkaline conditions, which is coupled with an amine in the presence of a coupling agent such as HATU or a Ghosez reagent to generate amide XLIII. The protecting group of intermediate XLIII is removed by using an appropriate deprotection method to obtain the final compound XLIV. Alternatively, ester XXXII is converted to acid XLV under alkaline conditions, which is coupled with an amine in the presence of a coupling agent such as HATU or a Ghosez reagent to generate amide XLVI. Subsequent halogenation, followed by an organometallic coupling reaction, such as the Suzuki-Miyaura reaction, provides intermediate XLVIII. The protecting group is removed by using an appropriate deprotection method, followed by treatment with an alkoxide to result in the formation of the final compound XLIV.

[0928] In some other embodiments, the compounds described herein are prepared as described in Scheme E.

[0929] Plan E:

[0930]

[0931] a)TEA, MeCN; b)Na 2 S 2 O 5 , DMSO; c) Pd, CO, R'OH; d) NaOH; e) coupling agent, DIPEA, R 6 R 7 NH, DMF; f) deprotection;

[0932] Nucleophilic substitution of I with protected aminopyrrolidine affords intermediate II, which is reacted under atmospheric oxygen in the presence or absence of Na 2 S 2 O 5 In the case of , benzimidazole LII is treated with 1,2-diaminobenzene by heating in wet DMF or NMP or DMSO or other solvents. Subsequently, LII is converted to ester LIII by organometallic carbonylation. Alternatively, compound II can be converted to ester L by organometallic carbonylation, which is reacted with or without Na under atmospheric oxygen. 2 S 2 O 5 In the case of , the benzimidazole LIII is generated by treatment with 1,2-diaminobenzene by heating in wet DMF or NMP or DMSO or other solvents. Alternatively, the benzoimidazole LIII can be prepared under atmospheric oxygen in the presence or absence of Na 2 S 2 O 5 In the case of aldehydes I is reacted with 1,2-diaminobenzene by heating in wet DMF or NMP or DMSO or other solvents to give imidazole LI, which is subjected to nucleophilic substitution with protected aminopyrrolidine to produce intermediate LII. Subsequently, ester LIII is converted to acid LIV under basic conditions, which is treated with amine in the presence of a coupling reagent such as HATU to give amide LV. The protecting group is removed by using an appropriate deprotection method to give the final compound LVI.

[0933] In some other embodiments, the compounds described herein are prepared as described in Scheme F.

[0934] Plan F:

[0935]

[0936] a) K2CO3, dioxane; b) R d B(OR) 2 or Rd BF 3 K, Pd; c) LiOH, THF / water; d) HATU, DIPEA, R 6 R 7 NH, DMF; (e) deprotection;

[0937] Nucleophilic substitution of LVII by protected aminopyrrolidine provides intermediate LVIII, which is converted to compound LIX by organometallic coupling reaction (e.g., Suzuki-Miyaura reaction). Basic hydrolysis of ester LIX leads to formation of acid LX, which reacts with amine in the presence of amide coupling agent (e.g., HATU) to generate intermediate LXI. Removal of protecting groups by using appropriate deprotection methods gives final compound LXII.

[0938] In some other embodiments, the compounds described herein are prepared as described in Scheme G.

[0939] Plan G:

[0940]

[0941] a) Pd, Zn(CN) 2 ; b) LDA, I 2 ; c) R d B(OR) 2 or R d BF 3 K, Pd; d) DIPEA, MCN; e) KOH, EtOH / water; f) HATU, DIPEA, R 6 R 7 NH, DMF; g) deprotection; h) R C B(OR) 2 or R C BF 3 K, Pd;

[0942] Transition metal-catalyzed cyanation of bromo-pyridine LXIII provides nitrile intermediate LXIV, which is iodinated in the presence of a strong base such as LDA to generate LXV. Compound LXV is converted to intermediate LXVI by an organometallic coupling reaction such as the Suzuki-Miyaura reaction. Subsequent nucleophilic substitution with a protected aminopyrrolidine provides intermediate LXVII, which is hydrolyzed to the acid LXVIII under basic conditions. Compound LXVIII is treated with an amine in the presence of a coupling agent such as HATU to generate the amide LXIX. The protecting group is removed by using an appropriate deprotection method to obtain the final compound LXX. Compound LXIX can be converted to intermediate LXXI by an organometallic coupling reaction such as the Suzuki–Miyaura reaction. The protecting group is removed by using an appropriate deprotection method to obtain the final compound LXXII.

[0943] In some embodiments, the compounds are prepared as described in the Examples.

[0944] Certain terms

[0945] Unless otherwise indicated, the following terms used in this application have the definitions given below. The use of the term "includes" as well as other forms such as "comprising" is non-limiting. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.

[0946] As used herein, C 1 -C x Including C 1 -C 2 , C 1 -C 3 ...C 1 -C x . For example only, it is referred to as "C 1 -C 6 " indicates that there are one to six carbon atoms in the moiety, i.e., a group containing 1 carbon atom, 2 carbon atoms, 3 carbon atoms, or 4 carbon atoms. Thus, by way of example only, "C 1 -C 4 "Alkyl" means that there are one to four carbon atoms in the alkyl group, i.e., the alkyl group is selected from methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.

[0947] An "alkyl" group refers to an aliphatic hydrocarbon group. An alkyl group is a branched or straight chain. In some embodiments, an "alkyl" group has 1 to 10 carbon atoms, i.e., C 1 -C 10Alkyl. Whenever it appears herein, a numerical range such as "1 to 10" refers to each integer in the given range; for example, "1 to 10 carbon atoms" means that the alkyl group consists of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc. up to and including 10 carbon atoms, but this definition also includes the occurrence of the term "alkyl" without specifying a numerical range. In some embodiments, the alkyl group is C 1 -C 6 Alkyl. In one aspect, the alkyl is methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl. Typical alkyls include but are not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl or hexyl.

[0948] An "alkylene" group refers to a divalent alkyl group. Any of the above-mentioned monovalent alkyl groups can be converted to an alkylene group by removing the second hydrogen atom from the alkyl group. In some embodiments, the alkylene group is C 1 -C 6 In other embodiments, the alkylene group is C 1 -C 4 Typical alkylene groups include, but are not limited to, -CH 2 -、-CH 2 CH 2 -、-CH 2 CH 2 CH 2 -、-CH 2 CH 2 CH 2 CH 2 -, etc. In some embodiments, alkylene is -CH 2 -.

[0949] An "alkoxy" group refers to an (alkyl)O- group where alkyl is as defined herein.

[0950] The term "alkylamine" refers to -N(alkyl) x H y A group wherein x is 0 and y is 2, or wherein x is 1 and y is 1, or wherein x is 2 and y is 0.

[0951] "Hydroxyalkyl" refers to an alkyl group in which one hydrogen atom is replaced by a hydroxy group. In some embodiments, the hydroxyalkyl group is C 1 -C 4 Typical hydroxyalkyl groups include, but are not limited to, -CH 2 OH, -CH 2 CH 2 OH, -CH 2 CH 2 CH 2OH, -CH 2 CH 2 CH 2 CH 2 OH, etc.

[0952] "Aminoalkyl" refers to an alkyl group in which one hydrogen atom is replaced by an amino group. In some embodiments, the aminoalkyl group is C 1 -C 4 Aminoalkyl. Typical aminoalkyl groups include, but are not limited to, -CH 2 NH 2 、-CH 2 CH 2 NH 2 、-CH 2 CH 2 CH 2 NH 2 、-CH 2 CH 2 CH 2 CH 2 NH 2 wait.

[0953] The term "alkenyl" refers to a type of alkyl group in which at least one carbon-carbon double bond is present. In one embodiment, the alkenyl group has the formula -C(R)=CR 2 , wherein R refers to the rest of the alkenyl group, which may be the same or different. In some embodiments, R is H or alkyl. In some embodiments, the alkenyl group is selected from vinyl, propenyl (i.e., allyl), butenyl, pentenyl, pentadienyl, and the like. Non-limiting examples of alkenyl groups include -CH=CH 2 、-C(CH 3 )=CH 2 、-CH=CHCH 3 、-C(CH 3 )=CHCH 3 and –CH 2 CH=CH 2 .

[0954] The term "alkynyl" refers to a class of alkyl groups in which at least one carbon-carbon triple bond is present. In one embodiment, the alkenyl group has the formula -C≡CR, wherein R refers to the remainder of the alkynyl group. In some embodiments, R is H or an alkyl group. In some embodiments, the alkynyl group is selected from ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Non-limiting examples of alkynyl groups include -C≡CH, -C≡CCH 3 、-C≡CCH 2 CH 3 、-CH 2 C≡CH.

[0955] The term "heteroalkyl" refers to an alkyl group in which one or more of the backbone atoms of the alkyl group is selected from atoms other than carbon, for example, oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, or a combination thereof. The heteroalkyl group is attached to the remainder of the molecule at a carbon atom of the heteroalkyl group. In one aspect, the heteroalkyl group is C 1 -C 6 Heteroalkyl.

[0956] The term "aromatic" refers to a planar ring having a delocalized π electron system containing 4n+2 π electrons, where n is an integer. The term "aromatic" includes carbocyclic aryl ("aryl", e.g., phenyl) and heterocyclic aryl (or "heteroaryl" or "heteroaromatic") groups (e.g., pyridine). The term includes monocyclic or fused-ring polycyclic (i.e., rings that share adjacent pairs of carbon atoms) groups.

[0957] The term "carbocyclic" or "carbocycle" refers to a ring or ring system in which the atoms constituting the ring backbone are all carbon atoms. Thus, the term distinguishes carbocycles from "heterocyclic" rings or "heterocycles" in which the ring backbone contains at least one atom different from carbon. In some embodiments, at least one of the two rings of a bicyclic carbocycle is aromatic. In some embodiments, both rings of a bicyclic carbocycle are aromatic. Carbocycles include aryl and cycloalkyl.

[0958] As used herein, the term "aryl" refers to an aromatic ring in which each atom constituting the ring is a carbon atom. In one aspect, aryl is phenyl or naphthyl. In some embodiments, aryl is phenyl. In some embodiments, aryl is phenyl, naphthyl, indanyl, indenyl, or tetrahydronaphthyl. In some embodiments, aryl is C 6 -C 10 Aryl. Depending on the structure, an aryl group is a monovalent or divalent group (ie, an arylene group).

[0959] The term "cycloalkyl" refers to a non-aromatic group of a monocyclic or polycyclic aliphatic group in which each atom (i.e., backbone atom) constituting the ring is a carbon atom. In some embodiments, the cycloalkyl is a spirocyclic or bridged ring compound. In some embodiments, the cycloalkyl is optionally fused to an aromatic ring, and the point of attachment is on a carbon that is not an aromatic ring carbon atom. The cycloalkyl group includes a group having 3 to 10 ring atoms. In some embodiments, the cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, spiro [2.2] pentyl, norbornyl, and bicyclo [1.1.1] pentyl. In some embodiments, the cycloalkyl is C 3 -C 6 In some embodiments, the cycloalkyl group is C 3 -C 4 Cycloalkyl.

[0960] The term "halo" or alternatively "halogen" or "halo" means fluoro, chloro, bromo or iodo. In some embodiments, halo is fluoro, chloro or bromo.

[0961] The term "fluoroalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by fluorine atoms. 1 -C 6 Fluoroalkyl.

[0962] The term "heterocycle" or "heterocyclic" refers to heteroaromatic rings (also known as heteroaryls) and heterocycloalkyl rings containing one to four heteroatoms in the ring, wherein each heteroatom in the ring is selected from O, S and N, wherein each heterocyclic group has 3 to 10 atoms in its ring system, but with the proviso that no ring contains two adjacent O or S atoms. Non-aromatic heterocyclic groups (also known as heterocycloalkyls) include rings having 3 to 10 atoms in their ring system, while aromatic heterocyclic groups include rings having 5 to 10 atoms in their ring system. Heterocyclic groups include benzo-fused ring systems. Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, oxazolidinyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thiooxanyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepine Base, diazepine Thiazepine 1,2,3,6-tetrahydropyridinyl, pyrrolin-2-yl, pyrrolin-3-yl, indolyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothiophenyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[ 4.1.0] heptyl, 3H-indolyl, indolin-2-one, isoindolyl-1-one, isoindolyl-1,3-dione, 3,4-dihydroisoquinolin-1(2H)-one, 3,4-dihydroquinolin-2(1H)-one, isoindolyl-1,3-disulfinyl, benzo[d]oxazol-2(3H)-one, 1H-benzo[d]imidazol-2(3H)-one, benzo[d]thiazol-2(3H)-one and quinolizinyl. Examples of aromatic heterocyclic groups are pyridyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furanyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolyl, isoquinolyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothienyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl and furopyridinyl. The above groups are C-attached (or C-attached) or N-attached (if such is possible). For example, groups derived from pyrrole include pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). In addition, the group derived from imidazole includes imidazole-1-yl or imidazole-3-yl (all N-connected) or imidazole-2-yl, imidazole-4-yl or imidazole-5-yl (all C-connected). Heterocyclic groups include benzo-fused ring systems. Non-aromatic heterocycles are optionally substituted with one or two oxo (=O) moieties, such as pyrrolidin-2-one. In some embodiments, at least one of the two rings of the bicyclic heterocycle is aromatic. In some embodiments, both rings of the bicyclic heterocycle are aromatic.

[0963] The term "heteroaryl" or alternative "heteroaromatic" refers to an aryl group including one or more ring heteroatoms selected from nitrogen, oxygen and sulfur. Illustrative examples of heteroaryl groups include monocyclic heteroaryl and bicyclic heteroaryl. Monocyclic heteroaryl includes pyridyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl and furazanyl. Monocyclic heteroaryl includes indolizine, indole, benzofuran, benzothiophene, indazole, benzimidazole, purine, quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine and pteridine. In some embodiments, heteroaryl contains 0-4 N atoms in the ring. In some embodiments, the heteroaryl group contains 1-4 N atoms in the ring. In some embodiments, the heteroaryl group contains 0-4 N atoms, 0-1 O atoms, and 0-1 S atoms in the ring. In some embodiments, the heteroaryl group contains 1-4 N atoms, 0-1 O atoms, and 0-1 S atoms in the ring. In some embodiments, the heteroaryl group is C 1 -C 9 In some embodiments, the monocyclic heteroaryl is C 1 -C 5 In some embodiments, the monocyclic heteroaryl is a 5-membered or 6-membered heteroaryl. In some embodiments, the bicyclic heteroaryl is C 6 -C 9 Heteroaryl.

[0964] "Heterocycloalkyl" refers to a cycloalkyl group that includes at least one heteroatom selected from nitrogen, oxygen, and sulfur. In some embodiments, the heterocycloalkyl group is fused with an aryl or heteroaryl group. In some embodiments, the heterocycloalkyl group is an oxazolidinone group, a pyrrolidinyl group, a tetrahydrofuranyl group, a tetrahydrothiophenyl group, a tetrahydropyranyl group, a tetrahydrothiopyranyl group, a piperidinyl group, a morpholinyl group, a thiomorpholinyl group, a piperazinyl group, a piperidin-2-one group, a pyrrolidine-2,5-disulfinyl group, a pyrrolidine-2,5-dione group, a pyrrolidinone group, an imidazolidinyl group, an imidazolidin-2-one group, or a thiazolidine-2-one group. In one aspect, the heterocycloalkyl group is C 2 -C 10 In another aspect, the heterocycloalkyl group is C 4 -C 10In some embodiments, heterocycloalkyl is monocyclic or bicyclic. In some embodiments, heterocycloalkyl is monocyclic and is 3-, 4-, 5-, 6-, 7- or 8-membered ring. In some embodiments, heterocycloalkyl is monocyclic and is 3-, 4-, 5- or 6-membered ring. In some embodiments, heterocycloalkyl is monocyclic and is 3- or 4-membered ring. In some embodiments, heterocycloalkyl contains 0-2 N atoms in the ring. In some embodiments, heterocycloalkyl contains 0-2 N atoms, 0-2 O atoms and 0-1 S atoms in the ring.

[0965] The term "bond" or "single bond" refers to a chemical bond between two atoms or moieties when the atoms connected by the bond are considered to be part of a larger substructure. In one aspect, when a group described herein is a bond, the group mentioned is absent, thereby allowing a bond to form between the remaining identified groups.

[0966] The term "moiety" refers to a specific fragment or functional group of a molecule. A chemical moiety is generally a recognized chemical entity embedded in or attached to a molecule.

[0967] The term "optionally substituted" or "substituted" means that the referenced group is optionally substituted with one or more other groups individually and independently selected from halogen, -CN, -NH 2 、-NH(alkyl), -N(alkyl) 2 、-OH、-CO 2 H, -CO 2 Alkyl, -C(=O)NH 2 、-C(=O)NH(alkyl)、-C(=O)N(alkyl) 2 、-S(=O) 2 NH 2 、-S(=O) 2 NH(alkyl), -S(=O) 2 N(alkyl) 2 , alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, heterocycloalkyl, aryl, heteroaryl, aryloxy, alkylthio, arylthio, alkyl sulfoxide, aryl sulfoxide, alkyl sulfone and aryl sulfone. In some other embodiments, the optional substituents are independently selected from halogen, -CN, -NH 2 、-NH(CH 3 )、-N(CH 3 ) 2 、-OH、-CO 2 H, -CO 2 (C 1 -C 4 alkyl), -C(=O)NH 2 、-C(=O)NH(C1 -C 4 alkyl), -C(=O)N(C 1 -C 4 alkyl) 2 、-S(=O) 2 NH 2 、-S(=O) 2 NH(C 1 -C 4 Alkyl), -S(=O) 2 N(C 1 -C 4 alkyl) 2 , C 1 -C 4 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 4 Fluoroalkyl, C 1 -C 4 Heteroalkyl, C 1 -C 4 Alkoxy, C 1 -C 4 Fluoroalkoxy, -SC 1 -C 4 Alkyl, -S(=O)C 1 -C 4 Alkyl and -S(=O) 2 C 1 -C 4 In some embodiments, the optional substituents are independently selected from halogen, -CN, -NH 2 、-OH、-NH(CH 3 )、-N(CH 3 ) 2 、-CH 3 、-CH 2 CH 3 , -CHF 2 , -CF 3 、-OCH 3 、-OCHF 2 and-OCF 3 In some embodiments, the substituted groups are substituted with one or two of the aforementioned groups. In some embodiments, optional substituents on aliphatic carbon atoms (non-cyclic or cyclic) include oxo (=0).

[0968] In some embodiments, each substituted alkyl, substituted fluoroalkyl, substituted heteroalkyl, substituted carbocycle, and substituted heterocycle is replaced by one or more R s The group is substituted, the R s The groups are independently selected from halogen, C1 -C 6 Alkyl, monocyclic carbocycle, monocyclic heterocycle, -CN, -OR 21 , -CO 2 R 21 、-C(=O)N(R 21 ) 2 、-N(R 21 ) 2 、-NR 21 C(=O)R 22 、-SR 21 、-S(=O)R 22 、-SO 2 R 22 or -SO 2 N(R 21 ) 2 ; Each R 21 are independently selected from hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Heteroalkyl, C 3 -C 6 Cycloalkyl, C 2 -C 6 heterocycloalkyl, phenyl, benzyl, 5-membered heteroaryl and 6-membered heteroaryl; or two R 21 The groups together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring; each R 22 Independently selected from C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Heteroalkyl, C 3 -C 6 Cycloalkyl, C 2 -C 6 Heterocycloalkyl, phenyl, benzyl, 5-membered heteroaryl and 6-membered heteroaryl.

[0969] As used herein, the term "acceptable" with respect to a formulation, composition or ingredient means having no persistent detrimental effect on the general health of the subject being treated.

[0970] As used herein, the term "modulate" means to interact directly or indirectly with a target to change the activity of the target, including, by way of example only, to enhance the activity of the target, inhibit the activity of the target, limit the activity of the target, or prolong the activity of the target.

[0971] The term "modulator" as used herein refers to a molecule that interacts directly or indirectly with a target. The interaction includes, but is not limited to, the interaction of an agonist, a partial agonist, an inverse agonist, an antagonist, a degrader, or a combination thereof. In some embodiments, the modulator is an agonist.

[0972] As used herein, the terms "administering", "administration" and similar terms refer to methods that can be used to enable a compound or composition to be delivered to a desired biological site of action. These methods include, but are not limited to, oral routes, intraduodenal routes, parenteral injections (including intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular or infusion), topical and rectal administration. Those skilled in the art are familiar with administration techniques that can be used with the compounds and methods described herein. In some embodiments, the compounds and compositions described herein are administered orally.

[0973] As used herein, the term "co-administration" or similar terms is intended to include administration of selected therapeutic agents to a single patient, and is intended to include treatment regimens in which the agents are administered by the same or different routes of administration, or at the same or different times.

[0974] As used herein, the term "effective amount" or "therapeutically effective amount" refers to a sufficient amount of an agent or compound administered that will alleviate to some extent one or more symptoms of the disease or condition being treated. Results include alleviation and / or relief of signs, symptoms, or causes of disease, or any other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound disclosed herein required to provide a clinically significant reduction in disease symptoms. An appropriate "effective" amount in any individual case is optionally determined using techniques such as dose escalation studies.

[0975] As used herein, the term "enhancing" means to increase or prolong either in potency or duration a desired effect. Thus, with respect to enhancing the effect of therapeutic agents, the term "enhancing" refers to the ability to increase or prolong, either in potency or duration, the effect of other therapeutic agents on a system. As used herein, an "enhancing-effective amount" refers to an amount sufficient to enhance the effect of another therapeutic agent in a desired system.

[0976] The term "pharmaceutical combination" as used herein means a product obtained by mixing or combining more than one active ingredient, and includes fixed and non-fixed combinations of active ingredients. The term "fixed combination" means that the active ingredients, such as a compound of formula (I) or a pharmaceutically acceptable salt thereof, and an adjuvant (co-agent) are all administered to the patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, such as a compound of formula (I) or a pharmaceutically acceptable salt thereof, and an adjuvant are administered to the patient simultaneously, jointly, or sequentially without specific interval time restrictions as separate entities, wherein such administration provides effective levels of the two compounds in the patient's body. The latter is also applicable to cocktail therapy, for example, the administration of three or more active ingredients.

[0977] The terms "article of manufacture" and "kit" are used synonymously.

[0978] The term "subject" or "patient" includes mammals. Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates such as chimpanzees, and other apes and monkeys; farm animals such as cattle, horses, sheep, goats, pigs; domestic animals such as rabbits, dogs and cats; laboratory animals, including rodents such as rats, mice and guinea pigs, etc. In one aspect, the mammal is a human.

[0979] As used herein, the term "treating" includes prophylactically and / or therapeutically alleviating, alleviating, or ameliorating at least one symptom of a disease or condition, preventing other symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, alleviating the conditions caused by the disease or condition, or cessation of symptoms of the disease or condition.

[0980] Pharmaceutical composition

[0981] In some embodiments, the compounds described herein are formulated into pharmaceutical compositions. Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients, which facilitate the processing of active compounds into pharmaceutically useful preparations. The appropriate formulation depends on the selected route of administration. An overview of the pharmaceutical compositions described herein is found in, for example, Remington: The Science and Practice of Pharmacy, 19th Edition (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition (Lippincott Williams & Wilkins 1999), which are incorporated herein by reference for their disclosure.

[0982] In some embodiments, the compounds described herein are administered alone or in combination with a pharmaceutically acceptable carrier, excipient or diluent in a pharmaceutical composition. The administration of the compounds and compositions described herein can be achieved by any method that enables the compound to be delivered to the site of action. These methods include, but are not limited to, by enteral routes (including oral, gastric or duodenal feeding tubes, rectal suppositories and rectal enemas), parenteral routes (injection or infusion, including intra-arterial, intracardiac, intradermal, intraduodenal, intramedullary, intramuscular, intraosseous, intraperitoneal, intrathecal, intravascular, intravenous, intravitreal, epidural and subcutaneous), inhalation, transdermal, transmucosal, sublingual, buccal and local (including skin, dermis, enema, eye drops, ear drops, intranasal, vaginal) administration to deliver, but the most suitable approach may depend on, for example, the condition and illness of the recipient. For example only, the compounds described herein can be applied topically to the area in need of treatment by, for example, local infusion, topical application such as cream or ointment, injection, catheter or implant in surgery. Administration can also be by direct injection at the site of diseased tissue or organ.

[0983] In some embodiments, pharmaceutical compositions suitable for oral administration are presented as discrete units such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. In some embodiments, the active ingredient is presented as a pill, electuary, or paste.

[0984] Orally usable pharmaceutical compositions include tablets, push-fit capsules made of gelatin, and sealed soft capsules made of gelatin and plasticizers such as glycerol or sorbitol. Tablets can be prepared by compressing or molding optionally with one or more auxiliary ingredients. Compressed tablets can be prepared by compressing the active ingredient of a free-flowing form such as a powder or granules optionally mixed with a binder, an inert diluent or lubricant, a surfactant or a dispersant in a suitable machine. Molded tablets can be prepared by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine. In some embodiments, the tablets are coated or scored and formulated to provide a slow or controlled release of the active ingredient therein. All preparations for oral administration should be suitable for the dosage of the administration. Push-fit capsules can contain active ingredients mixed with fillers such as lactose, binders such as starch, and / or lubricants such as talc or magnesium stearate, and optional stabilizers. In soft capsules, the active compound can be dissolved or suspended in a suitable liquid such as fatty oil, liquid paraffin or liquid polyethylene glycol. In some embodiments, a stabilizer is added. The lozenge core is provided with a suitable coating. To achieve this purpose, a concentrated sugar solution can be used, which can optionally contain gum arabic, talcum, polyvinyl pyrrolidone, carbomer (carbopol) gel, polyethylene glycol and / or titanium dioxide, lacquer solution and a suitable organic solvent or solvent mixture. Dye or pigment can be added to tablets or lozenge coatings to be used to identify or characterize the different combinations of active compound dosage.

[0985] In some embodiments, the pharmaceutical composition is formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion. The preparation for injection can be presented in, for example, an ampoule or a multi-dose container in a unit dosage form with the addition of a preservative. The composition can take the form of a suspension, solution or emulsion such as in an oily or aqueous vehicle, and can contain a formulation such as a suspending agent, a stabilizer and / or a dispersant. The composition can be presented in a unit dose or multi-dose container such as a sealed ampoule and a vial, and can be stored in a powder form or under freeze drying (lyophilization), only requiring the addition of a sterile liquid carrier, such as saline or sterile pyrogen-free water, just before use. Temporary injection solutions and suspensions can be prepared by such sterile powders, granules and tablets described above.

[0986] Pharmaceutical compositions for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compound, which may contain antioxidants, buffers, bacteriostats, and solutes that make the preparation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions, which may contain suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain a suitable stabilizer or an agent that increases the solubility of the compound to allow the preparation of a highly concentrated solution.

[0987] Pharmaceutical compositions can also be formulated as depot preparations. Such long-acting preparations can be administered by (e.g., subcutaneous or intramuscular) implantation or by intramuscular injection. Thus, for example, the compound can be formulated with a suitable polymeric material or hydrophobic material (e.g., an emulsion in an acceptable oil) or an ion exchange resin, or formulated as a slightly soluble derivative, e.g., as a slightly soluble salt.

[0988] For buccal or sublingual administration, the composition may take the form of tablets, lozenges, pastilles or gels formulated in conventional manner. Such compositions may contain the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.

[0989] The pharmaceutical composition can be administered topically, i.e., by non-systemic administration. This includes external application of the compounds of the invention to the epidermis or buccal cavity, as well as instillation of such compounds into the ears, eyes, and noses, so that the compounds do not enter the bloodstream significantly. In contrast, systemic administration refers to oral, intravenous, intraperitoneal, and intramuscular administration.

[0990] Pharmaceutical compositions suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin into the site of inflammation, such as gels, liniments, lotions, creams, ointments or pastes, and drops suitable for application to the eyes, ears or nose. For topical administration, the active ingredient may constitute 0.001% to 10% w / w, e.g. 1% to 2% (by weight) of the preparation.

[0991] Pharmaceutical compositions for administration by inhalation are conveniently delivered from insufflators, nebulizer pressurized packages, or other convenient means for delivering aerosol sprays. The pressurized package may contain a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of pressurized aerosols, the dosage unit may be determined by providing a valve for delivering a metered amount. Alternatively, for administration by inhalation or insufflation, the pharmaceutical preparation may take the form of a dry powder composition, such as a powder mixture of the compound and a suitable powder matrix such as lactose or starch. The powder composition may be presented in a unit dosage form, for example, in a capsule, cartridge, gelatin or blister pack from which the powder may be administered with the aid of an insufflator or insufflator.

[0992] It should be understood that in addition to the ingredients particularly mentioned above, the compounds and compositions described herein may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.

[0993] Dosage and treatment regimen

[0994] In one embodiment, a compound of formula (I) or a pharmaceutically acceptable salt thereof is used to prepare a medicament for treating a disease or condition in a mammal that would benefit from modulation of somatostatin activity. The method for treating any disease or condition described herein in a mammal in need of such treatment comprises administering to the mammal a pharmaceutical composition comprising at least one compound of formula (I) or a pharmaceutically acceptable salt, active metabolite, prodrug or pharmaceutically acceptable solvate thereof in a therapeutically effective amount.

[0995] In certain embodiments, a composition containing a compound as described herein is administered for preventive and / or therapeutic treatment. In certain therapeutic applications, the composition is administered to a patient already suffering from the disease or condition in an amount sufficient to cure or at least partially prevent at least one symptom of the disease or condition. The amount effective for this use depends on the severity and progression of the disease or condition, previous treatment, the patient's health, body weight, and response to the drug, and the judgment of the treating physician. The therapeutically effective amount is optionally determined by methods including, but not limited to, dose escalation and / or dose range clinical trials.

[0996] In preventive applications, a composition containing a compound as described herein is administered to a patient susceptible to or at risk of a particular disease, disorder or condition. Such an amount is defined as a "prophylactically effective amount or dose". In this use, the exact amount also depends on the patient's health, weight, etc. When used for a patient, the effective amount for this use will depend on the severity and progression of the disease, disorder or condition, previous treatment, the patient's health and response to the drug, and the judgment of the treating physician. In one aspect, preventive treatment includes administering a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof to a mammal that has previously experienced at least one symptom of the disease to be treated and is currently in remission, so as to prevent the recurrence of the symptoms of the disease or condition.

[0997] In certain embodiments where the patient's condition does not improve, at the discretion of the physician, administration of the compound is continued chronically, i.e., for an extended period of time, including throughout the patient's life, in order to alleviate or otherwise control or limit the symptoms of the patient's disease or condition.

[0998] Once the patient's condition improves, a maintenance dose is administered if necessary. Subsequently, in specific embodiments, the dosage or frequency of administration, or both, is reduced to a level at which the improved disease, disorder or condition is maintained, depending on the change in symptoms. However, in certain embodiments, patients require long-term intermittent treatment upon any recurrence of symptoms.

[0999] The amount of a given agent corresponding to such an amount varies depending on factors such as the specific compound, the disease condition and its severity, the characteristics of the subject or host in need of treatment (e.g., weight, sex), etc., but it is still determined according to the specific circumstances related to the case, which include, for example, the specific agent administered, the route of administration, the condition being treated, and the subject or host being treated.

[1000] However, in general, the dosage employed for adult treatment is generally within the range of 0.01 mg to 2000 mg per day. In one embodiment, the desired dose is conveniently presented in a single dose or in divided doses administered simultaneously or at appropriate intervals, for example 2, 3, 4 or more sub-doses per day.

[1001] In one embodiment, the daily dose suitable for the compound of formula (I) described herein or a pharmaceutically acceptable salt thereof is about 0.01 to about 50 mg / kg body weight. In some embodiments, the daily dose or the amount of active substance in the dosage form is lower or higher than the range indicated herein based on multiple variables related to a single treatment regimen. In various embodiments, the daily dose and unit dose vary according to multiple variables, including but not limited to the activity of the compound used, the disease or condition to be treated, the mode of administration, the needs of the individual subject, the severity of the disease or condition to be treated, and the judgment of the doctor.

[1002] Toxicity and therapeutic efficacy of such treatment regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including but not limited to LD 50 and ED 50 The dose ratio between toxic and therapeutic effects is the therapeutic index and is denoted as LD 50 With ED 50 In certain embodiments, the data obtained from cell culture assays and animal studies are used to formulate therapeutically effective daily dosage ranges and / or therapeutically effective unit dosages for mammals, including humans. In some embodiments, the daily dose of the compounds described herein is within the range of ED with minimal toxicity. 50 In certain embodiments, the daily dosage range and / or unit dosage varies within this range depending on the dosage form employed and the route of administration utilized.

[1003] Any of the above aspects is a further embodiment wherein an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof is: (a) systemically administered to a mammal; and / or (b) orally administered to a mammal; and / or (c) intravenously administered to a mammal; and / or (d) administered to a mammal by injection; and / or (e) topically administered to a mammal; and / or (f) non-systemically or topically administered to a mammal.

[1004] Any of the above aspects are further embodiments comprising a single administration of an effective amount of the compound, including further embodiments wherein (i) the compound is administered once daily; or (ii) the compound is administered to a mammal multiple times over the course of a day.

[1005] Any of the above aspects is a further embodiment comprising multiple administrations of an effective amount of the compound, including further embodiments wherein (i) the compound is administered continuously or intermittently: such as in a single dose; (ii) the time between multiple administrations is every 6 hours; (iii) the compound is administered to the mammal every 8 hours; (iv) the compound is administered to the mammal every 12 hours; (v) the compound is administered to the mammal every 24 hours. In further or alternative embodiments, the method comprises a drug holiday, wherein the administration of the compound is temporarily suspended or the dose of the compound administered is temporarily reduced; at the end of the drug holiday, administration of the compound is resumed. In one embodiment, the length of the drug holiday varies between 2 days and 1 year.

[1006] Combination therapy

[1007] In certain cases, it is appropriate to administer at least one compound of Formula (I) or a pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

[1008] In one embodiment, administration of an adjuvant enhances the therapeutic effectiveness of a compound described herein (i.e., the adjuvant has minimal therapeutic benefit on its own, but the overall therapeutic benefit to the patient is enhanced when combined with another therapeutic agent). Alternatively, in some embodiments, administering a compound described herein with another agent (also including a therapeutic regimen) that also has therapeutic benefit enhances the benefit felt by the patient.

[1009] In a specific embodiment, a compound of Formula (I) or a pharmaceutically acceptable salt thereof is co-administered with a second therapeutic agent, wherein the compound of Formula (I) or a pharmaceutically acceptable salt thereof and the second therapeutic agent modulate different aspects of the disease, disorder or condition being treated, thereby providing a greater overall benefit than administration of either therapeutic agent alone.

[1010] In any case, regardless of the disease, disorder or condition being treated, the overall benefit experienced by the patient is simply additive of the two therapeutic agents, or whether the patient experiences a synergistic benefit.

[1011] For the combination therapies described herein, dosages of the co-administered compounds vary depending on the type of co-drug employed, the specific drug employed, the disease or condition being treated, etc. In additional embodiments, when a compound provided herein is co-administered with one or more other therapeutic agents, it is administered simultaneously or sequentially with the one or more other therapeutic agents.

[1012] In combination therapy, the multiple therapeutic agents (one of which is a compound described herein) are administered in any order or even simultaneously. If administered simultaneously, the multiple therapeutic agents are provided in a single unified form, or in multiple forms (e.g., as a single pill or as two separate pills), by way of example only.

[1013] Formula (I) compound or its pharmaceutically acceptable salt and conjoint therapy are applied before, during or after the occurrence of a disease or condition, and the timing of applying the composition containing the compound is different. Therefore, in one embodiment, the compound as described herein is used as a preventive drug and is continuously applied to an object with a developmental condition or disease tendency to prevent the occurrence of the disease or condition. In another embodiment, the compound and composition are applied to the object as quickly as possible during or after the onset of symptoms. In a specific embodiment, after the onset of a disease or condition is detected or suspected, the compound as described herein is applied as quickly as possible, and continues for the duration necessary for treating the disease. In some embodiments, the duration required for treatment may vary, and the duration of treatment is adjusted to suit the specific needs of each object.

[1014] Example

[1015] As used above, and throughout the specification of the present invention, unless otherwise indicated, the following abbreviations shall be understood to have the following meanings:

[1016] abbreviation:

[1017] Pd(PPh 3 ) 4 : Tetrakis(triphenylphosphine)palladium(0);

[1018] Pd 2 (dba) 3 ·CHCl 3 : tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct;

[1019] Pd(dppf)Cl 2 :[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride;

[1020] Pd(PPh 3 ) 2 Cl 2 : bis(triphenylphosphine)palladium(II) dichloride;

[1021] PdAMphos or Pd(amphos)Cl 2 : bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II);

[1022] Pd(DtBPF)Cl 2 :[1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II);

[1023] DIEA or DIPEA: N,N-diisopropylethylamine;

[1024] Prep-HPLC: preparative high performance liquid chromatography;

[1025] LC-MS: liquid chromatography-mass spectrometry;

[1026] MS: mass spectrometry;

[1027] AcOH: acetic acid;

[1028] TFA: trifluoroacetic acid;

[1029] HCl: hydrochloric acid or hydrogen chloride;

[1030] MeCN or CH 3 CN or ACN: acetonitrile;

[1031] H 2 O: water;

[1032] DMSO: dimethyl sulfoxide;

[1033] DMF: dimethylformamide

[1034] DCM: dichloromethane

[1035] NBS: N-bromosuccinimide;

[1036] Br2: bromine;

[1037] NCS: N-chlorosuccinimide;

[1038] rt: room temperature;

[1039] SST: somatostatin;

[1040] SSTR: somatostatin receptor;

[1041] hrs: hours;

[1042] h or hr: hours;

[1043] min: minutes

[1044] N 2 : Nitrogen;

[1045] mg: milligram;

[1046] mL: milliliter;

[1047] eq. or equiv: equivalent;

[1048] mmol: millimole

[1049] μmol: micromole;

[1050] ppts: sediment;

[1051] K 2 CO 3 :Potassium carbonate

[1052] NaClO 2 : Sodium chlorite;

[1053] t-BuOH: tert-butyl alcohol

[1054] EtOAc: Ethyl acetate

[1055] Na 2 SO 4 :Sodium sulfate

[1056] NaHSO 4 : Sodium bisulfate;

[1057] Na 2 S 2 O 3 : Sodium thiosulfate.

[1058] The following examples are provided for illustrative purposes only and are not intended to limit the scope of the claims provided herein.

[1059] Synthesis of compounds

[1060] Example 1. 4-[(3S)-3-aminopyrrolidin-1-yl]-N,5-bis(3,5-dimethylphenyl)pyridine-3-carboxamide (Compound 1-1)

[1061]

[1062] Step 1-1, (S)-(1-(3-(3,5-dimethylphenyl)-5-formylpyridin-4-yl)pyrrolidin-3-yl)amino Preparation of tert-butyl formate: Under atmospheric nitrogen, tert-butyl N-[(3S)-1-(3-bromo-5-formylpyridin-4-yl)pyrrolidin-3-yl]carbamate (120 mg, 1.0 eq., 0.32 mmol, "Step 9-1, Example 9"), (3,5-dimethylphenyl)boronic acid (97 mg, 2.0 eq., 0.65 mmol), Pd 2 (dba) 3 ·CHCl 3 (33 mg, 0.10 eq., 0.032 mmol), P(t-Bu) 3 ·HBF 4(19 mg, 0.20 eq., 0.064 mmol) and K 3 PO 4 To a mixture of 4-nitropropene (206 mg, 3.0 equiv., 0.97 mmol) was added toluene (3.0 mL) and water (0.3 mL). The resulting mixture was stirred at 70 °C for 1 hour. The reaction solution was concentrated under vacuum, and the remaining residue was purified by silica gel chromatography eluting with ethyl acetate / petroleum ether (1:1) to provide 100 mg of the title compound. MS (M+H) + =396.5.

[1063] Step 1-2, (S)-4-(3-((tert-butoxycarbonyl)amino)pyrrolidin-1-yl)-5-(3,5-dimethylphenyl) Preparation of niacin : To a round-bottom flask, add (S)-tert-butyl (1-(3-(3,5-dimethylphenyl)-5-formylpyridin-4-yl)pyrrolidin-3-yl)carbamate (100 mg, 1.0 equivalent, 0.25 mmol), tert-butyl alcohol (4.2 mL), DCM (4.2 mL), NaH 2 PO 4 (91 mg, 3.0 eq., 0.76 mmol), 2-methylbut-2-ene (532 mg, 30 eq., 7.59 mmol), water (1.4 mL) and NaClO 2 (46 mg, 2.0 eq., 0.51 mmol). The resulting mixture was stirred at ambient temperature for 16 hours. The reaction mixture was concentrated under vacuum and the remaining residue was diluted with water (10 mL). The pH of the resulting aqueous solution was adjusted to about 4 and a solid product was precipitated. The resulting suspension was filtered and the solid was collected and dried under vacuum. This produced 70 mg of the title compound as a yellow solid. MS (M+H) + =412.5.

[1064] Step 1-3, (S)-(1-(3-(3,5-dimethylphenyl)-5-((3,5-dimethylphenyl)carbamoyl)pyrrolidone Preparation of tert-butyl (4-pyridin-4-yl)pyrrolidin-3-yl)carbamate: To a solution of (S)-4-(3-((tert-butoxycarbonyl)amino)pyrrolidin-1-yl)-5-(3,5-dimethylphenyl)nicotinic acid (50 mg, 1.0 eq., 0.12 mmol) in DCM (3.0 mL) was added Ghosez reagent (33 mg, 2.0 eq., 0.24 mmol). The resulting mixture was stirred at ambient temperature for 10 minutes, then pyridine (29 mg, 3.0 eq., 0.36 mmol) and 3,5-dimethylaniline (18 mg, 1.2 eq., 0.15 mmol) were added. The reaction mixture was stirred at ambient temperature for 2 hours. The crude reaction was concentrated under vacuum, and the remaining residue was purified by Prep-HPLC using the following conditions: column, XBridge Shield PR18 OBD, 5 μm, 19×150 mm; mobile phase, water (10 mmol / LNH4 HCO 3 +0.1% NH 3 ·H 2 O) and ACN (46% phase B up to 61% in 6 minutes); detector, UV 220 & 254 nm. This gave 15 mg of the title compound as a light yellow solid. MS (M+H) + =515.2.

[1065] Step 1-4, 4-[(3S)-3-aminopyrrolidin-1-yl]-N,5-bis(3,5-dimethylphenyl)pyridine-3-carboxylate Preparation of amines : To a solution of (S)-tert-butyl (1-(3-(3,5-dimethylphenyl)-5-((3,5-dimethylphenyl)carbamoyl)pyridin-4-yl)pyrrolidin-3-yl)carbamate in DCM (1.0 mL) was added TFA (1.0 mL). The resulting mixture was stirred at ambient temperature for 1 hour. The crude reaction was concentrated and dried under freeze to give 5.6 mg of 4-[(3S)-3-aminopyrrolidin-1-yl]-N,5-bis(3,5-dimethylphenyl)pyridine-3-carboxamide as a light yellow solid as TFA salt. MS (M+H) + =415.2.

[1066] The following compounds were prepared similarly to Example 1, using appropriate alternative reagents and substrates in different steps, which may require additional functional group modifications using appropriate reagents by known chemistry. The coupling reaction with aniline can be carried out using other coupling agents (e.g. HATU) under appropriate conditions. Different salts are available, such as HCl or formic acid or TFA salts.

[1067] Compound No. <![CDATA[MS(M+H) + ]]> 1-2 415.3 1-3 439.1 1-4 434.2 1-5 413.2 1-6 416.1

[1068] Example 2. 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide (Compound 1-16)

[1069]

[1070] Step 2-1, N-[(3S)-1-(3-bromo-5-formylpyridin-4-yl)-3-methylpyrrolidin-3-yl]carbamic acid Preparation of tert-butyl ester:To a MeCN solution (100 mL) of 5-bromo-4-chloropyridine-3-carbaldehyde (12 g, 1.0 eq., 54 mmol) was added tert-butyl N-[(3S)-3-methylpyrrolidin-3-yl]carbamate (12 g, 1.1 eq., 60 mmol) and DIPEA (21 g, 3.0 eq., 160 mmol). The obtained solution was stirred at 70 °C for 24 h. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layers were combined, dried and concentrated. The remaining residue was purified by silica gel column chromatography eluting with petroleum ether / EtOAc (1:1) to give tert-butyl (S)-(1-(3-bromo-5-formylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (18 g, 86%) as a yellow solid. MS (M+H) + =384.1, 386.1.

[1071] Step 2-2, Preparation of (S)-5-bromo-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)nicotinic acid Preparation : To a solution of tert-butyl (S)-(1-(3-bromo-5-formylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (190 mg, 1.0 eq., 0.49 mmol) in tert-butyl alcohol (9.0 mL) was added 2-methylbut-2-ene (0.66 mL, 12 eq., 5.9 mmol), sodium chlorite (0.43 g, 7.8 eq., 3.8 mmol, wt. 85%), sodium dihydrogen phosphate (0.35 g, 5.9 eq., 2.9 mmol) and water (2.8 mL). The resulting mixture was stirred at ambient temperature for 1 hour. The crude reaction was concentrated to remove most of the tert-butyl alcohol, and saturated NaHSO 4 (about 2 mL). The resulting aqueous solution was extracted with ethyl acetate (3×20 mL), and the organic layers were combined, dried and concentrated to give 160 mg of the title compound as a light yellow solid. This material was used in the next step without further purification. MS (M+H) + =400.1, 402.1.

[1072] Step 2-3, (S)-(1-(3-bromo-5-((4,4-difluorocyclohexyl)carbamoyl)pyridin-4-yl)-3-methyl Preparation of tert-butyl pyrrolidin-3-yl)carbamate:To a solution of (S)-5-bromo-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)nicotinic acid (250 mg, 1.0 eq., 0.63 mmol) in DMF (2.0 mL) was added HATU (356 mg, 1.5 eq., 0.94 mmol), DIPEA (0.60 mL, 5.5 eq., 3.4 mmol) and 4,4-difluorocyclohexane-1-amine hydrochloride (161 mg, 1.5 eq., 0.94 mmol). The resulting mixture was stirred at ambient temperature for 0.5 h. The reaction crude was purified by C18 reverse phase chromatography eluting with MeCN (0.1% TFA) / water (0.1% TFA) (5-60%). The pure fractions were combined, concentrated to remove most of the MeCN, and washed with saturated NaHCO 3 (5 mL), solid NaCl (15 g) was added, and the mixture was extracted with ethyl acetate (30 mL). The organic layer was washed with MgSO 4 Dry, filter and concentrate to give 270 mg of the title compound. MS (M+H) + =517.2,519.2.

[1073] Step 2-4, (S)-(1-(3-((4,4-difluorocyclohexyl)carbamoyl)-5-(3,5-difluorophenyl)pyridine- Preparation of tert-butyl 4-yl)-3-methylpyrrolidin-3-yl)carbamate: To (S)-tert-butyl (1-(3-bromo-5-((4,4-difluorocyclohexyl)carbamoyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (90 mg, 1.0 eq., 0.17 mmol), (3,5-difluorophenyl)boronic acid (55 mg, 2.0 eq., 0.35 mmol), K 2 CO 3 (72 mg, 3.0 eq., 0.52 mmol) and Pd(amphos)Cl 2 To a mixture of 4-nitropropene (12 mg, 0.10 equiv., 0.017 mmol) was added dioxane (2.0 mL). Nitrogen was bubbled through the reaction solution for 1 minute, then water (0.20 mL) was added. Nitrogen was bubbled for another 5 minutes. The resulting mixture was heated at 100 °C for 1 hour. The reaction crude was concentrated with silica gel, and the remaining residue was purified by silica gel chromatography to give 66 mg of the title compound as a clear oil. MS (M+H) + =551.4.

[1074] Step 2-5, (S)-4-(3-amino-3-methylpyrrolidin-1-yl)-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorocyclohexyl)- Preparation of (4-(2-fluorophenyl)nicotinamide: To a solution of (S)-tert-butyl (1-(3-((4,4-difluorocyclohexyl)carbamoyl)-5-(3,5-difluorophenyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (66 mg, 1.0 eq., 0.12 mmol) in DCM (0.8 mL) was added TFA (0.8 mL). The resulting mixture was stirred at ambient temperature for 0.5 h. The crude reaction product was concentrated and the remaining residue was purified by C18 reverse phase chromatography eluting with MeCN (0.1% TFA) / water (0.1% TFA) (5-35%). The pure fractions were combined and purified by saturated NaHCO 3 (4 mL), solid NaCl (8 g) was added, and extracted with ethyl acetate (25 mL). The organic layer was washed with MgSO 4 Dried, filtered, and concentrated with 1.0 M HCl in ethyl acetate (0.3 mL) to give 33 mg of the HCl salt of (S)-4-(3-amino-3-methylpyrrolidin-1-yl)-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)nicotinamide as a white solid. MS (M+H) + =451.2.

[1075] The following compounds were prepared analogously to Example 2 using appropriate alternative reagents and substrates in the different steps which may require additional functional group modifications using appropriate reagents by known chemistry. Different salts are available, for example HCl or formic acid or TFA salts.

[1076] Compound No. <![CDATA[MS(M+H) + ]]> 1-12 443.5 1-13 447.2 1-14 443.5 1-20 469.3 1-61 429.3 1-94 418.4 1-131 394.2 1-142 384.1 1-143 449.4 1-149 431.4 1-161 419.4 1-162 419.4 1-163 445.3 1-175 445.1

[1077] Example 3. 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-difluorocyclobutyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide (Compound 1-30)

[1078]

[1079] Step 3-1, (S)-(1-(3-(3,5-difluorophenyl)-5-formylpyridin-4-yl)-3-methylpyrrolidine-3-yl Preparation of tert-butyl carbamate: To tert-butyl (S)-(1-(3-bromo-5-formylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (380 mg, 1.0 equivalent, 0.989 mmol, "Step 2-1, Example 2"), (3,5-difluorophenyl)boronic acid (312 mg, 2.0 equivalent, 1.98 mmol), K 2 CO 3 (410 mg, 3.0 eq., 2.97 mmol) and Pd(amphos)Cl 2To a mixture of 4-nitropropene (35 mg, 0.05 eq., 0.050 mmol) was added dioxane (4.0 mL) and water (0.4 mL). Nitrogen was bubbled through the reaction solution for 5 minutes, and the resulting mixture was heated at 100 °C for 1 hour. The reaction crude was concentrated with silica gel, and the remaining residue was purified by silica gel chromatography to give 372 mg of the title compound as a clear oil. MS (M+H) + =418.1.

[1080] Step 3-2, (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-5-(3,5-difluoro Preparation of nicotinic acid: To a solution of tert-butyl (S)-(1-(3-(3,5-difluorophenyl)-5-formylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate in tert-butyl alcohol (11 mL) was added 2-methylbut-2-ene (1.2 mL, 12 eq., 10.7 mmol), sodium chlorite (0.84 g, 8.9 eq., 7.9 mmol, wt. 85%), sodium dihydrogen phosphate (0.75 g, 7.0 eq., 6.3 mmol) and water (4.0 mL). The resulting mixture was stirred at ambient temperature for 1 hour. The crude reaction was concentrated to remove most of the tert-butyl alcohol and saturated NaHSO 4 (about 3 mL). The resulting aqueous solution was extracted with ethyl acetate (3×20 mL), and the organic layers were combined, dried and concentrated to give 370 mg of the title compound. This material was used in the next step without further purification. MS (M+H) + =434.3.

[1081] Step 3-3, (S)-(1-(3-((3,3-difluorocyclobutyl)carbamoyl)-5-(3,5-difluorophenyl)pyridine- Preparation of tert-butyl 4-yl)-3-methylpyrrolidin-3-yl)carbamate: To a solution of (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-5-(3,5-difluorophenyl)nicotinic acid (44 mg, 1.0 eq., 0.10 mmol) in DMF (0.6 mL) was added HATU (58 mg, 1.5 eq., 0.15 mmol) and DIPEA (0.2 mL, 11 eq., 1.0 mmol). The resulting mixture was stirred at ambient temperature for 5 minutes, then 3,3-difluorocyclobutane-1-amine hydrochloride (44 mg, 3.0 eq., 0.30 mmol) was added. The resulting mixture was stirred at ambient temperature for 0.5 hours. The reaction crude was purified by C18 reverse phase chromatography eluting with MeCN (0.1% TFA) / water (0.1% TFA) (5-55%). The pure fractions were combined, concentrated to remove most of the MeCN, and washed with saturated NaHCO 3 (3 mL), solid NaCl (5 g) was added, and extracted with ethyl acetate (2 × 10 mL). The organic layers were combined and precipitated with MgSO 4Dry, filter and concentrate to give 42 mg of the title compound. MS (M+H) + =534.1.

[1082] Step 3-4, 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-difluorocyclobutyl)-5-(3,5- Preparation of difluorophenyl)pyridine-3-carboxamide : To a solution of (S)-tert-butyl (1-(3-((3,3-difluorocyclobutyl)carbamoyl)-5-(3,5-difluorophenyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (42 mg, 1.0 eq., 0.08 mmol) in DCM (0.7 mL) was added TFA (0.7 mL). The resulting mixture was stirred at ambient temperature for 0.5 h. The crude reaction product was concentrated and the remaining residue was purified by C18 reverse phase chromatography eluting with MeCN (0.1% TFA) / water (0.1% TFA) (5-35%). The pure fractions were combined and purified by saturated NaHCO 3 (3 mL), solid NaCl (5 g) was added, and extracted with ethyl acetate (2 × 10 mL). The organic layers were combined and precipitated with MgSO 4 Dry, filter and concentrate with 1.0 M HCl in ethyl acetate (0.10 mL) to give 25 mg of the HCl salt of 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-difluorocyclobutyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide as a white solid. MS (M+H) + =423.2.

[1083] The following compounds were prepared analogously to Example 3 using appropriate alternative reagents and substrates in the different steps which may require additional functional group modifications using appropriate reagents by known chemistry. Different salts are available, for example HCl or formic acid or TFA salts.

[1084]

[1085]

[1086]

[1087] Example 4. 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide (Compound 1-71)

[1088]

[1089] Step 4-1, Preparation of tert-butyl (S)-(1-(2-chloro-5-formylpyridin-4-yl)pyrrolidin-3-yl)carbamate Preparation:4,6-Dichloronicotinaldehyde (6.8 g, 1.0 eq., 39 mmol), (S)-tert-butyl pyrrolidin-3-ylcarbamate (7.6 g, 1.1 eq., 41 mmol) and TEA (16 mL, 3.1 eq., 120 mmol) were added to a DMF (70 mL) solution. The resulting mixture was stirred at 50 °C for 4 hours. The crude reaction was quenched with water (100 mL) and extracted with ethyl acetate (3×40 mL). The organic layers were combined, washed with brine, dried, and concentrated under vacuum. The remaining residue was purified by silica gel chromatography eluting with ethyl acetate / petroleum ether (1 / 3) to give (S)-tert-butyl (1-(2-chloro-5-formylpyridin-4-yl)pyrrolidin-3-yl)carbamate (5.3 g, 42%) as a yellow solid. MS (M+H) + =326.2.

[1090] Step 4-2, tert-butyl (S)-(1-(3-bromo-2-chloro-5-formylpyridin-4-yl)pyrrolidin-3-yl)carbamate Preparation of esters: To a solution of (S)-tert-butyl (1-(2-chloro-5-formylpyridin-4-yl)pyrrolidin-3-yl)carbamate (5.3 g, 1.0 eq., 16 mmol) in AcOH (60 mL) was added NBS (3.1 g, 1.1 eq., 17 mmol) at 10°C. The resulting mixture was stirred at the same temperature for 1 h. The reaction mixture was washed with saturated NaHCO 3 The mixture was quenched and extracted with ethyl acetate (3×40 mL). The organic layers were combined, washed with brine, dried, and concentrated under vacuum. The remaining residue was purified by silica gel chromatography eluting with ethyl acetate / petroleum ether (1 / 4) to give (S)-tert-butyl (1-(3-bromo-2-chloro-5-formylpyridin-4-yl)pyrrolidin-3-yl)carbamate (3.5 g, 53%) as a yellow solid. MS (M+H) + =404.1, 406.1.

[1091] Step 4-3, (S)-(1-(2-chloro-3-(3,5-difluorophenyl)-5-formylpyridin-4-yl)pyrrolidin-3-yl) Preparation of tert-butyl carbamate: Under atmospheric nitrogen, tert-butyl (S)-(1-(3-bromo-2-chloro-5-formylpyridin-4-yl)pyrrolidin-3-yl)carbamate (3.5 g, 1.0 equiv., 8.6 mmol), (3,5-difluorophenyl)boronic acid (0.88 equiv., 7.6 mmol, 1.2 g), Pd(DtBPF)Cl 2To a mixture of 4-(300 mg, 0.05 eq., 0.46 mmol) and potassium phosphate (5.4 g, 2.9 eq., 25 mmol) was added toluene (140 mL) and water (14 mL). The resulting mixture was stirred at 40 °C for 2 hours. The crude reaction was concentrated under reduced pressure, and the remaining residue was purified by silica gel column chromatography eluting with petroleum ether / EtOAc (3:1) to give (S)-tert-butyl (1-(2-chloro-3-(3,5-difluorophenyl)-5-formylpyridin-4-yl)pyrrolidin-3-yl)carbamate (2.7 g, 71%) as a yellow solid. MS (M+H) + =438.0, 440.0.

[1092] Step 4-4, (S)-(1-(2-cyano-3-(3,5-difluorophenyl)-5-formylpyridin-4-yl)pyrrolidine-3-yl Preparation of tert-butyl carbamate: Under atmospheric nitrogen, tert-butyl (S)-(1-(2-chloro-3-(3,5-difluorophenyl)-5-formylpyridin-4-yl)pyrrolidin-3-yl)carbamate (2.7 g, 1.0 equiv., 6.2 mmol), Pd 2 (dba) 3 ·CHCl 3 (310 mg, 0.05 eq., 0.31 mmol), Zn(CN) 2 DMF (30 mL) was added to a mixture of (1.4 g, 1.9 eq., 12 mmol) and (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (720 mg, 0.20 eq., 1.24 mmol). The resulting mixture was heated at 135 ° C under microwave irradiation for 1 hour. The crude reaction was quenched with water (100 mL) and extracted with EtOAc (3×40 mL). The organic layers were combined, washed with brine, and stirred in anhydrous Na 2 SO 4 The residue was dried over medium, filtered and concentrated under vacuum. The remaining residue was purified by silica gel chromatography eluting with petroleum ether / EtOAc (1:1) to give (S)-tert-butyl (1-(2-cyano-3-(3,5-difluorophenyl)-5-formylpyridin-4-yl)pyrrolidin-3-yl)carbamate (2.2 g, 83%) as a yellow solid. MS (M+H) + =429.2.

[1093] Step 4-5, (S)-4-(3-((tert-butoxycarbonyl)amino)pyrrolidin-1-yl)-6-cyano-5-(3,5-difluoro Preparation of nicotinic acidTo a solution of (S)-(1-(2-cyano-3-(3,5-difluorophenyl)-5-formylpyridin-4-yl)pyrrolidin-3-yl)carbamate (2.4 g, 1.0 eq., 5.1 mmol) in tert-butyl alcohol (20 mL) was added sodium dihydrogen phosphate (2.4 g, 3.0 eq., 15 mmol), 2-methylbut-2-ene (11.0 g, 31 eq., 157 mmol), sodium chlorite (1.0 g, 2.2 eq., 11 mmol) and water (6.6 mL). The resulting mixture was stirred at ambient temperature for 1 hour. The reaction mixture was washed with saturated NaHSO 4 (50 mL) and extracted with ethyl acetate (3×40 mL). The organic layers were combined, washed with brine, dried, and concentrated under vacuum to give (S)-4-(3-((tert-butoxycarbonyl)amino)pyrrolidin-1-yl)-6-cyano-5-(3,5-difluorophenyl)nicotinic acid (2.0 g, 88%) as a yellow solid. This material was used in the next step without purification. MS (M+H) + =445.2.

[1094] Step 4-6, ((S)-1-(2-cyano-3-(3,5-difluorophenyl)-5-(((S)-1,1,1-trifluoropropane-2-yl) Preparation of tert-butyl (4-(2-aminoformyl)pyridin-4-yl)pyrrolidin-3-yl)carbamate: To a solution of (S)-4-(3-((tert-butoxycarbonyl)amino)pyrrolidin-1-yl)-6-cyano-5-(3,5-difluorophenyl)nicotinic acid (70 mg, 1.0 eq., 0.16 mmol) in DMF (2.0 mL) was added (S)-1,1,1-trifluoropropane-2-amine hydrochloride (35 mg, 1.5 eq., 0.23 mmol), N-ethyl-N-isopropylpropane-2-amine (4.4 eq., 0.70 mmol, 0.12 mL) and HATU (60 mg, 1.0 eq., 0.16 mmol). The resulting mixture was stirred at ambient temperature for 2 hours. The crude reaction product was purified by Prep-HPLC using the following conditions: SunFirePrep C18 OBD column, 19*150mm 5μm; mobile phase, water (0.1% FA) and ACN (24.0% ACN to 46.0% in 7 minutes); total flow rate 20mL / min; detector, UV 220nm. This produced tert-butyl ((S)-1-(2-cyano-3-(3,5-difluorophenyl)-5-(((S)-1,1,1-trifluoropropan-2-yl)carbamoyl)pyridin-4-yl)pyrrolidin-3-yl)carbamate (45mg, 53%) as a light yellow solid. MS (M+H) + =540.3.

[1095] Step 4-7, 4-((S)-3-aminopyrrolidin-1-yl)-6-cyano-5-(3,5-difluorophenyl)-N-((S)-1,1, Preparation of 1-trifluoropropane-2-yl) nicotinamide: To a solution of tert-butyl ((S)-1-(2-cyano-3-(3,5-difluorophenyl)-5-(((S)-1,1,1-trifluoropropane-2-yl)carbamoyl)pyridin-4-yl)pyrrolidin-3-yl)carbamate (45 mg, 1.0 equiv, 0.083 mmol) in DCM (2.0 mL) was added TFA (1.0 mL). The resulting mixture was stirred at ambient temperature for 2 hours. The reaction solution was concentrated under vacuum and freeze-dried to give the TFA salt of 4-((S)-3-aminopyrrolidin-1-yl)-6-cyano-5-(3,5-difluorophenyl)-N-((S)-1,1,1-trifluoropropane-2-yl)nicotinamide bis(2,2,2-trifluoroacetate) (40.2 mg, 72%) as a light yellow solid. MS (M+H) + =440.2.

[1096] The following compounds were prepared analogously to Example 4 using appropriate alternative reagents and substrates in the different steps which may require additional functional group modifications using appropriate reagents by known chemistry. Different salts are available, for example HCl or formic acid or TFA salts.

[1097]

[1098]

[1099] Example 5. 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1S)-1-(pyridin-2-yl)ethyl]pyridine-3-carboxamide (Compound 1-103)

[1100]

[1101] Step 5-1, Preparation of 4-chloro-6-cyanonicotinoic acid ethyl ester : To 4,6-dichloronicotinic acid under atmospheric nitrogen Second To a mixture of ester (200.0 g, 1.0 eq., 909 mmol), zinc (II) cyanide (0.600 eq., 545 mmol, 64 g), tris(dibenzylideneacetone)dipalladium(0) chloroform adduct (9.41 g, 0.01 eq., 9.09 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (10.5 g, 0.02 eq., 18.1 mmol) was added DMF (1600 mL). The reaction mixture was stirred at 130 °C for 2 hours. The reaction mixture was poured into water (3000 mL) and extracted with EtOAc (3×1000 mL). The organic layers were combined, washed with water (3×2000 mL) and brine (1000 mL), and precipitated in anhydrous Na 2 SO 4The residue was purified by silica gel chromatography eluting with petroleum ether / EtOAc / DCM (10 / 1 / 2). This produced a pure batch (78 g, 95% purity) and a less pure batch (63 g, 50% purity). MS (M+H) + =211.1, 212.1.

[1102] Step 5-2, (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyanonicotinoic acid ethyl Preparation of esters : 4-chloro-6-cyanonicotinoic acid ethyl ester (15 g, 1.0 equivalent, 71 mmol), 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine To a mixture of (10 g, 0.92 eq., 66 mmol) and (S)-tert-butyl (3-methylpyrrolidin-3-yl)carbamate (30 g, 2.1 eq., 150 mmol) was added MeCN (200 mL). The resulting mixture was stirred at 50 °C for 1 hour. The crude reaction was quenched with water (100 mL) and extracted with EtOAc (3×40 mL). The organic layers were combined, washed with brine, dried, and concentrated under vacuum. The remaining residue was purified by silica gel chromatography eluting with petroleum ether / EtOAc (3 / 1) to give (S)-ethyl 4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyanonicotinate (16.0 g, 60%) as a yellow solid. MS (M+H) + =375.1.

[1103] Step 5-3, (S)-5-bromo-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyano Preparation of nicotinate ethyl ester: To a round-bottom flask was added (S)-ethyl 4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyanonicotinate (3.0 g, 1.0 eq., 8.0 mmol), AcOH (60 mL) and DCM (12 mL). At 0°C, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione (5.8 g 2.0 eq., 16 mmol) was added portionwise. The resulting mixture was stirred at the same temperature for 30 min. The crude reaction product was treated with NaHSO at 0°C. 3 The aqueous solution was quenched. The resulting suspension was filtered and the filtrate was extracted with EtOAc (3×100 mL). The organic layers were combined and washed with water (3×30 mL) and NaHCO 3 The organic layer was dried and concentrated under vacuum. The remaining residue was purified by silica gel chromatography eluting with petroleum ether / EtOAc (4 / 1) to give (S)-5-bromo-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyanonicotinate (2.2 g, 61%) as a yellow solid. MS (M+H) +=453.0, 455.0.

[1104] Step 5-4, (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyano-5-(3, Preparation of ethyl nicotinate (5-difluorophenyl): (S)-5-bromo-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyanonicotinate (5.0 g, 1.0 eq., 11 mmol), (3,5-difluorophenyl)boronic acid (3.5 g, 2.0 eq., 22 mmol), potassium phosphate (7.2 g, 3.1 eq., 34 mmol) and Pd(DtBPF)Cl were added under atmospheric nitrogen. 2 To a mixture of 4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyano-5-(3,5-difluorophenyl)nicotinate (4.4 g, 82%) was added toluene (50 mL) and water (5 mL). The resulting mixture was stirred at 80 °C for 1 hour. The reaction mixture was concentrated under reduced pressure, and the remaining residue was purified by silica gel column chromatography eluting with petroleum ether / EtOAc (5:1) to give (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyano-5-(3,5-difluorophenyl)nicotinate (4.4 g, 82%) as a yellow solid. MS (M+H) + =487.4.

[1105] Step 5-5, (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyano-5-(3, Preparation of nicotinic acid: To a solution of (S)-ethyl 4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyano-5-(3,5-difluorophenyl)nicotinate (5.0 g, 1.0 eq., 10 mmol) in MeOH (50 mL) was added water (5.0 mL). The resulting mixture was cooled to 10 °C and lithium hydroxide (2.5 g, 10 eq., 100 mmol) was added portionwise. The reaction mixture was stirred at 50 °C for 3 hours. The crude reaction was concentrated under vacuum and saturated NaHSO 4 Until the crude solution is acidic (pH 4-5). The resulting mixture was extracted with EtOAc (3×40 mL). The organic layers were combined, washed with water, dried and concentrated under vacuum to give (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyano-5-(3,5-difluorophenyl)nicotinic acid (4.0 g, 85%) as a yellow solid. The material was used in the next step without further purification. MS (M+H) + =459.2.

[1106] Step 5-6, ((S)-1-(2-cyano-3-(3,5-difluorophenyl)-5-(((S)-1-(pyridin-2-yl)ethyl)amino Preparation of tert-butyl (4-(2-methylpyrrolidine-3-yl)formyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate:To a mixture of (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyano-5-(3,5-difluorophenyl)nicotinic acid (90 mg, 1.0 eq., 0.20 mmol), HATU (0.11 g, 1.5 eq., 0.29 mmol) and (S)-1-(pyridin-2-yl)ethan-1-amine (36 mg, 1.50 eq., 0.29 mmol) were added DMF (0.8 mL) and DIPEA (0.10 mL, 3.0 eq., 0.59 mmol). The resulting mixture was stirred at ambient temperature for 0.5 h. The reaction crude was purified by C18 reverse phase chromatography eluting with MeCN (0.1% TFA) / water (0.1% TFA) (5-65%). The pure fractions were combined and washed with saturated NaHCO 3 (3 mL), solid NaCl (5 g) was added, and extracted with ethyl acetate (20 mL). The organic layer was washed with MgSO 4 Dry, filter and concentrate to give 75 mg of tert-butyl ((S)-1-(2-cyano-3-(3,5-difluorophenyl)-5-(((S)-1-(pyridin-2-yl)ethyl)carbamoyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate as a clear oil. MS (M+H) + =563.5.

[1107] Step 5-7, 4-((S)-3-amino-3-methylpyrrolidin-1-yl)-6-cyano-5-(3,5-difluorophenyl)-N- Preparation of ((S)-1-(pyridin-2-yl)ethyl)nicotinamide: To a solution of tert-butyl ((S)-1-(2-cyano-3-(3,5-difluorophenyl)-5-(((S)-1-(pyridin-2-yl)ethyl)carbamoyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (75 mg, 1.0 eq, 0.13 mmol) in DCM (0.6 mL) was added TFA (0.6 mL). The resulting mixture was stirred at ambient temperature for 0.5 h. The crude reaction was concentrated and the remaining residue was purified by C18 reverse phase chromatography eluting with MeCN (0.1% TFA) / water (0.1% TFA) (5-35%). The pure fractions were combined and purified by saturated NaHCO 3 (3 mL), solid NaCl (5 g) was added, and extracted with ethyl acetate (20 mL). The organic layer was washed with MgSO 4 Dry, filter and concentrate with 1.0 M HCl in ethyl acetate (0.2 mL) to give the HCl salt of 4-((S)-3-amino-3-methylpyrrolidin-1-yl)-6-cyano-5-(3,5-difluorophenyl)-N-((S)-1-(pyridin-2-yl)ethyl)nicotinamide as a white solid. MS (M+H) + =463.2.

[1108] The following compounds were prepared analogously to Example 5 using appropriate alternative reagents and substrates in the different steps which may require additional functional group modifications using appropriate reagents by known chemistry. Different salts are available, for example HCl or formic acid or TFA salts.

[1109]

[1110]

[1111] Example 6. 4-[3-(1-aminoethyl)azetidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3,5-difluorophenyl)pyridine-3-carboxamide (Compound 1-63)

[1112]

[1113] Step 6-1, preparation of 1-(azetidin-3-yl)ethan-1-one: TFA (5 mL) was added to a solution of tert-butyl 3-acetylazetidine-1-carboxylate (500 mg, 1.0 equivalent, 2.51 mmol) in DCM (5 mL). The resulting mixture was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated under reduced pressure. The mixture was diluted with water (30 mL) and saturated NaHCO was added. 3 The solution was stirred until the pH was about 7.0. The resulting mixture was concentrated under reduced pressure, and the remaining residue was washed with DCM / MeOH (3×50 mL). The organic layers were combined and stirred in anhydrous Na 2 SO 4 Dry over 400 °C, filter and concentrate under vacuum. This yielded 280 mg of 1-(azetidin-3-yl)ethan-1-one (80% purity) as a colorless oil. This material was used in the next step without further purification.

[1114] Step 6-2, preparation of 4-(3-acetylazetidin-1-yl)-5-bromonicotinaldehyde: To a mixture of 1-(azetidin-3-yl)ethane-1-one (280 mg, 1.0 equiv., 2.3 mmol), 5-bromo-4-chloronicotinaldehyde (446 mg, 0.90 equiv., 2.02 mmol), N-ethyl-N-isopropylpropane-2-amine (1.00 g, 3.4 equiv., 7.74 mmol) was added MeCN (5 mL). The resulting mixture was stirred at 80 °C for 2 hours. The reaction mixture was concentrated under reduced pressure, and the remaining residue was purified by silica gel chromatography eluting with petroleum ether / EtOAc (5:1) to give 4-(3-acetylazetidin-1-yl)-5-bromonicotinaldehyde (250 mg, 39%) as a colorless oil. MS (M+H) + =285.0.

[1115] Step 6-3, Preparation of 4-(3-acetylazetidin-1-yl)-5-(3,5-difluorophenyl)nicotinaldehyde:To a mixture of 4-(3-acetylazetidin-1-yl)-5-bromonicotinaldehyde (90 mg, 1.0 eq., 0.32 mmol), (3,5-difluorophenyl)boronic acid (150 mg, 3.0 eq., 0.95 mmol), potassium phosphate (200 mg, 3.0 eq., 0.942 mmol) and dichloro[1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) (21 mg, 0.10 eq., 0.032 mmol) was added 1,4-dioxane (1.0 mL) and water (0.1 mL) under atmospheric nitrogen. The reaction mixture was stirred at 80 °C for 1 hour. The resulting mixture was concentrated under reduced pressure and the remaining residue was purified by silica gel chromatography. This produced 65 mg of 4-(3-acetylazetidin-1-yl)-5-(3,5-difluorophenyl)nicotinaldehyde (65%) as a yellow solid. MS(M+H) + =317.1.

[1116] Step 6-4, Preparation of 4-(3-acetylazetidin-1-yl)-5-(3,5-difluorophenyl)nicotinic acid: To a solution of 4-(3-acetylazetidin-1-yl)-5-(3,5-difluorophenyl)nicotinaldehyde (150 mg, 1.0 eq., 0.474 mmol) in tert-butyl alcohol (6.0 mL) was added 2-methylbut-2-ene (1.66 g, 50 eq., 23.7 mmol), sodium chlorite (86 mg, 2.0 eq., 0.95 mmol), sodium dihydrogen phosphate dihydrate (222 mg, 3.0 eq., 1.42 mmol) and water (2 mL). The resulting mixture was stirred at ambient temperature for 1 hour. The reaction mixture was purified by Prep-HPLC using the following conditions: column, C18; mobile phase, water (0.1% TFA) and ACN (25% ACN to 45% in 8 minutes); total flow, 70 mL / min; detector, UV 220 nm. This resulted in 120 mg of 4-(3-acetylazetidin-1-yl)-5-(3,5-difluorophenyl)nicotinic acid as a colorless oil. MS (M+H) + =333.1.

[1117] Step 6-5, 4-(3-acetylazetidin-1-yl)-N-(bicyclo[1.1.1]pentan-1-yl)-5-(3,5- Preparation of difluorophenyl)nicotinamide:To a solution of 4-(3-acetylazetidin-1-yl)-5-(3,5-difluorophenyl)nicotinic acid (120 mg, 1.0 eq., 0.361 mmol) in DMF (2.0 mL) was added bicyclo[1.1.1]pentane-1-amine hydrochloride (65 mg, 1.5 eq., 0.54 mmol), N-ethyl-N-isopropylpropane-2-amine (163 mg, 3.49 eq., 1.26 mmol) and 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate (V) (206 mg, 1.50 eq., 0.54 mmol). The reaction mixture was stirred at ambient temperature for 1 hour. The crude reaction product was purified by Prep-HPLC using the following conditions: column, C18; mobile phase, water (0.1% TFA) and ACN (35% ACN to 60% in 8 minutes); total flow, 70 mL / min; detector, UV 220 nm. This produced 4-(3-acetylazetidin-1-yl)-N-(bicyclo[1.1.1]pentan-1-yl)-5-(3,5-difluorophenyl)nicotinamide (110 mg, 76.6%) as a yellow solid. MS (M+H) + =398.3.

[1118] Step 6-6, N-(bicyclo[1.1.1]pentan-1-yl)-5-(3,5-difluorophenyl)-4-(3-(1-(2,4-dimethylbenzene)- Preparation of (4-(2-(4-(2-oxybenzyl)amino)ethyl)azetidin-1-yl)nicotinamide: To a solution of 4-(3-acetylazetidin-1-yl)-N-(bicyclo[1.1.1]pentan-1-yl)-5-(3,5-difluorophenyl)nicotinamide (100 mg, 1.0 eq., 0.252 mmol) in DCE (2.0 mL) was added acetic acid (15 mg, 0.99 eq., 0.25 mmol), (2,4-dimethoxyphenyl)methanamine (63 mg, 1.5 eq., 0.38 mmol) and sodium triacetoxyborohydride (160 mg 3.0 eq., 0.755 mmol). The resulting mixture was stirred at ambient temperature for 6 hours. The crude reaction was concentrated under reduced pressure, and the remaining residue was purified by Prep-HPLC using the following conditions: column, C18; mobile phase, water (0.1% TFA) and ACN (30% ACN to 60% in 8 minutes); total flow, 70 mL / min; detector, UV 220 nm. This produced N-(bicyclo[1.1.1]pentan-1-yl)-5-(3,5-difluorophenyl)-4-(3-(1-((2,4-dimethoxybenzyl)amino)ethyl)azetidin-1-yl)nicotinamide (110 mg, 72%, 90% purity) as a yellow oil. MS (M+H) + =549.3.

[1119] Step 6-7, 4-(3-(1-aminoethyl)azetidin-1-yl)-N-(bicyclo[1.1.1]pentan-1-yl)-5- Preparation of (3,5-difluorophenyl)nicotinamide:N-(Bicyclo[1.1.1]pentan-1-yl)-5-(3,5-difluorophenyl)-4-(3-(1-((2,4-dimethoxybenzyl)amino)ethyl)azetidin-1-yl)nicotinamide (100 mg, 1.0 equiv., 0.182 mmol) was combined with TFA (2.0 mL), and the resulting mixture was heated at 80° C. for 16 hours. The mixture was concentrated under reduced pressure, and the remaining residue was purified by Prep-HPLC using the following conditions: column, SunFire Prep C18 OBD, 19*150 mm, 5 μm; mobile phase, water (0.1% TFA) and ACN (12% ACN to 17% in 7 minutes); total flow, 20 mL / min; detector, UV 220 nm. This resulted in the TFA salt of 4-(3-(1-aminoethyl)azetidin-1-yl)-N-(bicyclo[1.1.1]pentan-1-yl)-5-(3,5-difluorophenyl)nicotinamide (38.8 mg, 34.0%) as a white solid. MS (M+H) + =399.2.

[1120] Example 7. 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide (Compound 1-74)

[1121]

[1122] Step 7-1, tert-(S)-(1-(2-chloro-5-formylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamic acid Preparation of butyl ester: The title compound (3.4 g, 35%) was prepared from 4,6-dichloronicotinaldehyde (5.0 g, 1.0 eq., 28 mmol) and (S)-tert-butyl (3-methylpyrrolidin-3-yl)carbamate (6.0 g, 1.1 eq., 30 mmol) using a method similar to that described in "Example 4, Step 4-1". MS (M+H) + =340.1, 342.1.

[1123] Step 7-2, (S)-(1-(3-bromo-2-chloro-5-formylpyridin-4-yl)-3-methylpyrrolidin-3-yl)amino Preparation of tert-butyl ester: The title compound (2.3 g, 55%) was prepared from tert-butyl (S)-(1-(2-chloro-5-formylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (3.4 g, 1.0 eq., 10 mmol) using a method similar to that described in "Example 4, Step 4-2". MS (M+H) + =418.0,420.0.

[1124] Step 7-3, (S)-(1-(2-chloro-3-(3,5-difluorophenyl)-5-formylpyridin-4-yl)-3-methylpyrrole Preparation of tert-butyl (3-(4-(4-(4-(4-(4-alkyl)carbamate))carbamate:The title compound (1.7 g, 68%) was prepared from tert-butyl (S)-(1-(3-bromo-2-chloro-5-formylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (2.3 g, 1.0 eq., 5.5 mmol) and (3,5-difluorophenyl)boronic acid (0.80 g, 0.92 eq., 5.07 mmol) using a method similar to that described in "Example 4, Step 4-3". MS (M+H) + =452.2,454.2.

[1125] Step 7-4, (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-chloro-5-(3,5- Preparation of difluorophenyl)nicotinic acid: The title compound (100 mg, 97%, 80% purity) was prepared from tert-butyl (S)-(1-(2-chloro-3-(3,5-difluorophenyl)-5-formylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (80 mg, 1.0 eq., 0.18 mmol) using a method similar to that described in "Example 4, Step 4-5". MS (M+H) + ==539.7,541.7.

[1126] Step 7-5, (S)-(1-(5-(bicyclo[1.1.1]pentan-1-ylcarbamoyl)-2-chloro-3-(3,5-difluorobenzene Preparation of tert-butyl 2-(4-yl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate: The title compound (60 mg, 66%) was prepared from (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-chloro-5-(3,5-difluorophenyl)nicotinic acid (100 mg, 1.0 equiv., 0.17 mmol, 80% purity) using a method similar to that described in "Example 4, Step 4-6". MS (M+H) + =533.2,535.2.

[1127] Step 7-6, (S)-(1-(5-(bicyclo[1.1.1]pentan-1-ylcarbamoyl)-3-(3,5-difluorophenyl)- Preparation of tert-butyl (2-methylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate: To a precipitate of tert-butyl (S)-(1-(5-(bicyclo[1.1.1]pentan-1-ylcarbamoyl)-2-chloro-3-(3,5-difluorophenyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (35 mg, 1.0 equiv, 0.066 mmol), potassium carbonate (28 mg, 3.1 equiv, 0.20 mmol), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (30 mg, 3.6 equiv, 0.24 mmol) and Pd(amphos)Cl was added under atmospheric nitrogen. 2To a mixture of 4-nitro-1-yl-2-nitro-2-yl-4 ... + =513.1.

[1128] Step 7-7, (S)-4-(3-amino-3-methylpyrrolidin-1-yl)-N-(bicyclo[1.1.1]pentan-1-yl)-5- Preparation of (3,5-difluorophenyl)-6-methylnicotinamide: To a solution of (S)-tert-butyl(1-(5-(bicyclo[1.1.1]pentan-1-ylcarbamoyl)-3-(3,5-difluorophenyl)-2-methylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (20 mg, 1.0 equiv., 0.039 mmol) in DCM (2.0 mL) was added TFA (1.0 mL). The resulting mixture was stirred at ambient temperature for 2 hours. The reaction solution was concentrated under vacuum, and the remaining residue was purified by Prep-HPLC using the following conditions: column, SunFire Prep C18 OBD, 19*150mm 5μm 10nm; mobile phase, water (0.05% TFA) and ACN (16% can up to 33% in 7 minutes); total flow, 20 mL / min; detector, UV 220nm. This resulted in the TFA salt of (S)-4-(3-amino-3-methylpyrrolidin-1-yl)-N-(bicyclo[1.1.1]pentan-1-yl)-5-(3,5-difluorophenyl)-6-methylnicotinamide (11.8 mg, 47%) as a white solid. MS (M+H) + =413.2.

[1129] Example 8. 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyanopyridine-3-carboxamide (Compound 1-75)

[1130]

[1131] Step 8-1, (S)-(1-(2-cyano-5-formylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamic acid Preparation of tert-butyl ester: The title compound (20 mg, 59%) was prepared from (S)-tert-butyl (1-(2-chloro-5-formylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (50 mg, 1.0 eq., 0.10 mmol) using a method similar to that described in "Example 4, Step 4-4". MS (M+H)+ =331.3.

[1132] Step 8-2, (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyanonicotinic acid preparation: The title compound (25 mg, 83%) was prepared from (S)-tert-butyl (1-(2-cyano-5-formylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (20 mg, 1.0 eq., 0.061 mmol) using a method similar to that described in "Example 4, Step 4-5". MS (M+H) + =347.1.

[1133] Step 8-3, (S)-(1-(5-(bicyclo[1.1.1]pentan-1-ylcarbamoyl)-2-cyanopyridin-4-yl)- Preparation of tert-butyl 3-methylpyrrolidin-3-yl)carbamate: The title compound (10 mg, 48%) was prepared from (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-cyanonicotinic acid (25 mg, 1.0 eq., 0.051 mmol) using a method similar to that described in "Example 4, Step 4-6". MS (M+H) + =412.2.

[1134] Step 8-4, (S)-4-(3-amino-3-methylpyrrolidin-1-yl)-N-(bicyclo[1.1.1]pentan-1-yl)-6- Preparation of cyanonicotinamide: The title compound was prepared as a TFA salt (2.7 mg, 21%) from (S)-tert-butyl (1-(5-(bicyclo[1.1.1]pentan-1-ylcarbamoyl)-2-cyanopyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (10 mg, 1.0 eq., 0.024 mmol) using a method similar to that described in "Example 4, Step 4-7". MS (M+H) + =312.2.

[1135] Example 9. 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-[3-(difluoromethoxy)phenyl]pyridine-3-carboxamide (Compound 1-120)

[1136]

[1137] Step 9-1, (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-chloronicotinic acid ethyl ester Preparation:To a mixture of ethyl 4,6-dichloronicotinate (5.00 g, 1.0 eq., 22.7 mmol), tert-butyl (S)-(3-methylpyrrolidin-3-yl)carbamate (4.55 g, 1.0 eq., 22.7 mmol) and N-ethyl-N-isopropylpropane-2-amine (8.81 g, 3.0 eq., 68.2 mmol) was added MeCN (50 mL). The resulting mixture was stirred at 0 °C for 16 hours. The reaction mixture was concentrated under reduced pressure and the remaining residue was purified by recrystallization. This produced 6.0 g of ethyl (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-chloronicotinate (68%). MS (M+H) + =384.3.

[1138] Step 9-2, Preparation of (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-chloronicotinic acid Preparation: To a solution of (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-chloronicotinic acid ethyl ester (6.0 g, 1.0 eq, 15.6 mmol) in MeOH (50 mL) was added lithium hydroxide (3.74 g, 9.99 eq, 156 mmol) and water (5.0 mL). The resulting mixture was stirred at 50 °C for 1 hour. The organic layer was separated and concentrated under vacuum to give crude (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-chloronicotinic acid (5.60 g, 93%). This material was used in the next step without further purification. MS (M+H) + =356.2.

[1139] Step 9-3, ((S)-1-(2-chloro-5-(((S)-1-cyclopropylethyl)carbamoyl)pyridin-4-yl)-3-methyl Preparation of tert-butyl (3-pyrrolidin-3-yl)carbamate:To a solution of (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-chloronicotinic acid (1.0 eq., 15.5 mmol, 5.5 g) in DMF (50 mL) was added 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate (V) (8.82 g, 1.50 eq., 23.2 mmol) and N-ethyl-N-isopropylpropane-2-amine (3.0 eq., 46.3 mmol, 5.99 g). The resulting mixture was stirred at ambient temperature for 10 minutes, then (S)-1-cyclopropylethane-1-amine (2.63 g, 2.00 eq., 30.9 mmol) was added. The resulting mixture was stirred at ambient temperature for 1 hour. The reaction solution was diluted with water (100 mL) and extracted with ethyl acetate (3×100 mL). The organic layers were combined, washed with brine (2×100 mL), dried over anhydrous sodium sulfate and concentrated under vacuum. The remaining residue was purified by silica gel chromatography eluting with ethyl acetate / petroleum ether (1:2). This produced tert-butyl ((S)-1-(2-chloro-5-(((S)-1-cyclopropylethyl)carbamoyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (6.0 g, 87%). MS (M+H) + =423.3.

[1140] Step 9-4, 4-((S)-3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-5-(((S)-1-cyclohexyl)- Preparation of methyl 1-propylethyl)carbamoyl)picolinate: To a solution of tert-butyl ((S)-1-(2-chloro-5-(((S)-1-cyclopropylethyl)carbamoyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (1.2 g, 1.0 eq., 2.8 mmol) in MeOH (20 mL) under atmospheric nitrogen was added triethylamine (1.0 g, 3.5 eq., 9.9 mmol), Pd(dppf)Cl 2 (200 mg, 0.096 eq., 0.273 mmol). The resulting mixture was heated at 130 °C under 20 bar of carbon monoxide for 8 h. The reaction mixture was concentrated under reduced pressure and the remaining residue was purified by silica gel chromatography eluting with petroleum ether / EtOAc (1:2) to give methyl 4-((S)-3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-5-(((S)-1-cyclopropylethyl)carbamoyl)picolinate (1.0 g, 79%). MS (M+H) + =447.4.

[1141] Step 9-5, ((S)-1-(2-carbamoyl-5-(((S)-1-cyclopropylethyl)carbamoyl)pyridine-4-yl Preparation of tert-butyl 3-methylpyrrolidin-3-yl)carbamate:To a sealed tube was added methyl 4-((S)-3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-5-(((S)-1-cyclopropylethyl)carbamoyl)picolinate (1.3 g, 1.0 eq, 2.9 mmol) and ammonia (7.0 M) in MeOH (12 mL, 28 eq, 82.2 mmol). The resulting mixture was stirred at 80 °C for 2 h. The reaction solution was concentrated under vacuum to give crude tert-butyl ((S)-1-(2-carbamoyl-5-(((S)-1-cyclopropylethyl)carbamoyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (1.0 g, 80%). The material was used in the next step without further purification. MS (M+H) + =432.2.

[1142] Step 9-6, ((S)-1-(2-cyano-5-(((S)-1-cyclopropylethyl)carbamoyl)pyridin-4-yl)-3- Preparation of tert-butyl (methylpyrrolidin-3-yl)carbamate: To a solution of tert-butyl ((S)-1-(2-carbamoyl-5-(((S)-1-cyclopropylethyl)carbamoyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (1.0 g, 1.0 eq., 2.3 mmol) in DCM (30 mL) at 0°C was added TEA (1.1 mL, 3.4 eq., 7.82 mmol) and TFAA (1.3 mL, 4.1 eq., 9.5 mmol) dropwise. The resulting mixture was stirred at 0°C for 1 hour. The reaction mixture was washed with K 2 CO 3 The aqueous solution was quenched and extracted with EtOAc (3×40 mL). The organic layers were combined, washed with brine, dried, and concentrated under vacuum. The remaining residue was purified by silica gel chromatography eluting with ethyl acetate / petroleum ether (1 / 1) to give tert-butyl ((S)-1-(2-cyano-5-(((S)-1-cyclopropylethyl)carbamoyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (700 mg, 73%) as a yellow solid. MS (M+H) + =414.2.

[1143] Step 9-7, ((S)-1-(3-bromo-2-cyano-5-(((S)-1-cyclopropylethyl)carbamoyl)pyridine-4-yl Preparation of tert-butyl 3-methylpyrrolidin-3-yl)carbamate: To a solution of tert-butyl ((S)-1-(2-cyano-5-(((S)-1-cyclopropylethyl)carbamoyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (700 mg, 1.0 eq., 1.69 mmol) in DCM (4.0 mL) was added AcOH (20 mL). 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione (620 mg, 1.0 eq., 1.70 mmol) was added at 0°C and the resulting mixture was stirred at the same temperature for 20 minutes. The crude reaction product was washed with saturated Na 2 SO3 The mixture was quenched with 4-nitro-1-ylpyrrolidine-3-yl)-1-(3-bromo-2-cyano-5-(((S)-1-cyclopropylethyl)carbamoyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamic acid tert-butyl ester (410 mg, 49.2%) as a yellow solid. MS (M+H) + =492.1,494.1.

[1144] Step 9-8, ((S)-1-(2-cyano-5-(((S)-1-cyclopropylethyl)carbamoyl)-3-(3-(difluoromethyl)carbamoyl) Preparation of tert-butyl 2-(4-(2-(4-oxy)phenyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate: To tert-butyl ((S)-1-(3-bromo-2-cyano-5-(((S)-1-cyclopropylethyl)carbamoyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (50 mg, 1.0 eq., 0.10 mmol), (3-(difluoromethoxy)phenyl)boronic acid (45 mg, 2.2 eq., 0.22 mmol), potassium phosphate (66 mg, 3.1 eq., 0.31 mmol) and Pd(DtBPF)Cl was added under atmospheric nitrogen. 2 To a mixture of 4-nitropropene (7.0 mg, 0.11 equivalents, 0.011 mmol) was added toluene (2.0 mL) and water (0.2 mL). The resulting mixture was stirred at 80 °C for 1 hour. The reaction mixture was concentrated under reduced pressure, and the remaining residue was purified by silica gel chromatography eluting with ethyl acetate / petroleum ether (1:1) to give the crude product. The material was repurified by Prep-HPLC using the following conditions: column, SunFire prepOBD 19*150mm 5μm C-01; mobile phase, water (0.05% TFA) and ACN (30% ACN to 44% in 14 minutes); detector, 254nm. This resulted in tert-butyl ((S)-1-(2-cyano-5-(((S)-1-cyclopropylethyl)carbamoyl)-3-(3-(difluoromethoxy)phenyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (30 mg, 52%) as a white solid. MS (M+H) + =574.4.

[1145] Step 9-9, 4-((S)-3-amino-3-methylpyrrolidin-1-yl)-6-cyano-N-((S)-1-cyclopropylethyl)- Preparation of 5-(3-(difluoromethoxy)phenyl)nicotinamide:To a solution of tert-butyl ((S)-1-(2-cyano-5-(((S)-1-cyclopropylethyl)carbamoyl)-3-(3-(difluoromethoxy)phenyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (21 mg, 1.0 equiv, 0.037 mmol) in DCM (3.0 mL) was added TFA (1.0 mL). The resulting mixture was stirred at 25 °C for 1 hour. The reaction solution was concentrated under vacuum and freeze-dried to give the TFA salt of 4-((S)-3-amino-3-methylpyrrolidin-1-yl)-6-cyano-N-((S)-1-cyclopropylethyl)-5-(3-(difluoromethoxy)phenyl)nicotinamide (12.4 mg, 48%) as a white solid. MS (M+H) + =474.2.

[1146] The following compounds were prepared analogously to Example 9 using appropriate alternative reagents and substrates in the different steps which may require additional functional group modifications using appropriate reagents by known chemistry. Different salts are available, for example HCl or formic acid or TFA salts.

[1147]

[1148]

[1149] Example 10. 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide (Compound 1-122)

[1150]

[1151] Step 10-1, ((S)-1-(5-(((S)-1-cyclopropylethyl)carbamoyl)-2-methylpyridin-4-yl)-3- Preparation of tert-butyl (methylpyrrolidin-3-yl)carbamate:To a mixture of tert-butyl ((S)-1-(2-chloro-5-(((S)-1-cyclopropylethyl)carbamoyl)pyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (400 mg, 1.0 eq., 0.946 mmol, "Example 9, Step 9-3"), tetrachlorobis{[4-(N,N-dimethylamino)phenyl]-di-tert-butylphosphine}dipalladium(II) (67.0 mg, 0.10 eq., 0.095 mmol), potassium carbonate (392 mg, 3.0 eq., 2.84 mmol) and 2,4-dimethyl-1,3,5,2,4,6-trioxatriborinane (2.0 eq., 1.89 mmol, 209 mg) was added 1,4-dioxane (5.0 mL) under atmospheric nitrogen. The resulting mixture was stirred at 80°C for 1 hour. The reaction mixture was concentrated, diluted with water (20 mL), and extracted with ethyl acetate (3×20 mL). The organic layers were combined, washed with brine (2×20 mL), dried over anhydrous sodium sulfate, and concentrated under vacuum. The remaining residue was purified by silica gel chromatography eluting with ethyl acetate / petroleum ether (2:1) to give tert-butyl ((S)-1-(5-(((S)-1-cyclopropylethyl)carbamoyl)-2-methylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (400 mg, 95%). MS (M+H) + =403.4.

[1152] Step 10-2, ((S)-1-(3-bromo-5-(((S)-1-cyclopropylethyl)carbamoyl)-2-methylpyridine-4-yl Preparation of tert-butyl 3-methylpyrrolidin-3-yl)carbamate: To a mixture of tert-butyl ((S)-1-(5-(((S)-1-cyclopropylethyl)carbamoyl)-2-methylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (400 mg, 1.0 eq., 0.994 mmol), AcOH (5.0 mL) and DCM (1.0 mL) was added 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione (550 mg, 1.51 eq., 1.50 mmol) at 0°C. The resulting mixture was stirred at the same temperature for 15 min. The reaction mixture was washed with NaHSO at 4°C. 3 The aqueous solution was quenched and the solid was filtered off. The filtrate was collected and extracted with EtOAc (3×30 mL). The organic layers were combined and washed with water (3×30 mL) and NaHCO 3 The mixture was washed with aqueous solution, dried and concentrated under vacuum. The remaining residue was purified by silica gel chromatography eluting with ethyl acetate / petroleum ether (1 / 2) to give tert-butyl ((S)-1-(3-bromo-5-(((S)-1-cyclopropylethyl)carbamoyl)-2-methylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (300 mg, 60%). MS (M+H) + =481.2,483.2.

[1153] Step 10-3, ((S)-1-(5-(((S)-1-cyclopropylethyl)carbamoyl)-3-(3,5-difluorophenyl)-2- Preparation of tert-butyl (methylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate: To a mixture of tert-butyl ((S)-1-(3-bromo-5-(((S)-1-cyclopropylethyl)carbamoyl)-2-methylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (110 mg, 1.0 eq., 0.228 mmol), (3,5-difluorophenyl)boronic acid (72 mg, 2.0 eq., 0.457 mmol), dichloro[1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) (15 mg, 0.10 eq., 0.023 mmol) and potassium phosphate (145 mg 3.0 eq., 0.683 mmol) under atmospheric nitrogen was added toluene (3.0 mL) and water (0.3 mL). The resulting mixture was heated at 70 °C for 1 hour. The crude reaction product was purified by Prep-HPLC using the following conditions: column, SunFire Prep C18 OBD column, 19*150mm 5μm; mobile phase, water (0.05% TFA) and ACN (22.0% ACN to 45.0% in 7 minutes); total flow rate 20mL / min; detector UV 220nm. This produced tert-butyl ((S)-1-(5-(((S)-1-cyclopropylethyl)carbamoyl)-3-(3,5-difluorophenyl)-2-methylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (40mg, 33%). MS (M+H) + =515.4.

[1154] Step 10-4, 4-((S)-3-amino-3-methylpyrrolidin-1-yl)-N-((S)-1-cyclopropylethyl)-5-(3, Preparation of 5-difluorophenyl)-6-methylnicotinamide: To tert-butyl ((S)-1-(5-(((S)-1-cyclopropylethyl)carbamoyl)-3-(3,5-difluorophenyl)-2-methylpyridin-4-yl)-3-methylpyrrolidin-3-yl)carbamate (40 mg, 1.0 equiv, 0.078 mmol) in DCM (4.0 mL) was added TFA (2.0 mL). The resulting mixture was stirred at 25 °C for 1 hour. The reaction solution was concentrated under vacuum and lyophilized to give the TFA salt of 4-((S)-3-amino-3-methylpyrrolidin-1-yl)-N-((S)-1-cyclopropylethyl)-5-(3,5-difluorophenyl)-6-methylnicotinamide as a pale white solid. MS (M+H) + =415.2.

[1155] The following compounds were prepared analogously to Example 10 using appropriate alternative reagents and substrates in the different steps which may require additional functional group modifications using appropriate reagents by known chemistry. Different salts are available, for example HCl or formic acid or TFA salts.

[1156] Compound No. <![CDATA[MS(M+H) + ]]> 1-121 394.3 1-123 422.2 1-124 397.2 1-125 431.2 1-146 437.2 1-147 443.2 1-148 383.3 1-155 451.3 1-156 409.3 1-157 410.3 1-158 414.2 1-159 448.3 1-160 398.3

[1157] Example 11. 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide (Compound 1-144)

[1158]

[1159] Step 11-1, (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-chloronicotinic acid methyl Preparation of esters: To a mixture of methyl 4,6-dichloronicotinate (1.10 g, 1.0 eq., 5.34 mmol) and tert-butyl (S)-(3-methylpyrrolidin-3-yl)carbamate (1.05 g, 0.982 eq., 5.24 mmol) was added MeCN (10 mL). At 0°C, DIPEA (2.8 mL, 3.0 eq., 16.0 mmol) was added and the resulting mixture was stirred at the same temperature for 2 hours. The reaction solution was stirred overnight at ambient temperature. The crude reaction was concentrated and purified by silica gel chromatography eluting with EtOAc / hexanes (0-60%) to give methyl (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-chloronicotinate (1.97 g, 98%). MS (M+H) + =370.3.

[1160] Step 11-2, (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-methoxycarbonyl Preparation of methyl ester: To a solution of (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-chloronicotinic acid methyl ester (1.95 g, 1.0 eq., 5.27 mmol) in MeOH (5 mL) was added 25% sodium methoxide / MeOH (10.0 mL, 8.3 eq., 44 mmol). The resulting mixture was heated at 65 °C overnight. The reaction mixture was concentrated, diluted with ethyl acetate (30 mL), washed with saturated NH 4 The organic layer was concentrated and the remaining residue was purified by C18 reverse phase chromatography eluting with MeCN (0.1% TFA) / water (0.1% TFA) (5-45%). The pure fractions were combined, concentrated, washed with saturated NaHCO 3 (5.0 mL), solid NaCl (10 g) was added, and the mixture was extracted with ethyl acetate (2 × 20 mL). The organic layers were combined and precipitated with MgSO 4 Dry, filter and concentrate to give (S)-methyl 4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-methoxynicotinate (1.1 g, 57%) as a clear oil. MS (M+H) + =366.2.

[1161] Step 11-3, (S)-5-bromo-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-methoxy Preparation of methyl nicotinate: To a solution of (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-methoxynicotinate (1.06 g, 1.0 eq., 2.90 mmol) in DMF (5.0 mL) was added NBS (568 mg, 1.1 eq., 3.19 mmol) portionwise. The resulting mixture was stirred at ambient temperature for 15 min and LCMS showed complete conversion to the desired product. The crude reaction mixture was purified by C18 reverse phase chromatography eluting with MeCN (0.1% TFA) / water (0.1% TFA) (5-85%). The pure fractions were dried under vacuum to remove water and MeCN. The resulting residue was redissolved in ethyl acetate and washed with saturated NaHCO 3 (5.0 mL) and washed with brine, dried and concentrated to give (S)-5-bromo-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-methoxynicotinate (809 mg, 63%) as a clear oil. MS (M+H) + =444.3,446.1.

[1162] Step 11-4, (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-5-(3,5-difluoro Preparation of methyl 6-methoxynicotinate: To (S)-methyl 5-bromo-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-6-methoxynicotinate (754 mg, 1.0 eq., 1.70 mmol), (3,5-difluorophenyl)boronic acid (1.07 g, 4.0 eq., 6.79 mmol), potassium carbonate (1.17 g, 5.0 eq., 8.48 mmol) and Pd(amphos)Cl were added under atmospheric nitrogen. 2 To a mixture of (120 mg, 0.10 eq., 0.170 mmol) was added 1,4-dioxane (7.0 mL) and water (0.7 mL). The resulting mixture was heated at 95 °C for 1 hour. LCMS showed about 50% conversion. Under atmospheric nitrogen, a second batch of (3,5-difluorophenyl)boronic acid (1.07 g, 4.0 eq., 6.79 mmol), potassium carbonate (1.17 g, 5.0 eq., 8.48 mmol) and Pd(amphos)Cl were added. 2(120 mg, 0.10 equiv., 0.170 mmol) and the resulting mixture was heated at 95 °C for another 1 h. The crude reaction was diluted with ethyl acetate, washed with brine, concentrated and dried. The remaining residue was purified by silica gel chromatography eluting with EtOAc / hexanes (0-35%) to give (S)-methyl 4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-5-(3,5-difluorophenyl)-6-methoxynicotinate (286 mg, 35%) as a clear oil. MS (M+H) + =478.2.

[1163] Step 11-5, (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-5-(3,5-difluoro Preparation of 6-methoxynicotinic acid: To a solution of (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-5-(3,5-difluorophenyl)-6-methoxynicotinate (286 mg, 1.0 eq., 0.599 mmol) in MeOH (5 mL) was added lithium hydroxide hydrate (276 mg, 11.0 eq., 6.59 mmol) and water (1.0 mL). The resulting mixture was stirred at 50 °C for 24 h. The crude reaction was concentrated, diluted with ethyl acetate, and washed with saturated NaHSO 4 Washing, drying and concentration gave crude (S)-4-(3-((tert-butoxycarbonyl)amino)-3-methylpyrrolidin-1-yl)-5-(3,5-difluorophenyl)-6-methoxynicotinic acid (220 mg, 79%) as a white so...

Claims

1. A compound of formula (IIIa), or a pharmaceutically acceptable salt thereof: in: R c For hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted monocyclic carbocycle, or substituted or unsubstituted monocyclic heterocycle; R f For -L 1 -R g ; L 1 does not exist, C 1 -C 6 Alkylene, C 1 -C 6 Fluoroalkylene, or C 1 -C 6 heteroalkylene; R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 , or -C(=O)N(R 9 ) 2 , substituted or unsubstituted monocyclic heterocycle; R 3 Hydrogen, -CN, –CO 2 R 9 , –C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 heteroalkyl; R 4 and R 5 are independently hydrogen, halogen, –OR 9 , –N(R 9 ) 2 、–CN、–CO 2 R 9 , –C(=O)N(R 9 ) 2 , substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, substituted or unsubstituted C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 heteroalkyl; R 6 is substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 Fluoroalkyl, substituted or unsubstituted C 1 -C 8 Heteroalkyl, or -L 2 -R 6a ; L 2 is absent, substituted or unsubstituted C 1 -C 8 Alkylene, or -CHR 6b -; R 6a is substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl; R 6b C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl; R 7 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl; or R 6 and R 7 together with the nitrogen to which they are attached, form a substituted or unsubstituted N-containing heterocyclic ring; Each R 8 , R 11 and R 12 are independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted monocyclic carbocycle, substituted or unsubstituted monocyclic heterocycle, –CN, –OR 9 , –C(=O)R 10 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 ,–NR 9 C(=O)R 10 ,–NR 9 C(=O)OR 10 ,–NR 9 C(=O)N(R 9 ) 2 , –C(R 9 )=N-OR 9 ,–SR 9 , –S(=O)R 9 ,–SO 2 R 9 , or –SO 2 N(R 9 ) 2 ; or R 11 With adjacent R 8 And the R 11 and the adjacent R 8 The atoms joined together form a fused substituted or unsubstituted carbocyclic ring, or a fused substituted or unsubstituted heterocyclic ring; Each R 9 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 7 Cycloalkyl, substituted or unsubstituted monocyclic 3- to 8-membered heterocycloalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted monocyclic heteroaryl; or two R on the same N atom 9 together with the N atom to which they are attached, form a substituted or unsubstituted N-containing heterocyclic ring; Each R 10 are independently substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted C 3 -C 7 cycloalkyl, substituted or unsubstituted monocyclic 3- to 8-membered heterocycloalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted monocyclic heteroaryl; and n is 0-3.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in: R 3 For hydrogen, C 1 -C 6 Alkyl or C 1 -C 6 fluoroalkyl; and R 4 and R 5 are independently hydrogen, halogen, C 1 -C 6 Alkyl or C 1 -C 6 Fluoroalkyl.

3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure of formula (IVa-2) or a pharmaceutically acceptable salt thereof:

4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in: Each R 8 are independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 , or –NR 9 C(=O)R 10 .

5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in: Each R 8 are independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl.

6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in: Each R 8 are independently hydrogen or halogen.

7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure of formula (Va-3) or a pharmaceutically acceptable salt thereof: in: R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , –N(R 9 ) 2 , or –NR 9 C(=O)R 10 , or a substituted or unsubstituted monocyclic carbocyclic ring.

8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in: R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 , or a substituted or unsubstituted monocyclic cycloalkyl.

9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in: R 11 and R 12 are each independently halogen.

10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure of formula (VIa) or a pharmaceutically acceptable salt thereof: in: R 3 is hydrogen or -CH 3 ; R 8 is hydrogen or halogen; R 11 and R 12 are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl, –CN, –OR 9 ; R c For hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , –CO 2 R 9 , –C(=O)N(R 9 ) 2 , C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 Heteroalkyl, substituted or unsubstituted monocyclic C 3 -C 6 Cycloalkyl, substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl; R f For -L 1 -R g ; L 1 does not exist, or C 1 -C 6 an alkylene group; and R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 、-C(=O)N(R 9 ) 2 , substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl.

11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, in: R c For hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 heteroalkyl; R f For -L 1 -R g ; L 1 Does not exist or C 1 -C 6 an alkylene group; and R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, or -CO 2 R 9 .

12. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, in: R 8 is hydrogen, -F or -Cl; R 11 and R 12 are independently hydrogen, -F, -Cl, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , or -OCHF 2 ;and R c is hydrogen, -F, -Cl, -CN, -CH 3 -, -CH 2 CH 3 -, -CH 2 CH 2 CH 3 -, -CH(CH 3 ) 2 -, -CH 2 CH 2 CH 2 CH 3 -, -CH 2 CH(CH 3 ) 2 -, -CH(CH 3 )(CH 2 CH 3 ), -C(CH 3 ) 3 -, -CH 2 F, -CHF 2 -, -CF 3 -, -CH 2 CF 3 -, -OCH 3 -, -OCH 2 CH 3 -, -OCF 3 -, -OCH 2 CHF 2 -, -OCH 2 CF 3 -, -OCH 2 CH 2 OCH 3 -, -O-(cyclopropyl), -O-CH 2 -(cyclopropyl), -O-CH 2 -(phenyl), -OCH 2 CO 2 H, -OCH 2 CH 2 CO 2 H, -OCH 2 CH 2 CH 2 CO 2 H, -OCH 2 CO 2 CH 3 -, -OCH 2 CH 2 CO 2 CH 3 -, -OCH 2 CH 2 CH 2 CO 2 CH 3 、-OCH 2 CO 2 CH 2 CH 3 、-OCH 2 CH 2 CO 2 CH 2 CH 3 、-OCH 2 CH 2 CH 2 CO 2 CH 2 CH 3 , -CO 2 CH 3 , -CO 2 CH 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 、-C(=O)N(CH 3 ) 2 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl.

13. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure of formula (VIa-1) or a pharmaceutically acceptable salt thereof: in: R 3 is hydrogen or -CH 3 ; R c Hydrogen, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , -CO 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 , or -C(=O)N(CH 3 ) 2 ;and R 11 and R 12 are independently hydrogen, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, –CN, or –OR 9 .

14. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in: R 7 is hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 fluoroalkyl; and R 6 is substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 Fluoroalkyl, substituted or unsubstituted C 1 -C 8 Heteroalkyl, or -L 2 -R 6a ; L 2 is absent, substituted or unsubstituted C 1 -C 8 Alkylene, or -CHR 6b -; R 6a is substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl; R 6b C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl; or R 6 and R 7 Together with the nitrogen to which they are attached they form a substituted or unsubstituted N-containing heterocycloalkyl.

15. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in: R 7 H or C 1 -C 6 alkyl.

16. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in: R 7 is hydrogen or -CH 3 .

17. The compound according to claim 14, or a pharmaceutically acceptable salt thereof, in: R 6 is substituted or unsubstituted C 1 -C 8 Alkyl, substituted or unsubstituted C 1 -C 8 Fluoroalkyl, substituted or unsubstituted C 1 -C 8 Heteroalkyl.

18. The compound according to claim 14, or a pharmaceutically acceptable salt thereof, in: R 6 C 1 -C 6 Alkyl or C 1 -C 6 Fluoroalkyl.

19. The compound according to claim 18, or a pharmaceutically acceptable salt thereof, in: R 6 is -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 、-CH 2 CH 2 CH 2 CH 3 、-CH 2 CH(CH 3 ) 2 、-CH(CH 3 )(CH 2 CH 3 )、-CH(CH 2 CH 3 )(CH 2 CH 3 )、-CH(CH 2 CH 2 CH 3 )(CH 2 CH 3 )、-C(CH 3 )(CHCH 3 ) 2 、-C(CH 3 ) 3 、-CH 2 F、-CHF 2 、-CF 3 、-CH 2 CF 3 、-CH(CF 3 )(CH 3 )、-CH(CF 3 )(CH 2 CH 3 )、-CH 2 CF 2 CH 3 、or -CH(CH 3 )(CH 2 CF 3 )。 20. The compound according to claim 14, or a pharmaceutically acceptable salt thereof, in: R 6 For -L 2 -R 6a ; R 6a is a substituted or unsubstituted monocyclic C 3 -C 8 Cycloalkyl, substituted or unsubstituted polycyclic C 5 -C 10 cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted indanyl, substituted or unsubstituted tetrahydronaphthyl, substituted or unsubstituted naphthyl, substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, substituted or unsubstituted polycyclic C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted monocyclic C 1 -C 5 Heteroaryl, or substituted or unsubstituted bicyclic C 6 -C 9 Heteroaryl.

21. The compound according to claim 20, or a pharmaceutically acceptable salt thereof, in: R 6a is a substituted or unsubstituted monocyclic C 3 -C 6 Cycloalkyl, substituted or unsubstituted bridged C 5 -C 10 Cycloalkyl, substituted or unsubstituted spirocyclic C 5 -C 10 cycloalkyl, substituted or unsubstituted adamantyl, substituted or unsubstituted phenyl, substituted or unsubstituted indanyl, substituted or unsubstituted tetrahydronaphthyl, or substituted or unsubstituted naphthyl.

22. The compound according to claim 20, or a pharmaceutically acceptable salt thereof, in: R 6a is a substituted or unsubstituted monocyclic C 2 -C 5 Heterocycloalkyl, substituted or unsubstituted bridged C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted spirocyclic C 5 -C 10 Heterocycloalkyl, substituted or unsubstituted monocyclic C 1 -C 5 Heteroaryl, or substituted or unsubstituted bicyclic C 6 -C 9 Heteroaryl.

23. The compound according to claim 20, or a pharmaceutically acceptable salt thereof, in: L 2 does not exist, C 1 -C 4 Alkylene, or -CHR 6b -;and R 6b C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl.

24. The compound according to claim 20, or a pharmaceutically acceptable salt thereof, in: L 2 does not exist, C 1 -C 4 Alkylene, or -CHR 6b -; R 6a is substituted or unsubstituted C 3 -C 4 Cycloalkyl, or substituted or unsubstituted 3-membered or 4-membered C 2 -C 3 Heterocycloalkyl; R 6b C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 4 Cycloalkyl.

25. The compound according to claim 20, or a pharmaceutically acceptable salt thereof, in: L 2 Does not exist, -CH 2 -、-CH 2 CH 2 -、-CH 2 CH 2 CH 2 -, or -CHR 6b -; R 6a is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted azetidinyl, or substituted or unsubstituted oxetanyl; R 6b -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 , -CHF 2 、-CH 2 F, -CF 3 , cyclopropyl or cyclobutyl.

26. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in: for 27. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in: Each R 9 are independently hydrogen, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl; or two R on the same N atom 9 together with the N atom to which they are attached, form a substituted or unsubstituted N-containing heterocyclic ring; and Each R 10 are independently substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Fluoroalkyl.

28. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in: R c For hydrogen, halogen, –CN, –N(R 9 ) 2 ,–OR f , C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, C 1 -C 6 Fluoroalkoxy, or substituted or unsubstituted C 1 -C 6 heteroalkyl; R f For -L 1 -R g ; L 1 does not exist, C 1 -C 6 Alkylene, or C 1 -C 6 Fluoroalkylene; R g is hydrogen, substituted or unsubstituted C 3 -C 6 Cycloalkyl, substituted or unsubstituted phenyl, -CO 2 R 9 , or -C(=O)N(R 9 ) 2 ; R 3 For hydrogen, C 1 -C 6 Alkyl or C 1 -C 6 Fluoroalkyl; R 4 For hydrogen, halogen, C 1 -C 6 Alkyl or C 1 -C 6 Fluoroalkyl; R 5 For hydrogen, halogen, C 1 -C 6 Alkyl or C 1 -C 6 Fluoroalkyl; R 6 C 1 -C 8 Alkyl, C 1 -C 8 Fluoroalkyl, or -L 2 -R 6a ; L 2 does not exist, C 1 -C 6 Alkylene, or -CHR 6b -; R 6a is substituted or unsubstituted C 3 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted C 2 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl; R 6b C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or substituted or unsubstituted C 3 -C 6 Cycloalkyl; R 7 H or C 1 -C 6 alkyl; or R 6 and R 7 Together with the nitrogen to which they are attached they form a substituted or unsubstituted heterocyclic ring.

29. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, in: R c Hydrogen, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , -CO 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 , or -C(=O)N(CH 3 ) 2 ; R 3 is hydrogen, -CH 3 , -CH 2 OH, -CH 2 OCH 3 , -CH 2 CH 2 F, -CH 2 CHF 2 , or -CH 2 CF 3 ; R 4 is hydrogen or F; R 5 is hydrogen or F; R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl, or -L 2 -R 6a ; L 2 does not exist, C 1 -C 6 Alkylene or -CHR 6b -; R 6a is a substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 5 -C 10 Cycloalkyl, substituted or unsubstituted C 6 -C 10 Aryl, substituted or unsubstituted monocyclic C 2 -C 3 Heterocycloalkyl, substituted or unsubstituted monocyclic or bicyclic C 4 -C 10 Heterocycloalkyl, or substituted or unsubstituted C 1 -C 9 heteroaryl; R 6b C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, or substituted or unsubstituted monocyclic C 3 -C 4 Cycloalkyl; R 7 H or C 1 -C 6 alkyl; or R 6 and R 7 Together with the nitrogen to which they are attached they form a substituted or unsubstituted heterocyclic ring.

30. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure of Formula (VIa) or a pharmaceutically acceptable salt thereof: in: R c Hydrogen, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , -CO 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 , or -C(=O)N(CH 3 ) 2 ; R 3 is hydrogen or -CH 3 ; R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl or -L 2 -R 6a ; L 2 Does not exist, -CH 2 -、-CH 2 CH 2 -、-CH 2 CH 2 CH 2 -, or -CHR 6b -; R 6a is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted azetidinyl, or substituted or unsubstituted oxetanyl; R 6b -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 , -CHF 2 、-CH 2 F, -CF 3 , cyclopropyl or cyclobutyl; R 7 is hydrogen or C 1 -C 6 alkyl; R 8 is hydrogen, -F or -Cl; R 11 and R 12 are independently hydrogen, -F, -Cl, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , or -OCHF 2 .

31. The compound according to claim 30, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure of formula (VIa-1) or a pharmaceutically acceptable salt thereof: R 6 is -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 、-CH 2 CH 2 CH 2 CH 3 、-CH 2 CH(CH 3 ) 2 、-CH(CH 3 )(CH 2 CH 3 )、-CH(CH 2 CH 3 )(CH 2 CH 3 )、-CH(CH 2 CH 2 CH 3 )(CH 2 CH 3 )、-C(CH 3 )(CHCH 3 ) 2 、-C(CH 3 ) 3 、-CH 2 F、-CHF 2 、-CF 3 、-CH 2 CF 3 、-CH(CF 3 )(CH 3 )、-CH(CF 3 )(CH 2 CH 3 )、-CH 2 CF 2 CH 3 、or -CH(CH 3 )(CH 2 CF 3 ); R 7 is hydrogen or -CH 3 ; R 11 is -F or -Cl; and R 12 It is -F or -Cl.

32. The compound according to claim 30, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure of formula (VIa-1) or a pharmaceutically acceptable salt thereof: R 6 For -L 2 -R 6a ; R 7 is hydrogen or -CH 3 ; R 11 is -F or -Cl; and R 12 It is -F or -Cl.

33. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure of formula (VIb) or a pharmaceutically acceptable salt thereof: in: R c Hydrogen, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , -CO 2 CH 3 、-C(=O)NH 2 、-CONHCH 3 , or -C(=O)N(CH 3 ) 2 ; R 3 is hydrogen or -CH 3 ; R 6 C 1 -C 6 Alkyl, C 1 -C 6 Fluoroalkyl or -L 2 -R 6a ; L 2 Does not exist, -CH 2 -、-CH 2 CH 2 -、-CH 2 CH 2 CH 2 -, or -CHR 6b -; R 6a is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted azetidinyl, or substituted or unsubstituted oxetanyl; R 6b -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 , -CHF 2 、-CH 2 F, -CF 3 , cyclopropyl or cyclobutyl; R 7 is hydrogen or C 1 -C 6 alkyl; R 8 is hydrogen, -F or -Cl; R 11 and R 12 are independently hydrogen, -F, -Cl, -CN, -CH 3 , -CF 3 、-OCH 3 、-OCF 3 , or -OCHF 2 .

34. The compound according to claim 33, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure of formula (VIb-1) or a pharmaceutically acceptable salt thereof: R 6 is -CH 3 、-CH 2 CH 3 、-CH 2 CH 2 CH 3 、-CH(CH 3 ) 2 、-CH 2 CH 2 CH 2 CH 3 、-CH 2 CH(CH 3 ) 2 、-CH(CH 3 )(CH 2 CH 3 )、-CH(CH 2 CH 3 )(CH 2 CH 3 )、-CH(CH 2 CH 2 CH 3 )(CH 2 CH 3 )、-C(CH 3 )(CHCH 3 ) 2 、-C(CH 3 ) 3 、-CH 2 F、-CHF 2 、-CF 3 、-CH 2 CF 3 、-CH(CF 3 )(CH 3 )、-CH(CF 3 )(CH 2 CH 3 )、-CH 2 CF 2 CH 3 、or -CH(CH 3 )(CH 2 CF 3 ); R 7 is hydrogen or -CH 3 ; R 11 is -F or -Cl; and R 12 It is -F or -Cl.

35. The compound according to claim 33, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure of formula (VIb-1) or a pharmaceutically acceptable salt thereof: R 6 For -L 2 -R 6a ; R 7 is hydrogen or -CH 3 ; R 11 is -F or -Cl; and R 12 It is -F or -Cl.

36. A compound selected from: 1-1: 4-[(3S)-3-aminopyrrolidin-1-yl]-N,5-bis(3,5-dimethylphenyl)pyridine-3-carboxamide; 1-3: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-(3-chloro-5-fluorophenyl)-5-(3,5-dimethylphenyl)pyridine-3-carboxamide; 1-4: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-4-fluorophenyl)-N-(2-fluorophenyl)pyridine-3-carboxamide; 1-7: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-cyanophenyl)-N-cyclohexylpyridine-3-carboxamide; 1-8: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-cyanophenyl)-N-(1-methylcyclobutyl)pyridine-3-carboxamide; 1-9: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-benzyl-5-(3-cyanophenyl)pyridine-3-carboxamide; 1-10: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyanophenyl)-N-(4,4-difluorocyclohexyl)pyridine-3-carboxamide; 1-11: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-dimethylcyclohexyl)-5-(3,5-dimethylphenyl)pyridine-3-carboxamide; 1-12: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-dimethylphenyl)pyridine-3-carboxamide; 1-13: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide; 1-14: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-difluorocyclohexyl)-5-(3,5-dimethylphenyl)pyridine-3-carboxamide; 1-15: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-fluoro-5-methylphenyl)-N-[1-(trifluoromethyl)cyclopentyl]pyridine-3-carboxamide; 1-16: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-17: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(2,3-dihydro-1H-inden-1-yl)-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide; 1-18: N-(adamantan-2-yl)-4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide; 1-19: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(1-ethylcyclobutyl)-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide; 1-20: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,4,5-trifluorophenyl)pyridine-3-carboxamide; 1-21: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-22: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(3,3-dimethylcyclobutyl)pyridine-3-carboxamide; 1-23: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclopropyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-24: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(1-cyclopropylethyl)-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide; 1-25: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(dicyclopropylmethyl)-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide; 1-26: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(cyclopropylmethyl)-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide; 1-27: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-fluoro-5-methylphenyl)-N-(1-methyl-1H-pyrazol-3-yl)pyridine-3-carboxamide; 1-28: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide; 1-29: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-tert-butyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-30: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-difluorocyclobutyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-31: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(pentan-3-yl)pyridine-3-carboxamide; 1-32: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(1-methylcyclopropyl)methyl]pyridine-3-carboxamide; 1-33: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(cyclobutylmethyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-34: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(1-methylcyclobutyl)pyridine-3-carboxamide; 1-35: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-(3,3-difluorocyclobutyl)pyridine-3-carboxamide; 1-37: 4-[(3R,4R)-3-amino-4-fluoropyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-38: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(3-methylbutan-2-yl)pyridine-3-carboxamide; 1-39: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(2,4-dimethylpentan-3-yl)pyridine-3-carboxamide; 1-40: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(2-cyclopropylpropan-2-yl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-41: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-42: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(2,2-difluorocyclopropyl)methyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-43: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(2,2-dimethylcyclopropyl)methyl]pyridine-3-carboxamide; 1-44: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1R)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-45: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(1,1,1-trifluoro-3-methylbutan-2-yl)pyridine-3-carboxamide; 1-46: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(2-methylpropyl)pyridine-3-carboxamide; 1-47: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(1-fluorocyclobutyl)methyl]pyridine-3-carboxamide; 1-48: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-49: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-50: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(3,3-difluorocyclobutyl)methyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-51: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(dicyclopropylmethyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-52: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[trans-2-fluorocyclohexyl]pyridine-3-carboxamide; 1-53: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(2R)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-54: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-55: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(trans-3-fluorocyclobutyl]pyridine-3-carboxamide; 1-56: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(1-cyclobutyl-2,2,2-trifluoroethyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-57: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(2-methylbutyl)pyridine-3-carboxamide; 1-58: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(2-ethylbutyl)pyridine-3-carboxamide; 1-59: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[cis-3-fluorocyclobutyl]pyridine-3-carboxamide; 1-60: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(4,4,4-trifluorobutan-2-yl)pyridine-3-carboxamide; 1-61: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-(dicyclopropylmethyl)pyridine-3-carboxamide; 1-62: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-(2,2-difluoropropyl)pyridine-3-carboxamide; 1-64: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-65: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3-fluorophenyl)pyridine-3-carboxamide; 1-66: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,4-difluorophenyl)pyridine-3-carboxamide; 1-67: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-68: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-(3,3-difluorocyclobutyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-69: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-70: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-(dicyclopropylmethyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-71: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-72: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(pentan-3-yl)pyridine-3-carboxamide; 1-73: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-cycloheptyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-74: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide; 1-76: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(pentan-3-yl)pyridine-3-carboxamide; 1-77: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-78: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-cyclopentyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-79: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-(3,3-difluorocyclobutyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-80: 4-[(3S)-3-aminopyrrolidin-1-yl]-3-(3,5-difluorophenyl)-5-(piperidine-1-carbonyl)pyridine-2-carbonitrile; 1-81: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-cyclohexyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-82: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-N-cyclopentyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-83: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[cis-2-fluorocyclohexyl]pyridine-3-carboxamide; 1-84: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3-chlorophenyl)-6-cyanopyridine-3-carboxamide; 1-85: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(2-methylpropyl)pyridine-3-carboxamide; 1-86: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-(cyclopropylmethyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-87: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-cyclobutyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-88: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(oxan-4-yl)pyridine-3-carboxamide; 1-89: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(oxan-3-yl)pyridine-3-carboxamide; 1-90: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3-chloro-5-fluorophenyl)-6-cyanopyridine-3-carboxamide; 1-91: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(propan-2-yl)pyridine-3-carboxamide; 1-92: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide; 1-93: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-cyclohexyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-94: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3-cyano-5-methoxyphenyl)pyridine-3-carboxamide; 1-95: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1S)-1-(pyridin-2-yl)ethyl]pyridine-3-carboxamide; 1-96: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-methoxyphenyl)-N-[(1S)-1-cyclopropylethyl]pyridine-3-carboxamide; 1-97: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1S)-1-phenylethyl]pyridine-3-carboxamide; 1-98: 4-[(3S)-3-amino-3-(hydroxymethyl)pyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-101: 4-[(3R,4R)-3-amino-4-fluoropyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-103: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1S)-1-(pyridin-2-yl)ethyl]pyridine-3-carboxamide; 1-104: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1-methyl-1H-pyrazol-5-yl)methyl]pyridine-3-carboxamide; 1-105: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1-methyl-1H-pyrazol-3-yl)methyl]pyridine-3-carboxamide; 1-106: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1-methyl-1H-imidazol-2-yl)methyl]pyridine-3-carboxamide; 1-107: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1-methyl-1H-pyrazol-4-yl)methyl]pyridine-3-carboxamide; 1-108: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(pyrimidin-2-yl)methyl]pyridine-3-carboxamide; 1-109: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(4-benzylpiperazine-1-carbonyl)-3-(3,5-difluorophenyl)pyridine-2-carbonitrile; 1-110: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(3-phenylpropyl)pyridine-3-carboxamide; 1-111: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(1-phenylpiperidin-4-yl)pyridine-3-carboxamide; 1-112: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclohexyl-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-113: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(2,2-dimethyloxan-4-yl)pyridine-3-carboxamide; 1-114: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(1,2-oxazol-3-yl)methyl]pyridine-3-carboxamide; 1-115: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2-hydroxyphenyl)methyl]pyridine-3-carboxamide; 1-116: 4-[(3R)-3-amino-3-(methoxymethyl)pyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-118: 4-[(3S)-3-amino-3-(2,2-difluoroethyl)pyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-120: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-[3-(difluoromethoxy)phenyl]pyridine-3-carboxamide; 1-122: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide; 1-123: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methylpyridine-3-carboxamide; 1-124: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3-fluorophenyl)-6-methylpyridine-3-carboxamide; 1-125: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methylpyridine-3-carboxamide; 1-126: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[1-(pyrimidin-2-yl)ethyl]pyridine-3-carboxamide; 1-127: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-[3-(trifluoromethoxy)phenyl]pyridine-3-carboxamide; 1-130: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide; 1-132: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[1-(1,2-oxazol-3-yl)ethyl]pyridine-3-carboxamide; 1-133: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[1-(1-methyl-1H-1,2,3-triazol-4-yl)ethyl]pyridine-3-carboxamide; 1-135: 4-[(3R,4R)-3-amino-4-fluoropyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-137: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-difluorocyclobutyl)-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide; 1-138: 4-[(3R,4R)-3-amino-4-fluoropyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-cyano-N-[(1S)-1-cyclopropylethyl]pyridine-3-carboxamide; 1-140: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-141: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide; 1-143: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-[3-(difluoromethoxy)-5-fluorophenyl]pyridine-3-carboxamide; 1-144: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide; 1-145: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-3,3-difluorocyclopentyl]-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide; 1-146: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-difluorocyclobutyl)-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide; 1-147: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-6-methyl-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-149: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-[3-(difluoromethoxy)phenyl]pyridine-3-carboxamide; 1-150: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide; 1-151: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3,5-difluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-152: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide; 1-153: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methoxypyridine-3-carboxamide; 1-154: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-6-methoxy-5-[3-(trifluoromethoxy)phenyl]pyridine-3-carboxamide; 1-163: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(2,2-difluoro-2H-1,3-benzodioxol-4-yl)pyridine-3-carboxamide; 1-164: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-[3-fluoro-5-(trifluoromethyl)phenyl]-6-methoxypyridine-3-carboxamide; 1-165: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-[3-(difluoromethoxy)phenyl]-6-methoxypyridine-3-carboxamide; 1-168: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-[3-(difluoromethoxy)phenyl]-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-171: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methyl-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-172: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(3,3-difluorocyclobutyl)-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methylpyridine-3-carboxamide; 1-173: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methylpyridine-3-carboxamide; 1-174: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methylpyridine-3-carboxamide; 1-175: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)pyridine-3-carboxamide; 1-176: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-ethoxypyridine-3-carboxamide; 1-177: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-6-(2,2-difluoroethoxy)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-178: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-6-(cyclopropylmethoxy)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-179: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-(2-methoxyethoxy)pyridine-3-carboxamide; 1-180: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-[3-(difluoromethoxy)-5-fluorophenyl]-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-181: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide; 1-184: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(2,2-difluoro-2H-1,3-benzodioxol-4-yl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-188: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-189: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide; 1-190: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide; 1-191: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyclopropyloxy-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-192: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide; 1-193: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3,5-difluorophenyl)-6-methoxy-N-[4-(trifluoromethyl)cyclohexyl]pyridine-3-carboxamide; 1-194: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-(1-cyclopropyl-2,2,2-trifluoroethyl)-5-(3,5-difluorophenyl)-6-methoxypyridine-3-carboxamide; 1-195: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-(trifluoromethyl)pyridine-3-carboxamide; 1-196: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-{3-fluorobicyclo [ 1.1.1]pentan-1-yl}-6-methoxypyridine-3-carboxamide; 1-197: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-methoxyphenyl)-N-[(1S)-1-cyclopropylethyl]-6-(trifluoromethyl)pyridine-3-carboxamide; 1-198: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-(trifluoromethyl)pyridine-3-carboxamide; 1-199: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide; 1-200: ethyl 2-({4-[(3S)-3-aminopyrrolidin-1-yl]-5-[(4,4-difluorocyclohexyl)carbamoyl]-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)acetate; 1-201: ethyl 3-({4-[(3S)-3-aminopyrrolidin-1-yl]-5-[(4,4-difluorocyclohexyl)carbamoyl]-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)propanoate; 1-202: ethyl 4-({4-[(3S)-3-aminopyrrolidin-1-yl]-5-[(4,4-difluorocyclohexyl)carbamoyl]-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)butanoate; 1-203: 2-({4-[(3S)-3-aminopyrrolidin-1-yl]-5-[(4,4-difluorocyclohexyl)carbamoyl]-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)acetic acid 1-204: 3-({4-[(3S)-3-aminopyrrolidin-1-yl]-5-[(4,4-difluorocyclohexyl)carbamoyl]-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)propanoic acid; 1-205: 4-({4-[(3S)-3-aminopyrrolidin-1-yl]-5-[(4,4-difluorocyclohexyl)carbamoyl]-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)butanoic acid; 1-209: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,4-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide; 1-210: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-cyclohexyl-5-(3,5-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide; 1-211: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide; 1-212: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3,5-difluorophenyl)-6-(trifluoromethyl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-213: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-cyclohexyl-5-(3,5-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide; 1-214: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide; 1-215: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-dichlorophenyl)-6-(trifluoromethyl)pyridine-3-carboxamide; 1-216: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-{3-fluorobicyclo[ 1.1.1]pentan-1-yl}-6-(trifluoromethyl)pyridine-3-carboxamide; 1-217: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-{3-fluorobicyclo[ 1.1.1]pentan-1-yl}-6-(trifluoromethyl)pyridine-3-carboxamide; 1-218: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-(cyclopropylmethyl)-5-(3,5-difluorophenyl)-N-methylpyridine-3-carboxamide; 1-219: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-N-methylpyridine-3-carboxamide; 1-222: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide; 1-223: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-[(1-hydroxycyclopentyl)methyl]-6-methylpyridine-3-carboxamide; 1-224: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(1-cyclopropyl-2-hydroxyethyl)-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide; 1-225: 4-(3-aminopyrrolidin-1-yl)-6-cyano-5-(3,5-difluorophenyl)-N-(1,1,1-trifluoropropane-2-yl)pyridine-3-carboxamide; 1-226: 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-(1,1,1-trifluoropropan-2-yl)pyridine-3-carboxamide; 1-227: 4-[(3R)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2R)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-228: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-229: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methoxypyridine-3-carboxamide; 1-230: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3,5-difluorophenyl)-6-methyl-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-231: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methyl-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-232: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-[3-(difluoromethoxy)phenyl]-6-methyl-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide; 1-233: 4-[(3S)-3-aminopyrrolidin-1-yl]-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)-6-methylpyridine-3-carboxamide; 1-234: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-{3-fluorobicyclo[ 1.1.1]pentan-1-yl}pyridine-3-carboxamide; 1-235: (3S)-1-[3-(3,5-difluorophenyl)-2-methoxy-5-(piperidine-1-carbonyl)pyridin-4-yl]pyrrolidin-3-amine; 1-236: (3S)-1-[3-(3,5-difluorophenyl)-5-(4,4-difluoropiperidine-1-carbonyl)-2-methoxypyridin-4-yl]pyrrolidin-3-amine; 1-237: (3S)-1-[3-(3,5-difluorophenyl)-5-(3,3-difluoropiperidine-1-carbonyl)-2-methoxypyridin-4-yl]pyrrolidin-3-amine; 1-238: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methoxy-N-[(1,2-oxazol-3-yl)methyl]pyridine-3-carboxamide; 1-239: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methoxy-N-[(1,2-oxazol-3-yl)methyl]pyridine-3-carboxamide; 1-240: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methoxy-N-[(1S)-1-(pyridin-2-yl)ethyl]pyridine-3-carboxamide; 1-241: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-[3-(difluoromethoxy)-5-fluorophenyl]-6-methoxy-N-[(1S)-1-(pyridin-2-yl)ethyl]pyridine-3-carboxamide; 1-242: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methyl-N-[(1,2-oxazol-3-yl)methyl]pyridine-3-carboxamide; 1-243: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methyl-N-[(1S)-1-(pyridin-2-yl)ethyl]pyridine-3-carboxamide; 1-244: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-cyano-N-[(1,2-oxazol-3-yl)methyl]pyridine-3-carboxamide; 1-245: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-cyano-N-[(1S)-1-(pyridin-2-yl)ethyl]pyridine-3-carboxamide; 1-246: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-(2-hydroxyethoxy)pyridine-3-carboxamide; 1-247: 2-({4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-{[(1S)-1-cyclopropylethyl]carbamoyl}-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)acetic acid; 1-259: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,4-difluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-260: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(4-chloro-3-fluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-261: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-4-fluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide; 1-262: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,4-difluorophenyl)-6-methoxypyridine-3-carboxamide; 1-263: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(4-chloro-3-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methoxypyridine-3-carboxamide; 1-264: 3-({4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-{[(1S)-1-cyclopropylethyl]carbamoyl}-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)propanoic acid; 1-265: 4-({4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-{[(1S)-1-cyclopropylethyl]carbamoyl}-3-(3,5-difluorophenyl)pyridin-2-yl}oxy)butanoic acid; 1-266: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)-6-[(oxetan-3-yl)methoxy]pyridine-3-carboxamide; 1-267: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-(benzyloxy)-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-268: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-methoxyphenyl)-N-(4,4-difluorocyclohexyl)-6-methylpyridine-3-carboxamide; 1-269: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-methoxyphenyl)-N-(3,3-difluorocyclobutyl)-6-methylpyridine-3-carboxamide; 1-272: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methylpyridine-3-carboxamide; 1-273: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,5-difluorophenyl)-N-{3-fluorobicyclo[ 1.1.1]pentan-1-yl}-6-methoxypyridine-3-carboxamide; 1-275: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-methoxyphenyl)-6-methyl-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide; 1-276: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methyl-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-277: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-(4,4-difluorocyclohexyl)-6-methylpyridine-3-carboxamide; 1-278: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-{3-fluorobicyclo[ 1.1.1]pentan-1-yl}-6-methylpyridine-3-carboxamide; 1-279: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3,4-difluorophenyl)-6-methyl-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-280: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-cyano-5-methoxyphenyl)-N-[(1S)-1-cyclopropylethyl]-6-methylpyridine-3-carboxamide; 1-281: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyclopropyl-N-(4,4-difluorocyclohexyl)-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-282: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methoxypyridine-3-carboxamide; 1-283: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide; 1-284: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-(4,4-difluorocyclohexyl)-6-methoxypyridine-3-carboxamide; 1-285: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-(3,3-difluorocyclobutyl)-6-methoxypyridine-3-carboxamide; 1-286: 4-[(3S)-3-aminopyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-N-{3-fluorobicyclo[ 1.1.1]pentan-1-yl}-6-methoxypyridine-3-carboxamide; 1-287: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-4-fluorophenyl)-6-methyl-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide; 1-288: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(3,4-difluorophenyl)-6-methylpyridine-3-carboxamide; 1-289: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(3-chloro-4-fluorophenyl)-N-[(1S)-1-cyclopropylethyl]-6-methylpyridine-3-carboxamide; 1-290: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyclopropyl-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-161: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(1-methyl-1H-indazol-6-yl)pyridine-3-carboxamide; 1-162: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-[(1S)-1-cyclopropylethyl]-5-(1-methyl-1H-indazol-4-yl)pyridine-3-carboxamide; 1-182: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-methoxy-5-(1-methyl-1H-1,3-benzodiazol-6-yl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-183: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-methoxy-5-(1-methyl-1H-indazol-4-yl)-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-186: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-5-(2,1,3-benzoxadiazol-5-yl)-6-methoxy-N-[(2S)-1,1,1-trifluoropropane-2-yl]pyridine-3-carboxamide; 1-2: 4-[(3R)-3-aminopyrrolidin-1-yl]-N,5-bis(3,5-dimethylphenyl)pyridine-3-carboxamide; 1-36: 4-[3-amino-3-(methoxymethyl)pyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-99: 4-[(3R)-3-amino-3-(hydroxymethyl)pyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-102: 4-[(3S,4S)-3-amino-4-fluoropyrrolidin-1-yl]-N-{bicyclo[1.1.1]pentan-1-yl}-6-cyano-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-117: 4-[(3S)-3-amino-3-(methoxymethyl)pyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-119: 4-[(3R)-3-amino-3-(2,2-difluoroethyl)pyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-136: 4-[(3S,4S)-3-amino-4-fluoropyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-139: 4-[(3S,4S)-3-amino-4-fluoropyrrolidin-1-yl]-5-(3-chloro-5-fluorophenyl)-6-cyano-N-[(1S)-1-cyclopropylethyl]pyridine-3-carboxamide; 1-220: 4-[(3S)-3-amino-3-(fluoromethyl)pyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; 1-221: 4-[(3R)-3-amino-3-(fluoromethyl)pyrrolidin-1-yl]-6-cyano-N-[(1S)-1-cyclopropylethyl]-5-(3,5-difluorophenyl)pyridine-3-carboxamide; or a pharmaceutically acceptable salt thereof.

37. The compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein the compound is: 1-17: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-N-(2,3-dihydro-1H-inden-1-yl)-5-(3-fluoro-5-methylphenyl)pyridine-3-carboxamide or a pharmaceutically acceptable salt thereof.

38. The compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein the compound is: 1-192: 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide or a pharmaceutically acceptable salt thereof.

39. A pharmaceutical composition comprising a compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

40. The pharmaceutical composition of claim 39, wherein the pharmaceutical composition is formulated for administration to a mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, dermal administration, or ocular administration.

41. The pharmaceutical composition of claim 39, wherein the pharmaceutical composition is in the form of a tablet, pill, capsule, liquid, suspension, gel, dispersion, solution, emulsion, ointment or lotion.

42. Use of a compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease or condition in a mammal that would benefit from modulation of somatostatin receptor subtype 5 (SSTR5) activity.

43. The use according to claim 42, wherein the disease or condition is hyperinsulinemic hypoglycemia.

44. The use according to claim 42, wherein the disease or condition is hypoglycemia due to endogenous insulin, drug-induced hyperinsulinemia, or hypoglycemia caused by exogenous insulin.

45. Use of a compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating hyperinsulinemia in a mammal.

Citation Information

Patent Citations

  • Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes

    US10214540B2